<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Vet Sci</journal-id><journal-id journal-id-type="iso-abbrev">Front Vet Sci</journal-id><journal-id journal-id-type="pmc-domain-id">2864</journal-id><journal-id journal-id-type="pmc-domain">fvets</journal-id><journal-id journal-id-type="publisher-id">Front. Vet. Sci.</journal-id><journal-title-group><journal-title>Frontiers in Veterinary Science</journal-title></journal-title-group><issn pub-type="epub">2297-1769</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9339783</article-id><article-id pub-id-type="pmcid-ver">PMC9339783.1</article-id><article-id pub-id-type="pmcaid">9339783</article-id><article-id pub-id-type="pmcaiid">9339783</article-id><article-id pub-id-type="pmid">35923818</article-id><article-id pub-id-type="doi">10.3389/fvets.2022.925773</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Veterinary Science</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Evaluation of Brucellosis Vaccines: A Comprehensive Review</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Heidary</surname><given-names initials="M">Mohsen</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/580992/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dashtbin</surname><given-names initials="S">Shirin</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ghanavati</surname><given-names initials="R">Roya</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mahdizade Ari</surname><given-names initials="M">Marzie</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bostanghadiri</surname><given-names initials="N">Narjess</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Darbandi</surname><given-names initials="A">Atieh</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Navidifar</surname><given-names initials="T">Tahereh</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Talebi</surname><given-names initials="M">Malihe</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1780671/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Cellular and Molecular Research Center, Sabzevar University of Medical Sciences</institution>, <addr-line>Sabzevar</addr-line>, <country>Iran</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Microbiology, School of Medicine, Iran University of Medical Sciences</institution>, <addr-line>Tehran</addr-line>, <country>Iran</country></aff><aff id="aff3"><sup>3</sup><institution>School of Paramedical Sciences, Behbahan Faculty of Medical Sciences</institution>, <addr-line>Behbahan</addr-line>, <country>Iran</country></aff><aff id="aff4"><sup>4</sup><institution>Shoushtar Faculty of Medical Sciences</institution>, <addr-line>Shoushtar</addr-line>, <country>Iran</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Jiabo Ding, Institute of Animal Sciences (CAAS), China</p></fn><fn fn-type="edited-by"><p>Reviewed by: Qisheng Peng, Jilin University, China; Hai Jiang, Chinese Center for Disease Control and Prevention, China</p></fn><corresp id="c001">*Correspondence: Malihe Talebi <email>talebi_25@yahoo.com</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Veterinary Infectious Diseases, a section of the journal Frontiers in Veterinary Science</p></fn></author-notes><pub-date pub-type="epub"><day>18</day><month>7</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>9</volume><issue-id pub-id-type="pmc-issue-id">400313</issue-id><elocation-id>925773</elocation-id><history><date date-type="received"><day>21</day><month>4</month><year>2022</year></date><date date-type="accepted"><day>03</day><month>6</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>02</day><month>08</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-15 01:25:29.720"><day>15</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2022 Heidary, Dashtbin, Ghanavati, Mahdizade Ari, Bostanghadiri, Darbandi, Navidifar and Talebi.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Heidary, Dashtbin, Ghanavati, Mahdizade Ari, Bostanghadiri, Darbandi, Navidifar and Talebi</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fvets-09-925773.pdf"/><abstract><p>Brucellosis is a bacterial zoonosis caused by <italic toggle="yes">Brucella</italic> spp. which can lead to heavy economic losses and severe human diseases. Thus, controlling brucellosis is very important. Due to humans easily gaining brucellosis from animals, animal brucellosis control programs can help the eradication of human brucellosis. There are two popular vaccines against animal brucellosis. Live attenuated <italic toggle="yes">Brucella abortus</italic> strain 19 (S19 vaccine) is the first effective and most extensively used vaccine for the prevention of brucellosis in cattle. Live attenuated <italic toggle="yes">Brucella melitensis</italic> strain Rev.1 (Rev.1 vaccine) is the most effective vaccine against caprine and ovine brucellosis. Although these two vaccines provide good immunity for animals against brucellosis, the expense of persistent serological responses is one of the main problems of both vaccines. The advantages and limitations of <italic toggle="yes">Brucella</italic> vaccines, especially new vaccine candidates, have been less studied. In addition, there is an urgent need for new strategies to control and eradicate this disease. Therefore, this narrative review aims to present an updated overview of the available different types of brucellosis vaccines.</p></abstract><kwd-group><kwd>brucellosis</kwd><kwd>vaccine</kwd><kwd><italic toggle="yes">Brucella</italic></kwd><kwd>review</kwd><kwd><italic toggle="yes">Brucella abortus</italic></kwd><kwd><italic toggle="yes">Brucella melitensis</italic></kwd></kwd-group><counts><fig-count count="0"/><table-count count="5"/><equation-count count="0"/><ref-count count="172"/><page-count count="27"/><word-count count="18882"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Despite many studies conducted to eradicate brucellosis infection worldwide, the episodic situation of brucellosis is still worrying and ambiguous (<xref rid="B1" ref-type="bibr">1</xref>). Brucellosis is a bacterial zoonosis caused by microorganisms belonging to the genus <italic toggle="yes">Brucella</italic>. They are various pathogens of domestic and wild mammals, found inside the host. <italic toggle="yes">Brucella</italic> could multiply in professional and non-professional phagocytes and cause heavy economic losses and many diseases in humans. Controlling brucellosis is of great importance (<xref rid="B2" ref-type="bibr">2</xref>). Human brucellosis is caused by direct or indirect contact with various species of infected animals, notably cattle, sheep, goats, and swine. Thus, the wipeout of the illness in animals causes the eradication of human sickness (<xref rid="B3" ref-type="bibr">3</xref>). Since the late 1980's, the brucellosis epidemic has been growing rapidly in some countries and parts of the world, infecting over 60 species of wildlife, causing disease worldwide, and causing great economic damage to livestock (<xref rid="B4" ref-type="bibr">4</xref>). Humans could easily gain brucellosis through animals and their products, even though humans are not carriers of the disease. Brucellosis is a complex disease due to the diversity of <italic toggle="yes">Brucella</italic> active species that, despite causing species-specific disease syndromes, could sometimes cause cross-infection (<xref rid="B5" ref-type="bibr">5</xref>). From the beginning of the twentieth century, the study and research on the production of brucellosis vaccines have begun. The development of brucellosis vaccines has experienced inactivated, live-attenuated, and rough-attenuated vaccines. Inactivated vaccines were first developed to prevent the disease, then live-attenuated vaccines, which are more effective in terms of immunogenicity, were superseded to control brucellosis (<xref rid="B6" ref-type="bibr">6</xref>). Existing vaccines that are currently used could cause problems. For example, some of these vaccines could cause human infection and abortion in pregnant cows; however, despite some shortcomings, they play an essential role in preventing and controlling brucellosis. These vaccines are used all over the world. With the development of precise molecular techniques and an accurate understanding of the mechanism of <italic toggle="yes">Brucella</italic> pathogenesis, new genetically-engineered vaccines have been developed and replaced traditional vaccines to prevent and control brucellosis (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). In this review, different types of brucellosis vaccines and their advances evaluated.</p></sec><sec id="s2"><title>Live-Attenuated Vaccines</title><p>In recent decades, the most effective way to control brucellosis has been to vaccinate animals. Although vaccination of individuals living in brucellosis endemic areas, veterinarians, livestock, and laboratory personnel is essential, human vaccines have not yet been developed (<xref rid="B9" ref-type="bibr">9</xref>). Live-attenuated vaccines are the most effective vaccines used to control animal brucellosis (<xref rid="B10" ref-type="bibr">10</xref>). Due to the lower efficacy of inactivated and subunit brucellosis vaccines, multiple doses should be administered, whilst live-attenuated vaccines are less expensive and more effective and induce immunity through humoral and cell-mediated responses (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B11" ref-type="bibr">11</xref>). However, some drawbacks have been reported to the administration of live-attenuated brucellosis vaccines, including antibiotic resistance, interference with serological diagnostic tests, and residual virulence in animals and humans (<xref rid="B10" ref-type="bibr">10</xref>&#8211;<xref rid="B12" ref-type="bibr">12</xref>).</p><p>Live-attenuated vaccines have been broadly used against brucellosis, such as <italic toggle="yes">B. abortus</italic> strains S19, <italic toggle="yes">B. melitensis</italic> strain Rev1, and M5, and <italic toggle="yes">B. suis</italic> strain S2 derived as an attenuated phenotype by repeated <italic toggle="yes">in vitro</italic> passage of strain 2308. Numerous research on the effectiveness of these vaccines has been carried out in experimental animals and proven that vaccinated animals are effectively protected against wild-type (WT) bacteria. The main disadvantage of vaccine strains S19 and Rev1 is that the agglutinins induced by these vaccines persist in immunized animals for a long time and interfere with the standard serodiagnostic tests, even if the antibodies are produced by these two vaccines are durable. Therefore, it is difficult to distinguish between infected and vaccinated animals with the vaccine strain S19 or Rev1. Although the incidence rate of abortion is low, to overcome these defects, a safe and effective vaccine is needed (<xref rid="B13" ref-type="bibr">13</xref>&#8211;<xref rid="B15" ref-type="bibr">15</xref>). Another vaccine in this category is <italic toggle="yes">Brucella suis</italic> S2 vaccine, which is one of the brucellosis control programs in China. Studies show that this vaccine provides a good humoral and cellular immune response and protects against <italic toggle="yes">Brucella</italic> heterologous species (<xref rid="B16" ref-type="bibr">16</xref>), but has a limited host range (<xref rid="B17" ref-type="bibr">17</xref>).</p><p>Identification of genes linked to virulence or survival of organism's aids to develop new vaccines that are both safe and protective. The best approach to developing new vaccines with minimal residual virulence is currently engineered live-attenuated vaccines based on deletions in virulence genes, which induce high safety levels compared to classical live-attenuated vaccines (<xref rid="B18" ref-type="bibr">18</xref>). A variety of vaccines are under development based on different deletions in <italic toggle="yes">B. abortus</italic> or <italic toggle="yes">B. melitensis</italic> virulence genes, which eventually result in significant attenuation and increased production of T cells, pro-inflammatory cytokines, and antibodies. There are many mutants listed in <xref rid="T1" ref-type="table">Table 1</xref>, which have been generated by attenuation of genes and confer protective responses against <italic toggle="yes">Brucella</italic> challenge in experimental animals.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Genetically modified live attenuated vaccines against brucellosis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Gene deleted</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Function</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Host</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Vaccination (dose, route)</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>Challenge (<italic toggle="yes">Brucella</italic> species)</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>Challenge (weeks or days p.v.)</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>Protection</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>References</bold>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">cydC, cydD, purD</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">ATP-binding cassette-type transporter <break/> Phosphoribosylamine&#8211;glycine ligase</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="left" rowspan="1" colspan="1">2.4&#8211;3.1 &#215; 10<sup>8</sup> CFU, i.p.</td><td valign="top" align="center" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 2308</td><td valign="top" align="center" rowspan="1" colspan="1">7w <break/> 21w <break/> 7w <break/> 21w</td><td valign="top" align="center" rowspan="1" colspan="1">2.37-log <break/> 2.64- log <break/> 1.48-log <break/> 2.72- log</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B19" ref-type="bibr">19</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Hfq</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Regular expression of some target genes, affects mRNA stability</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="left" rowspan="1" colspan="1">1 &#215; 10<sup>6</sup> CFU, i.p.</td><td valign="top" align="center" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M</td><td valign="top" align="center" rowspan="1" colspan="1">2w <break/> 4w</td><td valign="top" align="center" rowspan="1" colspan="1">1.64 -log <break/> 2.06- log</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B20" ref-type="bibr">20</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">bp26</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Periplasmic or cytoplasmic protein</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="left" rowspan="1" colspan="1">1 &#215; 10<sup>6</sup> CFU, i.p.</td><td valign="top" align="center" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M</td><td valign="top" align="center" rowspan="1" colspan="1">5w</td><td valign="top" align="center" rowspan="1" colspan="1">2.89-log</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B21" ref-type="bibr">21</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">omp31</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Outer membrane protein</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="left" rowspan="1" colspan="1">5 &#215; 10<sup>5</sup> CFU, i.p.</td><td valign="top" align="center" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> Bm133</td><td valign="top" align="center" rowspan="1" colspan="1">3w <break/> 6w <break/> 9w</td><td valign="top" align="center" rowspan="1" colspan="1">&#8776;4.1- log <break/> &#8776;3.9- log <break/> &#8776;2.3- log</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B22" ref-type="bibr">22</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">VjbR</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">HTH-type-quorum-sensing-dependent transcriptional regulator</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="left" rowspan="1" colspan="1">1 &#215; 10<sup>6</sup> CFU, i.p.</td><td valign="top" align="center" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M</td><td valign="top" align="center" rowspan="1" colspan="1">2w <break/> 4w</td><td valign="top" align="center" rowspan="1" colspan="1">1.70-log <break/> 3.05-log</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B23" ref-type="bibr">23</xref>)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">C57BL/6 mice</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>7</sup> CFU, i.p.</td><td valign="top" align="center" rowspan="1" colspan="1"><italic toggle="yes">B. canis</italic> RM6/66</td><td valign="top" align="center" rowspan="1" colspan="1">1 w</td><td valign="top" align="center" rowspan="1" colspan="1">3.092- log</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B24" ref-type="bibr">24</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">MucR</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Transcriptional regulatory protein</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> and 10<sup>6</sup> CFU, i.p.</td><td valign="top" align="center" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M</td><td valign="top" align="center" rowspan="1" colspan="1">20w</td><td valign="top" align="center" rowspan="1" colspan="1">4.14&#8211;4.75-log</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B25" ref-type="bibr">25</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">ZnuA</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Zn<sup>2+</sup> transport system</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="left" rowspan="1" colspan="1">3 &#215; 10<sup>11</sup> cells, oral</td><td valign="top" align="center" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M</td><td valign="top" align="center" rowspan="1" colspan="1">4w</td><td valign="top" align="center" rowspan="1" colspan="1">3- log</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B26" ref-type="bibr">26</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">ManB</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Phosphomannomutase (LPS synthesis)</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="left" rowspan="1" colspan="1">1 &#215; 10<sup>6</sup> CFU, i.p.</td><td valign="top" align="center" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M</td><td valign="top" align="center" rowspan="1" colspan="1">2w <break/> 4w</td><td valign="top" align="center" rowspan="1" colspan="1">1.74- log <break/> 1.87- log</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B21" ref-type="bibr">21</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">Pgm</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Phosphoglucomutase (LPS synthesis)</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c mice</td><td valign="top" align="left" rowspan="1" colspan="1">1 &#215; 10<sup>6</sup> CFU, i.p.</td><td valign="top" align="center" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M</td><td valign="top" align="center" rowspan="1" colspan="1">2w <break/> 4w</td><td valign="top" align="center" rowspan="1" colspan="1">3.43-log <break/> 2.83-log</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B27" ref-type="bibr">27</xref>)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ip, Intraperitoneal; CFU, colony-forming unit; W, week; log, logarithm</italic>.</p></table-wrap-foot></table-wrap><p>Double-deletion (&#916;<italic toggle="yes">cydC</italic>&#916;<italic toggle="yes">cydD</italic> and &#916;<italic toggle="yes">cydC</italic>&#916;<italic toggle="yes">purD</italic>) mutants of virulent <italic toggle="yes">B. abortus</italic> induce significant attenuation of virulence and long-term protective immunity. Sera collected from immunized mice with these strains were shown in a study to be associated with significant levels of IgG1 and IgG2a antibodies as well as Th1-type IFN-&#947; and Th2-type IL-10 cytokines; also, cytokine production was higher in these mice compared to RB51-immunized mice (<xref rid="B19" ref-type="bibr">19</xref>). Zhang et al. prepared <italic toggle="yes">B. melitensis</italic> 16M <italic toggle="yes">hfq</italic> (16M&#916;<italic toggle="yes">hfq</italic>) mutant strain which induced strong protective immunity, humoral responses especially IgG1 and IgG2a, and cellular responses with IFN-&#947; and IL-4 cytokine profiles; however, no significant difference in the production of IFN-&#947; and IL-4 was reported between 16MD<italic toggle="yes">hfq</italic> and Rev1 (<xref rid="B20" ref-type="bibr">20</xref>). Another study constructed a <italic toggle="yes">B. melitensis</italic> TcfSR promoter mutant (16M&#916;TcfSR) to introduce a vaccine candidate against <italic toggle="yes">B. melitensis</italic> infection. TcfSR is one of the two-component regulatory systems which allow host cells to detect environmental variations and respond appropriately to <italic toggle="yes">Brucella</italic>. Induction of a high level of protection and no interference with serodiagnostic tests were the main features of this candidate (<xref rid="B28" ref-type="bibr">28</xref>). The M5-90wboA mutant derived from <italic toggle="yes">B. melitensis</italic> M5-90 is a potential attenuated live vaccine and induces less virulence and inflammatory responses compared to its parental strains. The safety of this mutant is evaluated by the lack of splenomegaly in the host. Compared to the original strain, a higher level of protection is provided following vaccination with this mutant (95% survival). Also, another advantage of this mutant is the elicitation of an anti-<italic toggle="yes">Brucella</italic>-specific IgG response following vaccination, which is a diagnostic antigen for differentiation of immunization from infection (<xref rid="B10" ref-type="bibr">10</xref>). 16MDwzt as a rough mutant of <italic toggle="yes">B. melitensis</italic>, generated by the disruption of the wzt gene, which encodes the O-polysaccharide (O-PS) export system ATP-binding protein. The level of protection induced by this mutant against <italic toggle="yes">B. melitensis</italic> 16M challenge is similar to that conferred by the <italic toggle="yes">B. melitensis</italic> M5 vaccine. The two advantages of this vaccine are its safety in pregnant animals without inducing abortion as well as its ability to synthesize O-PS without inducing detectable specific antibodies in sheep, which make this vaccine candidate suitable for the eradication of animal brucellosis. The disadvantage reported for this vaccine is its more susceptibility to polymyxin B and complement-mediated killing compared to <italic toggle="yes">B. melitensis</italic> 16M (<xref rid="B29" ref-type="bibr">29</xref>). <italic toggle="yes">RM57</italic> is the other Rough attenuated mutant that is generated from <italic toggle="yes">B. melitensis</italic> isolate M1981 has been administered in different animal models (both mice and 186 guinea pigs) and indicated good protective efficacy, especially in guinea pig model. Another advantage of this mutant includes no interference with serological diagnosis. The drawback of this mutant, which could be associated with its reduced virulence in mice and guinea pigs, is its sensitivity to polymyxin B (<xref rid="B30" ref-type="bibr">30</xref>). <italic toggle="yes">2308DNodVDNodW</italic> rough vaccine originated from the virulent <italic toggle="yes">B. abortus</italic> 2308 (S2308) by deleting genes encoding a two-component regulatory system (TCS) in chromosome II in S2308. In a study, 2308DNodVDNodW showed significantly reduced survival in murine macrophages (RAW 264.7) and BALB/c mice. In this study, the mutant conferred levels of IgG antibody similar to those conferred by S19; also, a slightly higher level of protection was reported for single- and double-mutant NodVW. This mutant induced a mix of Th1- and Th2-type immune responses as well as strong humoral and cell-mediated immunity in immunized mice. Furthermore, this mutant persisted for a short time in RAW 264.7 macrophages and BALB/c mice. Another advantage of this vaccine is the provision of an ideal diagnostic antigen that could be used to differentiate immunized animals from infected ones (<xref rid="B12" ref-type="bibr">12</xref>).</p><p><italic toggle="yes">B. ovis</italic> &#916;<italic toggle="yes">abcBA</italic> (<italic toggle="yes">Bo</italic>&#916;<italic toggle="yes">abcBA</italic>) vaccine, which has been tested in two formulations (encapsulation with alginate and alginate plus vitelline protein B&#8212;VpB), is effective for immunization of mice against <italic toggle="yes">B. melitensis</italic> strain 16M by inducing Th1 (T helper1)-mediated immune responses. Due to its efficacy, the hypothesis of conferring protection against virulent <italic toggle="yes">B. melitensis</italic> in small ruminants could be supported. Also, this vaccine could be administrated for caprine and ovine brucellosis due to <italic toggle="yes">B. melitensis</italic> infection. In rams, this vaccine has an additional advantage, including conferring protection against <italic toggle="yes">B. ovis</italic>, which is another <italic toggle="yes">Brucella</italic> species that commonly infects sheep; immunization with <italic toggle="yes">Bo</italic>&#916;<italic toggle="yes">abcBA</italic> against <italic toggle="yes">B. ovis</italic> is highly protective (<xref rid="B31" ref-type="bibr">31</xref>). In another study &#916;abcBA vaccine could prevent the infection, the secretion of wild-type <italic toggle="yes">B. ovis</italic> in semen and urine of rams, the shedding of neutrophils in semen, and the development of clinical changes and gross lesions induced by wild-type <italic toggle="yes">B. ovis</italic>. This vaccine could induce both humoral and cellular immune responses (<xref rid="B32" ref-type="bibr">32</xref>). In a study conducted by Sancho et al., administration of <italic toggle="yes">B. ovis</italic> attenuated mutants (&#916;omp25d and &#916;omp22) and <italic toggle="yes">B. melitensis</italic> Rev1 vaccines were compared in mice. The study indicated that mice vaccinated with <italic toggle="yes">B. ovis</italic> mutants developed higher serum levels of anti-<italic toggle="yes">B. ovis</italic> antibodies of IgG1, IgG2a, and IgG2b subclasses as well as IL-1&#945;, as an enhancer of T cell responses to antigen, compared to Rev1-vaccinated mice. Immunization with <italic toggle="yes">B. ovis</italic> mutants indicates appropriate persistence, limited splenomegaly, and protective efficacy against <italic toggle="yes">B. ovis</italic>. Also, <italic toggle="yes">B. ovis</italic> mutants vaccine candidates would likely be the most appropriate vaccines against ram contagious epididymitis (<xref rid="B33" ref-type="bibr">33</xref>).</p><p>VTRS2 is the other type of rough vaccine which is originated from <italic toggle="yes">B. suis</italic>. This vaccine was constructed by deletion mutations in genes wboA (encoding glycosyltransferase) and leuB (encoding isopropyl malate dehydrogenase). The strain VTRS2 expressing mGnRH can elicit a significant IgG immune response against the mGnRH antigen at 4 and 6 weeks post-inoculation. The rough <italic toggle="yes">B. suis</italic> strain is an effective vaccine candidate in swine (<xref rid="B34" ref-type="bibr">34</xref>). <italic toggle="yes">B. suis</italic> &#916; <italic toggle="yes">pgm</italic> could stimulate cellular immune responses and induce good levels of protection against the virulent <italic toggle="yes">B. suis</italic> strain, abortion, heifer colonization, and bacterial excretion in milk. Also, using this strain, immunized animals could be differentiated from infected ones. Due to the lack of lipopolysaccharide and the inability to synthesize cyclic beta-glucans, this strain is sensitive to detergents and polymyxin B (<xref rid="B35" ref-type="bibr">35</xref>). Compared to the smooth vaccine, the rough mutant strain of <italic toggle="yes">B. neotomae</italic> stimulates further activation of dendritic cells <italic toggle="yes">in vitro</italic> and confers protection against the heterologous challenge by <italic toggle="yes">B. suis</italic> in mice (<xref rid="B36" ref-type="bibr">36</xref>).</p><p><italic toggle="yes">B. abortus</italic> 2308 ery promoter mutant (&#916;ery) safety is evaluated by the lack of splenomegaly in inoculated mice. This vaccine has good protective efficacy and could induce the secretion of higher levels of IFN-&#947; and IL-4 compared to S19. Post-vaccination humoral responses provide an ideal diagnostic EryA antigen for the differentiation of immunization from infection using EryA-iELISA. Also, sensitivity to erythritol and reduced survival in macrophages and BALB/c mice could be observed in this vaccine (<xref rid="B37" ref-type="bibr">37</xref>). <italic toggle="yes">IVK15</italic>&#916;<italic toggle="yes">cydD and IVK15</italic>&#916;<italic toggle="yes">cydC</italic> mutants are created by deleting only <italic toggle="yes">cydD</italic> and <italic toggle="yes">cydC</italic> genes, encoding ATP-binding cassette transporter proteins, from the chromosome of the virulent <italic toggle="yes">B. abortus</italic> strain isolated from Korean cow (referred to as IVK15). Mice immunization with these mutants could protect them against the virulent <italic toggle="yes">B. abortus</italic> strains and S2308. Also, higher levels of anti-<italic toggle="yes">Brucella</italic>-specific IgG, IgG1, and IgG2a antibodies and higher levels of IgG2a than IgG1 could be observed in immunized mice compared to unvaccinated mice. Splenomegaly is a consequence of inflammatory responses is not observed in immunized mice with IVK15&#916;<italic toggle="yes">cydD</italic> and IVK15&#916;<italic toggle="yes">cydC</italic>. Both mutants exhibit increased sensitivity to metal ions, acidic pH, and hydrogen peroxide, which resemble the intracellular environment during host infection (<xref rid="B11" ref-type="bibr">11</xref>). The <italic toggle="yes">B. abortus</italic> S2308 mutant strain &#916;22915 is constructed by deleting the putative lytic transglycosylase gene <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="BAB_RS22915" ext-link-type="DDBJ/EMBL/GenBank">BAB_RS22915</ext-link>. This mutant induces an effective immune response with fewer inflammatory responses. Higher levels of antibody and better protection against <italic toggle="yes">B. abortus</italic> S2308 are induced by &#916;22915 mutant compared with RB51 (<xref rid="B12" ref-type="bibr">12</xref>). Several mutants listed in <xref rid="T2" ref-type="table">Table 2</xref>, such as &#916;<italic toggle="yes">mucR</italic> and &#916;<italic toggle="yes">vjbR</italic>, have been studied to evaluate the level of protection and the ability to induce humoral and cellular responses (<xref rid="B23" ref-type="bibr">23</xref>&#8211;<xref rid="B25" ref-type="bibr">25</xref>). Understanding the immune responses and protective mechanisms against <italic toggle="yes">Brucella</italic> infection is important for the development of an effective vaccine. T-cell subsets and antibody responses are necessary to confer protection against virulent stains. Cytokine profiles, including TNF-&#945;, IFN-&#947;, IL-1, and IL-12, contribute to controlling <italic toggle="yes">Brucella</italic> infection in its early stages. Therefore, inducing a high level of immune system responses contributes to the effectiveness of vaccines and should be considered in vaccine development (<xref rid="B14" ref-type="bibr">14</xref>). The main features of these vaccine candidates are mentioned in <xref rid="T2" ref-type="table">Table 2</xref>. However, in all the reviewed studies, the positive aspects of these candidates have been mentioned, but the drawbacks of these candidates must also be considered, including not complete elimination of persistent strains (<xref rid="B44" ref-type="bibr">44</xref>) or the risk of spreading antibiotic resistance in cloning procedures. In addition, they should be evaluated in livestock and trial studies (<xref rid="B45" ref-type="bibr">45</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Introduced genetically engineered live-attenuated vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Name of vaccine</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Advantage</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>References</bold>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Double deletion mutants of <italic toggle="yes">B. abortus</italic> (BA15&#916;<italic toggle="yes">cydC</italic>&#916;<italic toggle="yes">cydD</italic> and BA15&#916;<italic toggle="yes">cydC</italic>&#916;<italic toggle="yes">purD</italic>)</td><td valign="top" align="left" rowspan="1" colspan="1">- Incapability of intracellular survival and replication within macrophages<break/>- Attenuated virulence and limited persistence in the host<break/>- Conferring long-term protection in mice<break/>- Inducing significant levels of IgG antibodies<break/>- Inducing significant amounts of IFN-&#947; and IL-10<break/>- Conferring a high level of protection with each mutant<break/>- Level of safety</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B19" ref-type="bibr">19</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M&#916;<italic toggle="yes">hfq</italic></td><td valign="top" align="left" rowspan="1" colspan="1">- Attenuated virulence and limited persistence in the host<break/>- Inducing significant levels of IgG1and IgG2a antibodies<break/>- Inducing higher amounts of IFN-&#947; and IL-4<break/>- Level of safety<break/>- Conferring a high level of protection</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B20" ref-type="bibr">20</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M&#916;TcfSR</td><td valign="top" align="left" rowspan="1" colspan="1">- Conferring a high level of protection<break/>- Significantly inducing higher IgG levels<break/>- Inducing higher amounts of IFN-&#947;<break/>- Inducing high levels of IgG<break/>- Differentiation between the vaccination and infection</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B28" ref-type="bibr">28</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> M5-90&#916;<italic toggle="yes">bp26</italic></td><td valign="top" align="left" rowspan="1" colspan="1">- Conferring slightly better protection than M5-90<break/>- Low virulence and higher immunoprotectivity following 16M strain challenge<break/>- Inducing higher amounts of IL-6 and TNF-&#945;<break/>- Eliciting an anti-<italic toggle="yes">Brucella</italic>-specific IgG response</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B21" ref-type="bibr">21</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensi</italic>s LVM31 mutant strain</td><td valign="top" align="left" rowspan="1" colspan="1">- Conferring protection similar to that induced by the <italic toggle="yes">B. melitensis</italic> Rev1 vaccine strain<break/>- Decreasing splenic colonization<break/>- Presenting no lesions or apparent histopathological changes<break/>- Significantly lower persistence of bacteria in the spleen</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B22" ref-type="bibr">22</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> IVKB9007 <italic toggle="yes">looP</italic>::Tn<italic toggle="yes">5</italic> and <italic toggle="yes">cydC</italic>::Tn<italic toggle="yes">5</italic></td><td valign="top" align="left" rowspan="1" colspan="1">- Conferring a high level of protection<break/>- Significantly attenuated virulence</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B38" ref-type="bibr">38</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M&#916;<italic toggle="yes">hfq</italic></td><td valign="top" align="left" rowspan="1" colspan="1">- Conferring a high level of protection<break/>- Inducing higher amounts of IFN-&#947; and IL-4<break/>- Downregulating the expression of IL-2 and IL-10 in mice in the 16M&#916;hfq group, while upregulating expression of IL-4 and IFN-&#947;<break/>- Significantly inducing higher antibody levels in the <italic toggle="yes">hfq</italic> mutant-immunized mice at 14 and 28 days post-challenge compared to the PBS group as control</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B39" ref-type="bibr">39</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> M5-90&#916;<italic toggle="yes">vjbR</italic></td><td valign="top" align="left" rowspan="1" colspan="1">- Reduced survival capability in macrophages<break/>- Conferring a high level of protection<break/>- Serological differentiation between infected and vaccinated animals<break/>- Significantly attenuated virulence<break/>- Inducing significant levels of IgG antibodies<break/>- Significantly inducing higher amounts of IFN-&#947; and IL-4</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B23" ref-type="bibr">23</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. canis</italic> RM6/66 &#916;<italic toggle="yes">vjbR</italic></td><td valign="top" align="left" rowspan="1" colspan="1">- Conferring a significant level of protection against organ colonization and development of histopathologic lesions following intraperitoneal challenge<break/>- Inducing a significant increase in IgG1 and IgG2a levels<break/>- Significantly inducing higher levels of IFN-&#947;</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B24" ref-type="bibr">24</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M&#916;<italic toggle="yes">mucR</italic></td><td valign="top" align="left" rowspan="1" colspan="1">- Conferring a significant level of protection following both intraperitoneal and aerosol challenge<break/>- Absence of <italic toggle="yes">Brucella</italic> associated pathological changes, including splenomegaly, hepatomegaly, or granulomatous disease<break/>- Eliciting a strong protective immunity<break/>- Significantly reducing the colonization compared to the parental strain</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B25" ref-type="bibr">25</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> &#916;<italic toggle="yes">znuA</italic></td><td valign="top" align="left" rowspan="1" colspan="1">- Oral live vaccine candidate &#916;<italic toggle="yes">znuA B. melitensis</italic> induces protection against nasal challenge with wt <italic toggle="yes">B. melitensis</italic> 16M<break/>- Rapid clearance from mice within 2 weeks<break/>- Conferring an effective protection in mice upon nasal challenge<break/>- Enhancing clearance of <italic toggle="yes">Brucella</italic> from the lungs and spleen<break/>- Inducing both systemic and mucosal Th1 and Th17 responses, while Th17 produces IL-17 and IL-22</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B26" ref-type="bibr">26</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> M5-90&#916;<italic toggle="yes">manB</italic></td><td valign="top" align="left" rowspan="1" colspan="1">- Significantly reduced survival in macrophages and mice<break/>- Inducing a strong protective immunity in BALB/c mice<break/>- Eliciting anti-<italic toggle="yes">Brucella</italic>-specific IgG1 and IgG2a subtype responses<break/>- Inducing the secretion of IFN-&#947; and IL-4<break/>- Serological differentiation between infected and vaccinated animals</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B21" ref-type="bibr">21</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">B. melitensis M5-90Dpgm</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">- Significantly reduced survival in embryonic trophoblast cells and in mice<break/>- Conferring a high protective immunity in BALB/c mice<break/>- Eliciting an anti-<italic toggle="yes">Brucella</italic>-specific immunoglobulin G response<break/>- Inducing the secretion of IFN-&#947; and IL-2<break/>- Serological differentiation between infected and vaccinated animals<break/>- Inducing the secretion of IFN-&#947; in immunized sheep</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B27" ref-type="bibr">27</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> &#916;<italic toggle="yes">norD</italic> &#916;<italic toggle="yes">znuA</italic></td><td valign="top" align="left" rowspan="1" colspan="1">- Highly attenuated in mouse and human macrophages<break/>- Complete clearance from mouse spleens within 8 weeks post-vaccination<break/>- Significantly inducing more protection than the conventional RB51 vaccine<break/>- Significantly inducing higher levels of IFN-&#947; and TNF-&#945;<break/>- Conferring a high level of protection</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B40" ref-type="bibr">40</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. ovis</italic> &#916;abcBA</td><td valign="top" align="left" rowspan="1" colspan="1">- Preventing the infection, the secretion of wild type <italic toggle="yes">B. ovis</italic> in semen and urine, the shedding of neutrophils in semen<break/>- Development of clinical changes as well as gross and microscopic lesions induced by wild type <italic toggle="yes">B. ovis</italic> reference strain<break/>- Inducing humoral and cellular immune responses</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B32" ref-type="bibr">32</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. ovis</italic> (&#916;omp25d and &#916;omp22)</td><td valign="top" align="left" rowspan="1" colspan="1">- <italic toggle="yes">B. ovis</italic> mutants: appropriate persistence, limited splenomegaly, and protective efficacy against <italic toggle="yes">B. ovis</italic>- <italic toggle="yes">B. ovis</italic> attenuated strain: probably the most interesting candidate to develop a specific vaccine against ram contagious epididymitis<break/>- <italic toggle="yes">B. ovis</italic> mutants: developing anti-<italic toggle="yes">B. ovis</italic> antibodies in serum<break/>- <italic toggle="yes">B. ovis</italic> &#916;omp25d: representing a spleen colonization profile similar to that of <italic toggle="yes">B. melitensis</italic> Rev 1 and <italic toggle="yes">B. ovis</italic> &#916;omp22 and eliciting only a moderate degree of splenomegaly<break/>- <italic toggle="yes">B. ovis</italic> &#916;omp25d and &#916;omp22: inducing protective activity and a limited degree of splenomegaly</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B33" ref-type="bibr">33</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. ovis</italic> IVK15&#916;<italic toggle="yes">cydD</italic> and IVK15&#916;<italic toggle="yes">cydC</italic></td><td valign="top" align="left" rowspan="1" colspan="1">- Reduced intracellular survival in macrophages<break/>- Wild-type IVK15 induces splenomegaly due to inflammatory responses, but not IVK15&#916;<italic toggle="yes">cydD</italic> and IVK15&#916;<italic toggle="yes">cydC</italic>.<break/>- Rapid elimination from the spleens<break/>- Significantly inducing higher levels of <italic toggle="yes">Brucella</italic>-specific IgG, IgG1, and IgG2a responses mostly induced by Th1<break/>- Possessing sufficient immunogenic properties to confer protective immunity in mice against <italic toggle="yes">B. abortus</italic> infection<break/>- Markedly attenuated virulence both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic></td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B11" ref-type="bibr">11</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> mutant strain &#916;22915</td><td valign="top" align="left" rowspan="1" colspan="1">- Inducing fewer inflammatory responses than the wild-type strain<break/>- Inducing an effective immune response against the wild-type strain S2308.<break/>- Decreasing bacterial loads after vaccination for up to 4 wpv<break/>- Increasing specific antibody titers to a peak at 12 wpv<break/>- Inducing higher levels of antibody and providing longer and better protection against <italic toggle="yes">B. abortus</italic> S2308 than RB51<break/>- Significantly attenuated virulence of the mutant strain &#916;22915</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B12" ref-type="bibr">12</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> M5-90 wboA</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Faster response<break/>&#8226; Safety<break/>&#8226; Reduced virulence and inflammatory response<break/>&#8226; Inducing a high level of protection<break/>&#8226; Suitable live vaccine candidate</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B10" ref-type="bibr">10</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 2308DNodVDNodW</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Significantly reduced virulence<break/>&#8226; Inducing a slightly higher level of protection than the <italic toggle="yes">B. abortus</italic> vaccine S19<break/>&#8226; Inducing a mix of Th1- Th2, humoral, and cellular immunity<break/>&#8226; Persistence for a short period of time in RAW 264.7 macrophages and BALB/c mice, thereby reducing virulence of <italic toggle="yes">Brucella</italic><break/>&#8226; Suitable live vaccine candidates</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B41" ref-type="bibr">41</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. canis vjbR</italic> mutant strain</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Inducing no impairment in bacterial growth rate or obvious pathological damage<break/>&#8226; Inducing a considerable protective immune response against <italic toggle="yes">B. canis</italic> RM6/66 strain</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B42" ref-type="bibr">42</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 2308&#916;gntR</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Inducing humoral immunity, cytokine responses, and high protective immunity against the virulent strain<break/>&#8226; Eliciting an anti-<italic toggle="yes">Brucella</italic>-specific immunoglobulin G (IgG) response<break/>&#8226; Inducing the secretion of IFN-&#947; and IL-4</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B43" ref-type="bibr">43</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. suis</italic> Delta-pgm</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; <italic toggle="yes">B. suis</italic> pgm strain is able to trigger a robust cellular immune response.<break/>&#8226; Inducing a significant level of protection against the virulent <italic toggle="yes">B. suis</italic><break/>&#8226; Inducing high levels of protection against abortion, heifer colonization, and excretion in milk<break/>&#8226; Replication in cultured cells<break/>&#8226; Completely avirulent in the mouse model of infection, but inducing protection against the virulent strain challenge<break/>&#8226; Inducing the production of pro-inflammatory cytokines</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B35" ref-type="bibr">35</xref>)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">IFN, Interferon; TNF, Tumor necrosis factor; IL, interleukin; Th, T helper; IgG, Immunoglobulin G</italic>.</p></table-wrap-foot></table-wrap></sec><sec id="s3"><title>Vector Vaccines</title><p>Recently, various viral or bacterial vector-based <italic toggle="yes">Brucella</italic> vaccines have been fostered as efficient delivery systems to deliver different heterologous or homologous antigens (<xref rid="B46" ref-type="bibr">46</xref>). They are live vector-based genetically modified vaccines (<xref rid="B47" ref-type="bibr">47</xref>). Cell-mediated immune responses induced by intracellular organisms may represent that the best choice is to present <italic toggle="yes">Brucella</italic> antigens to the immune system of the target host; the main goal of these candidates is to promote the formation of an antigen-specific T-cell immune response (<xref rid="B48" ref-type="bibr">48</xref>). These types of vaccines replicate in the host cell, producing multiple copies of the <italic toggle="yes">Brucella</italic> antigen (<xref rid="B49" ref-type="bibr">49</xref>). There are various bacterial or viral vectors for the expression of <italic toggle="yes">Brucella</italic> proteins, including Lactococcus <italic toggle="yes">Lactis, Escherichia coli, Salmonella</italic> strains, or influenza virus (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B50" ref-type="bibr">50</xref>). Each of these vectors has several advantages and disadvantages. <italic toggle="yes">Salmonella</italic>, as an intracellular pathogen, delivers antigens effectively to antigen-presenting cells such as macrophages. Other advantages of using <italic toggle="yes">Salmonella</italic> as a vector include inherent adjuvant effect, adequacy of a single-dose vaccination to obtain long-lasting immunity, the ability to multiply and present multiple antigens, and dynamic entrance into the natural barrier protecting antigens from host degenerative enzymes. Some research studies have indicated that multiple infections caused by <italic toggle="yes">Salmonella</italic> could lead to increased disease outcomes in infected animals. The potentiation of this pathogenesis may be due to the immunomodulatory effect of <italic toggle="yes">Salmonella</italic>, which inhibits or delays the host immune response and promotes systemic <italic toggle="yes">Salmonella</italic> infection. In acute conditions, salmonellosis could also cause miscarriage and death, which could lead to reduced animal productivity (<xref rid="B51" ref-type="bibr">51</xref>). Influenza viral vectors (IVV) have also been developed due to the lack of pre-existing immunity against H5N1 influenza virus in the human population (<xref rid="B47" ref-type="bibr">47</xref>). There is a confirmed IVV-based <italic toggle="yes">B. abortus</italic> vaccine (Flu-BA) developed in Kazakhstan for cattle vaccination; although bovines are not highly susceptible hosts to influenza A virus infection, and there is a natural immunity to influenza infection in this host. However, it could be more effective for humans because influenza A is a common human infection. There is widespread concern about the use of IVV of the H5N1 subtype, which is a pathogenic influenza virus spreading in poultry. The main concern is related to the interspecies transmission of the disease from birds to humans, which could lead to human disease. Although the replication capacity of this virus has been limited in this vaccine by eliminating the proteolytic cleavage site in HA, the risk of pandemic strains must be considered (<xref rid="B52" ref-type="bibr">52</xref>). Lactic acid bacteria (LAB) are also considered a desirable antigen delivery system for mucosal immunization. It has been reported that <italic toggle="yes">L. casei</italic>-based vaccines show a protective response against challenges (<xref rid="B53" ref-type="bibr">53</xref>). Recently, mucosal vaccination has been considered because the main route of natural transmission of brucellosis is usually through mucosal exposure. One of the disadvantages of using live LAB-based mucosal vaccines is related to the risk of spreading genetically engineered organisms carrying drug resistance markers to the environment and the host flora. In addition, <italic toggle="yes">L. lactis</italic> strains are considered to be non-colonizing bacteria that survive when passing through the gastrointestinal tract (GIT) and trigger immune responses when taken up by M cells (<xref rid="B54" ref-type="bibr">54</xref>). Adenovirus-based vaccines are another type of vector vaccine with several disadvantages including high levels of pre-existing immunity, transient expression of the transgene, and highly immunogenic (<xref rid="B55" ref-type="bibr">55</xref>). Moreover, due to the complexity of the target pathogen, multiple antigens are required to enhance effective immune responses, which incur more clinical evaluations and higher manufacturing costs (<xref rid="B56" ref-type="bibr">56</xref>).</p><p>Different antigens are used for developing this type of vaccine, such as proline racemase subunit A (PrpA), Cu/Zn superoxide dismutase (SOD), <italic toggle="yes">Brucella</italic> lumazine synthase (BLS), lipoprotein outer-membrane protein 19(Omp19) (<xref rid="B57" ref-type="bibr">57</xref>), and ribosomal protein L7/L12 (<xref rid="B58" ref-type="bibr">58</xref>). These antigens efficiently induce immune responses restricting the pathogen in the early stages of infection. The function of antigen-presenting cells such as macrophages and dendritic cells is to stimulate the production of specific antibodies, T cells responses such as CD4<sup>+</sup> and CD8<sup>+</sup>, and the secretion of cytokines involved in bacterial resistance and elimination. BLS, Omp19, PrpA, and SOD could efficiently induce the secretion of Th1-type cytokines. PrpA also stimulates B cell responses. Omp19 induces Th1 responses and mouse dendritic cell maturation. In a study, an attenuated <italic toggle="yes">S. typhimurium</italic> strain expressing BLS, Omp19, PrpA, or SOD of <italic toggle="yes">B. abortus</italic> in goats was shown to elicit strong cell-mediated immune responses against PrpA, BLS, Omp19, and SOD, but greater humoral responses were elicited against Omp19 and SOD. This type of vaccine could provide a high level of protection for individual groups. Regardless of high protection, this type of vaccine requires multiple boosters and adjuvants to obtain long-lasting immunity, but without affecting bacterial viability (<xref rid="B57" ref-type="bibr">57</xref>). <italic toggle="yes">Brucella</italic> ribosomal protein L7/L12 has a high antigenicity due to the dominant epitopes. The combination of protein L7/L12 with <italic toggle="yes">Salmonella</italic> delivery system (JOL1800 strain) induces humoral and cell-mediated immune responses. High numbers of stimulated cells, including CD4<sup>+</sup> and CD8<sup>+</sup> T cells, and the production of IFN-&#947; have been reported in L7/L12-immunized mice. Besides the high antigenicity of L7/L12, the JOL1800 strain has a high level of safety, and a single dose of vaccine effectively eliminates the pathogen (<xref rid="B58" ref-type="bibr">58</xref>). Oral administration of attenuated <italic toggle="yes">Salmonella</italic> strain secreting <italic toggle="yes">Brucella</italic> antigens, including Cu&#8211;Zn superoxide dismutase (SodC) and outer membrane protein 19 (Omp19), with sodium bicarbonate antacid, significantly induces the secretion of a high level of systemic IgG and a mixed Th1&#8211;Th2 response. The rate of <italic toggle="yes">Salmonella</italic> colonization following the development of this type of vaccine has increased, stimulating protective immune responses (<xref rid="B59" ref-type="bibr">59</xref>). Attenuated <italic toggle="yes">Salmonella</italic> strains expressing <italic toggle="yes">B. abortus</italic> BCSP31, Omp3b, and superoxide dismutase proteins have also been investigated as a vaccine candidates (<xref rid="B60" ref-type="bibr">60</xref>).</p><p>Numerous recombinant viral vector vaccines have been evaluated so far. In a study, an influenza viral vector of the H5N1 subtype, as a non-replicable viral vector, expressing <italic toggle="yes">Brucella</italic> Omp16, L7/L12, Omp19, and Cu&#8211;Zn SOD immunodominant proteins was investigated in guinea pigs against human brucellosis. Although no immune response was reported in this study, different administration routes and vaccine doses were evaluated. To determine the best immunization route, different routes were evaluated, such as conjunctival (c.), intranasal (i.n.), and sublingual (s.l.). A significant protective effect was reported for this vaccine when administered through i.n. (2.8 log <sub>10</sub>) and c. (2.3 log <sub>10</sub>) administration routes, comparable to <italic toggle="yes">B. melitensis</italic> Rev1 vaccine results; also, the optimum dose conferring a high level of protection was determined to be 10<sup>6</sup> EID50 and 10<sup>7</sup> EID50 (<xref rid="B47" ref-type="bibr">47</xref>). Recently, Bugybayeva et al. suggested the tetravalent vaccine formulation Flu-NS1-80-Omp16+Flu-NS1-80-L7/L12+Flu-NS1-80-Omp19+Flu-NS1-80-SOD to develop a safe and effective human vaccine. In this study, a recombinant influenza viral vector (rIVV) of H5N1 subtype, expressing <italic toggle="yes">Brucella</italic> L7 / L12, Omp16, Omp19, or Cu-Zn SOD immunodominant protein containing a sequence of 80 N-terminal amino acids from the open reading frame (ORF) of the NS1 gene, was evaluated. The results of this study indicated that this formulation had a high level of safety and efficacy. This research is an important report on the development of a safe and protective vaccine against human brucellosis (<xref rid="B52" ref-type="bibr">52</xref>). In another study, recombinant influenza A viruses of the subtypes H5N1 and H1N1, expressing L7/L12 or Omp16, were developed and shown to elicit Th1 CD4<sup>+</sup> and CD8<sup>+</sup> T-cell immune responses and confer good protection against challenge (<xref rid="B61" ref-type="bibr">61</xref>). The expression of BP26 as a highly conserved immunogenic protein in <italic toggle="yes">Brucella</italic> by pseudorabies virus was also screened as a vaccine candidate in another study by Yao et al. This type of vaccine can induce humoral and cellular immune responses. The extensive tropism of this vaccine makes it a suitable vector (<xref rid="B62" ref-type="bibr">62</xref>). Guo-Zhen et al. reported that Adenovirus-LL/BP vaccinated mice had higher levels of IgG, IgG1, and IgG2a antibodies. Their study results indicated that this vaccine-induced primarily cellular and partially humoral immunity and provided a mild protection level against <italic toggle="yes">B. abortus</italic> infection. Although this type of vaccine conferred significant protection against challenge, the level of protection was lower compared to the live A19 vaccine (<xref rid="B55" ref-type="bibr">55</xref>). As mentioned earlier, probiotics such as <italic toggle="yes">L. casei</italic> are considered as a vector to elicit a good immune response and a high level of protection comparable to that induced by the IRIBA Strain Vac Calf vaccine. <italic toggle="yes">L. casei</italic> strains expressing the outer membrane protein OMP19 prompt Th1/Th2 immune responses and the production of IFN-&#947;, IL-2, and IL-4. As <italic toggle="yes">Brucella</italic> is an intracellular pathogen, cell-mediated immune responses are required to control the pathogen. Therefore, immunodominant antigens should be considered in developing new vaccines to stimulate cellular immune responses. In this regard, the production of cytokines such as IFN-&#947;, IL-2, and IL-4 is critical (<xref rid="B53" ref-type="bibr">53</xref>). The initial step of infection occurs in mucosal areas; thus, mucosal vaccination could be done to elicit a good response. In this context, mucosal administration of <italic toggle="yes">L. casei</italic> or <italic toggle="yes">L. lactis</italic> vector vaccines, generally regarded as safe, is a potential vaccine delivery approach. It has been suggested that the danger of eliciting immunological tolerance may also be faded compared with the persistent strains (<xref rid="B63" ref-type="bibr">63</xref>). Although other viral and bacterial vectors have been investigated, it should be noted that to introduce a safe vaccine, the non-pathogenicity of organisms must be proven (<xref rid="T3" ref-type="table">Table 3</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Characteristics of the vector-based vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Vector</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Antigens</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Host</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Challenge</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Advantage</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Disadvantage</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>References</bold>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">S. typhimurium</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">BLS, Omp19, PrpA, or SOD</td><td valign="top" align="left" rowspan="1" colspan="1">Goat</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">Brucella</italic> strain- HJL254</td><td valign="top" align="left" rowspan="1" colspan="1">1. Safety of vaccine<break/>2. Higher titers of IgG against Omp19<break/>3. Successful delivery of Omp19<break/>4. Higher production of IFN-&#947; in SOD stimulated goats<break/>5. A significant level of protection with individual antigens in vaccine<break/>6. A strong cell-mediated immune response</td><td valign="top" align="left" rowspan="1" colspan="1">1. Low levels of anti-PrpA and -BLS IgG<break/>2. Limited scope of efficacy of this vaccine (generally &lt; 2 log10 units)<break/>3. Several boosters would be required to achieve a long-term immunity.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B57" ref-type="bibr">57</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">S. typhimurium</italic> JOL1800</td><td valign="top" align="left" rowspan="1" colspan="1">Ribosomal protein L7/L12</td><td valign="top" align="left" rowspan="1" colspan="1">Mice</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544</td><td valign="top" align="left" rowspan="1" colspan="1">1. Efficient elicitation of both IgG (IgG1 and IgG2a) and sIgA<break/>2. A significant increase in IFN-&#947; and IL-4 expression levels<break/>3. A significant increase in both CD4<sup>+</sup> and CD8<sup>+</sup> expressing cells<break/>4. Enhancing the chance of antigen presentation by <italic toggle="yes">Salmonella</italic> secreting L7/L12 antigen<break/>5. Clearly inducing both IgG and IgA by a single dose<break/>6. JOL1800 strain induces no mortality in immunized mice due to attenuation by deletion of <italic toggle="yes">lon, cpxR</italic>, and <italic toggle="yes">rfaL</italic> genes.<break/>7. Minimum pre-existing lipopolysaccharides (LPS)-specific anti-<italic toggle="yes">Salmonella</italic> immunity in the host</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B58" ref-type="bibr">58</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">S. typhimurium</italic> (ST) strain JOL1800</td><td valign="top" align="left" rowspan="1" colspan="1">Cu&#8211;Zn superoxide dismutase (SodC) and outer membrane protein 19 (Omp19)</td><td valign="top" align="left" rowspan="1" colspan="1">Mice</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> strain 544</td><td valign="top" align="left" rowspan="1" colspan="1">1. Enhancement of humoral and cellular immune responses and subsequent protection due to the use of sodium bicarbonate antacid formulation<break/>2. PH buffering action around the neutral values could be particularly an advantage for the present vaccine strain to produce an effective immune response.<break/>3. Increasing the number of <italic toggle="yes">Salmonella</italic> in the intestinal environment<break/>4. Activation of both Th1 and Th2 antibody responses</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B59" ref-type="bibr">59</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HJL228, HJL219, and HJL213</td><td valign="top" align="left" rowspan="1" colspan="1">BSCP31, Omp3b and superoxide dismutase</td><td valign="top" align="left" rowspan="1" colspan="1">Mice</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> strain 544</td><td valign="top" align="left" rowspan="1" colspan="1">1. Significantly inducing higher serum levels of IgG, TNF&#945;, and IFN-&#947; in group E (immunized with ~1&#215;10<sup>6</sup> CFU)<break/>2. Significantly inducing higher levels of TNF-&#945; in response to all antigens in groups D (immunized with ~1&#215;10<sup>5</sup> CFU) and E<break/>3. Significantly inducing higher levels of IFN-&#947; in response to all antigens in groups D and E than in groups A (immunized with PBS) and B (immunized with <italic toggle="yes">Salmonella</italic> containing vector only)</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B60" ref-type="bibr">60</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Influenza viral vectors (rIVV) subtypes H5N1</td><td valign="top" align="left" rowspan="1" colspan="1">Omp 16, L7/L12, Omp19, or Cu&#8211;Zn SOD</td><td valign="top" align="left" rowspan="1" colspan="1">Guinea pigs</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16 M</td><td valign="top" align="left" rowspan="1" colspan="1">1. Inducing a significant protection after intranasal (<italic toggle="yes">i.n</italic>.) administration of the vaccine<break/>2. Comparability of the protection level induced by conjunctival (<italic toggle="yes">c</italic>.) administration route to that induced by the commercial <italic toggle="yes">B. melitensis</italic> Rev1 vaccine<break/>3. Inducing the highest level of protection (vaccination efficiency) against the infection in guinea pigs immunized at doses of 10<sup>6</sup> EID50 and 10<sup>7</sup> EID50 (80%) compared with the control group (PBS) after the challenge</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B47" ref-type="bibr">47</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Influenza viral vector (rIVV) subtype H5N1</td><td valign="top" align="left" rowspan="1" colspan="1">Omp 16 and 19, ribosomal L7/L12, and Cu-Zn superoxide dismutase (SOD)</td><td valign="top" align="left" rowspan="1" colspan="1">Mice and guinea pigs</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M</td><td valign="top" align="left" rowspan="1" colspan="1">1. Tetravalent formulation is a safe vector, and its protective efficacy against <italic toggle="yes">B. melitensis</italic> 16M infection in the prime-boost regimen is comparable to that induced by the commercial <italic toggle="yes">B. melitensis</italic> Rev1 vaccine in mouse and guinea pig models.</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B52" ref-type="bibr">52</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Influenza viral vectors (IVV) subtypes A/H5N1</td><td valign="top" align="left" rowspan="1" colspan="1">Omp16, L7/L12, Omp19, or Cu-Zn superoxide dismutase (SOD)</td><td valign="top" align="left" rowspan="1" colspan="1">Sheep and goats</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B50" ref-type="bibr">50</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pseudorabies virus</td><td valign="top" align="left" rowspan="1" colspan="1">BP26</td><td valign="top" align="left" rowspan="1" colspan="1">Mice</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">1. The virus is infective and fatal for most livestock.<break/>2. Its multiple species tropism makes PRV vaccine virus as one of the best vectors to develop bivalent or trivalent vaccines.</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B62" ref-type="bibr">62</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Adenovirus</td><td valign="top" align="left" rowspan="1" colspan="1">L7/L12 and BCSP31</td><td valign="top" align="left" rowspan="1" colspan="1">Mice</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> strain CVCC12</td><td valign="top" align="left" rowspan="1" colspan="1">1. Eliciting higher IgG, IgG1, and IgG2a antibody levels<break/>2. Inducing high levels of IL-12 (Th1-type cytokine) and IL-10 (Th2 type cytokine)</td><td valign="top" align="left" rowspan="1" colspan="1">Weaker efficacy of this vaccine than that of the live A19 vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B55" ref-type="bibr">55</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">L. casei</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">OMP19</td><td valign="top" align="left" rowspan="1" colspan="1">Mice</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544</td><td valign="top" align="left" rowspan="1" colspan="1">1. Increasing serum levels of IFN&#947;, IL-2, and IL-4<break/>2. Immunization with recombinant <italic toggle="yes">L. casei</italic>- OMP19 prompts a mixed Th1/Th2 immune response.<break/>3. Significantly inducing a high level of protection<break/>4. Comparability of the protection level obtained with recombinant <italic toggle="yes">L. casei</italic> to that acquired by the IRIBA Strain Vac Calf vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B53" ref-type="bibr">53</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">L lactis</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Cu,Zn superoxide dismutase</td><td valign="top" align="left" rowspan="1" colspan="1">Mice</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 2308</td><td valign="top" align="left" rowspan="1" colspan="1">1. Inducing protective immune responses at the mucosal level<break/>2. Eliciting agent-specific immunity at the systemic level<break/>3. Induction of systemic and mucosal SOD specific-immune responses in mice orally immunized with <italic toggle="yes">L. lactis</italic> genetically modified to secrete SOD</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B63" ref-type="bibr">63</xref>)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">NR, not reported; IFN, Interferon; TNF, Tumor necrosis factor; IL, interleukin; Th, T helper; IgG, Immunoglobulin G; Omp, outer membrane protein; SOD, Superoxide dismutase; sIgA, Secretory Immunoglobulin A; CFU, colony-forming unit; PRV, Pseudorabies virus</italic>.</p></table-wrap-foot></table-wrap></sec><sec id="s4"><title>Subunit Vaccines</title><p>Brucellosis is a chronic zoonotic disease that is mainly transmitted from animals to humans and could pose significant risks to public health and safety. <italic toggle="yes">Brucella</italic> spp. but only is an intracellular pathogen that survives within neutrophil leukocytes without inducing significant activation, also strongly resistant to the bactericidal action of antimicrobial peptides and serum (<xref rid="B64" ref-type="bibr">64</xref>). Thus, the successful development of brucellosis vaccines is a major challenge. Vaccination is a major policy decision to prevent both animal and human brucellosis. The subunit vaccines are promising vaccine candidates due to their safety profile, well-defined non-infectious nature, inability to revert to a virulent strain, non-viability unlike attenuated vaccines, ability to induce the production of high levels of antibody, and capability of manipulation to maximize desirable activities. The formulation of these vaccines is the use of a recombinant highly-conserved protein that could affect multiple <italic toggle="yes">Brucella</italic> species. However, they could not replicate and mimic a natural <italic toggle="yes">Brucella</italic> infection (tissue and cell tropism) and therefore provide a lower protective efficacy compared with live-attenuated vaccines (<xref rid="B65" ref-type="bibr">65</xref>). The poor antigenicity, instability, and short half-life of recombinant subunit antigens are the main impediments in the design of an effective subunit vaccine against brucellosis (<xref rid="B66" ref-type="bibr">66</xref>). In this context, the use of adjuvants, immunomodulators, antigen delivery systems, or TLR (toll-like receptor) ligands is necessary to enhance well-balanced immune responses. The type of induced immune response depends on the type of antigen and adjuvant used in recombinant <italic toggle="yes">Brucella</italic> protein vaccines. Freund's adjuvant (the most commonly used adjuvant), Alum adjuvant, and aluminum hydroxide (the only adjuvant licensed for use in human vaccines) generate Th2-type immune responses, while monophosphoryl lipid A and CpG induce Th1-type responses. To screen and evaluate protective antigens, a combination of an appropriate antigen, adjuvant, booster, and delivery vehicle/vector is needed to trigger a strong protective immune response, such as the Th1 immune response as the dominant immunity against brucellosis (<xref rid="B44" ref-type="bibr">44</xref>). For the development of an effective vaccine against intracellular pathogen represented by <italic toggle="yes">Brucella</italic>, the production of Th1- derived cytokines (IL-12, TNF&#945;, IFN&#947;) as well as the activation of macrophages, dendritic cells, and CD4+ and CD8+ T cells are the key factors for the clearance of infection; whereas Th2 immune responses, which are induced by the humoral immune system, have a minor role in the clearance of infection (<xref rid="B67" ref-type="bibr">67</xref>). Cytokines play a main role in the development, maturation, differentiation, and activation of immune cells. For instance, IL-4 (Th2 cytokines) induces IgG1 antibody formation by differentiation of naive CD4+ T cells into Th2 cells, whereas IFN-&#947; (Th1 cytokines) induces IgG2 antibody formation by differentiation of naive CD4<sup>+</sup> T cells into Th1 cells (<xref rid="B68" ref-type="bibr">68</xref>). IL-10 is an immune-regulatory cytokine that induces the balance of Th1 or Th2 immune responses to prevent over activity of the immune system and limit further tissue damage (<xref rid="B69" ref-type="bibr">69</xref>). Numerous cell surface and intracellular components could be expressed by <italic toggle="yes">E. coli</italic> and serve as protective antigens in mouse models, such as outer Omp2b, OMP16, OMP19, L7/L12 ribosomal protein (<xref rid="B70" ref-type="bibr">70</xref>&#8211;<xref rid="B72" ref-type="bibr">72</xref>), Omp31 (<xref rid="B73" ref-type="bibr">73</xref>), outer membrane protein Omp25 (<xref rid="B71" ref-type="bibr">71</xref>), p39 (a putative periplasmic binding protein) (<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B75" ref-type="bibr">75</xref>), AsnC (<xref rid="B76" ref-type="bibr">76</xref>), Omp16 (<xref rid="B77" ref-type="bibr">77</xref>), lumazine synthase (<xref rid="B78" ref-type="bibr">78</xref>), rE2o (<xref rid="B79" ref-type="bibr">79</xref>), rCysK (<xref rid="B80" ref-type="bibr">80</xref>), DnaK (<xref rid="B81" ref-type="bibr">81</xref>), chimeric protein from OMP19 and p39 domains (<xref rid="B75" ref-type="bibr">75</xref>), OMP25-BLS fusion protein (<xref rid="B82" ref-type="bibr">82</xref>), OMP25c protein mixed with freund's adjuvant (<xref rid="B83" ref-type="bibr">83</xref>), and AspC, Dps, lnpB, and Ndk (<xref rid="B84" ref-type="bibr">84</xref>); however, none of them have shown a successful clearance. Previous studies have shown that combining several recombinant proteins which generate a wide array of immunogenicity could induce stronger immune responses and better protection against <italic toggle="yes">Brucella</italic> than their univalent counterparts (<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B85" ref-type="bibr">85</xref>, <xref rid="B86" ref-type="bibr">86</xref>). Also, several studies have shown that subunit vaccines could induce protection levels and immune responses similar to those induced by live or attenuated vaccine strains (<xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B72" ref-type="bibr">72</xref>, <xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B84" ref-type="bibr">84</xref>, <xref rid="B87" ref-type="bibr">87</xref>&#8211;<xref rid="B89" ref-type="bibr">89</xref>). At the same time, other studies have not observed such findings (<xref rid="B90" ref-type="bibr">90</xref>). There is a wide range of factors influencing immune responses and protection induced by vaccination in the mouse model, including intrinsic host factors (sex, age, and type of mice), vaccine factors (such as vaccine type, adjuvant type, number and dose of vaccination), administration factors (schedule, site, route, time of vaccination), and challenge factors (challenge pathogen strain, route, challenge-killing interval, time interval between vaccination and challenge and/or between challenge and assessment of splenic bacterial loads) (<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B92" ref-type="bibr">92</xref>). Although subunit vaccines have the advantage of safety, they require multiple boosters and a combination of several antigens, adjuvant, and delivery vehicle/vector to induce an effective immunity and protection against brucellosis in cattle, which isn't economically viable (<xref rid="B44" ref-type="bibr">44</xref>). Moreover, it is important to consider those immune responses elicited in mice may not accurately reflect the protection and immune responses elicited in natural hosts after vaccination. Therefore, more extensive studies are needed to identify new recombinant vaccines containing more than one <italic toggle="yes">Brucella</italic> antigen. Unfortunately, no successful subunit vaccine for brucellosis has been developed so far despite many efforts (<xref rid="T4" ref-type="table">Table 4</xref>).</p><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><p>Subunit vaccine regimens and protective efficacies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Type of vaccine</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Name of vaccine</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Properties</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Immunization dose/ route</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Comparator/</bold><break/>
<bold>route</bold></th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Challenge stain/ dose/ rout</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Adjuvant</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Booster</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Interval</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Humoral immune response</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Cellular immune response</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Lymphocyte bias</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>References</bold>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Gene code (vector)</td><td valign="top" align="left" rowspan="1" colspan="1">1. rBP26<break/>2. rOmp25<break/>3. rL7/L12<break/>4. rBP26 +<break/> rOmp25 +<break/> rL7/L12</td><td valign="top" align="left" rowspan="1" colspan="1">26 kDa periplasmic protein, 25 kD OMP, ribosomal protein</td><td valign="top" align="left" rowspan="1" colspan="1">40 &#956;g, 30 &#956;g, 40 &#956;g/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">S19/i.p</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544 / 2 &#215; 10<sup>5</sup>/-</td><td valign="top" align="left" rowspan="1" colspan="1">Alum</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">TNF-&#945; &#8593; <break/>IFN-&#947; &#8593;<break/>IL-10 &#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Mixed Th1/Th2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B71" ref-type="bibr">71</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Multi-epitope protein (B cell epitopes and T cell epitope) bioenf</td><td valign="top" align="left" rowspan="1" colspan="1">rMEP</td><td valign="top" align="left" rowspan="1" colspan="1">Epitope of rOMP16 rOMP2b rOMP31 BP26</td><td valign="top" align="left" rowspan="1" colspan="1">30 &#956;g</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> M5-90 /1 &#215; 10<sup>9</sup>/s.c</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16 M / 5 &#215; 10<sup>5</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">CFA/IFA</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgM&#8593; <break/>IgG1&#8593; <break/>IgG2a&#8593;<break/>IgG2b&#8593; <break/>IgG3&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947; &#8593; <break/>IL-6 &#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Mixed Th1/Th2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B77" ref-type="bibr">77</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gene code</td><td valign="top" align="left" rowspan="1" colspan="1">1. rTF+<break/>2. rBp26+<break/>3. rOmp31</td><td valign="top" align="left" rowspan="1" colspan="1">Trigger factor, 26 kDa periplasmic protein, 31 kD OMP</td><td valign="top" align="left" rowspan="1" colspan="1">20 &#956;g, 30 &#956;g, 40 &#956;g/s.c</td><td valign="top" align="left" rowspan="1" colspan="1">RB51/ 2&#215;10<sup>8</sup>/i.p <break/>Rev1/ 2&#215;10<sup>8</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/ 2&#215;10<sup>5</sup>/i.p <break/><italic toggle="yes">B. melitensis</italic> 16M/ 2&#215;10<sup>5</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">CFA/IFA</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947; &#8593; <break/>IL-4&#8593; <break/>IL-10&#8593; <break/>IL-12&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B73" ref-type="bibr">73</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins</td><td valign="top" align="left" rowspan="1" colspan="1">1. rPGM<break/>2. rDapB</td><td valign="top" align="left" rowspan="1" colspan="1">Enzyme</td><td valign="top" align="left" rowspan="1" colspan="1">30 &#956;g</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> (S2308) (invitro)</td><td valign="top" align="left" rowspan="1" colspan="1">CFA/IFA</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947; &#8593; <break/>IL-2 &#8593; <break/>IL-4 &#8593; <break/>IL-5 &#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B93" ref-type="bibr">93</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Protein</td><td valign="top" align="left" rowspan="1" colspan="1">OMV</td><td valign="top" align="left" rowspan="1" colspan="1">OMV <italic toggle="yes">B. abortus S</italic> 99</td><td valign="top" align="left" rowspan="1" colspan="1">5 &#956;g/sc</td><td valign="top" align="left" rowspan="1" colspan="1">S19 / 1&#215; 10<sup>4</sup>/ i.p</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">-</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">CFA/IFA</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B94" ref-type="bibr">94</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins</td><td valign="top" align="left" rowspan="1" colspan="1">1- Omp10-Omp28-L7/L12 (<italic toggle="yes">P. pastoris</italic> /<italic toggle="yes">E. coli</italic>)<break/>2- Omp10-Omp28-L7/L12+ adjuvant (<italic toggle="yes">P. pastoris</italic> /<italic toggle="yes">E. coli</italic>) <break/>r Omp10<break/>3- rOmp28<break/>4- rL7/L12</td><td valign="top" align="left" rowspan="1" colspan="1">Lipoprotein, soluble protein or BP26, ribosomal protein</td><td valign="top" align="left" rowspan="1" colspan="1">0.1 mg of each/</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> M5 /5 &#215; 10<sup>4</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M/ 5 &#215; 10<sup>5</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">TPPPS</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">1 wk</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947; &#8593; <break/>IL-2 &#8593; <break/>IL-4 &#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B70" ref-type="bibr">70</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNA vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">1. rTOmp2bpcDNA3.1<break/>2. TOmp2bpcDNA3.1<break/>3. TOmp2b priming/ rTOmp2b boosting</td><td valign="top" align="left" rowspan="1" colspan="1">Truncated 36 kDa<break/> Omp</td><td valign="top" align="left" rowspan="1" colspan="1">rProtein: <break/>30 &#956;g/s.c <break/>plasmid: <break/>50 &#956;g/s.c</td><td valign="top" align="left" rowspan="1" colspan="1">Rev1/ 2 &#215; 10<sup>8</sup>/ i.p, <break/>RB51/ 2 &#215; 10<sup>8</sup>/ i.p</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/ 4&#215;10<sup>4</sup>/ i.p, <break/><italic toggle="yes">B. melitensis</italic> 16 M/ 2&#215; 10<sup>4</sup>/ i.p/</td><td valign="top" align="left" rowspan="1" colspan="1">Montanide ISA 70VG + <break/>CpG ODN 1826</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">3 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">&#8593; IFN-&#947; <break/>&#8595; IL-10<break/>IL-4&#8595;</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B95" ref-type="bibr">95</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins</td><td valign="top" align="left" rowspan="1" colspan="1">1. rL7/L12-rTOmp31-rSOmp2b+ Poly (I:C)<break/>2. rL7/L12-rTOmp31 -rSOmp2b+ CpG+ Montanide</td><td valign="top" align="left" rowspan="1" colspan="1">Ribosomal protein <break/>Truncated 31 kDa<break/> Omp <break/>Truncated 36 kDa<break/> Omp without the signal peptide</td><td valign="top" align="left" rowspan="1" colspan="1">rProtein: <break/>20 &#956;g of each/s.c <break/>Adjuvant: 50 &#956;g</td><td valign="top" align="left" rowspan="1" colspan="1">Rev1/ 2 &#215; 10<sup>8</sup>/i.p <break/>RB51/ 2 &#215; 10<sup>8</sup>/i.p/</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> S 544/ 4 &#215; 10<sup>4</sup>/i.p <break/><italic toggle="yes">B. melitensis</italic> S16 M/ 2 &#215; 10<sup>4</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">CpG ODN 1826+ <break/>Montanide ISA 70VG / Poly (I:C)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">3wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947; &#8593; <break/>IL-2 &#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B72" ref-type="bibr">72</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gene cod</td><td valign="top" align="left" rowspan="1" colspan="1">rBCG-P39-L7/L12</td><td valign="top" align="left" rowspan="1" colspan="1">39-kD periplasmic binding protein, Ribosomal protein</td><td valign="top" align="left" rowspan="1" colspan="1">4 &#215; 10<sup>8</sup> CFUs/s.c</td><td valign="top" align="left" rowspan="1" colspan="1">PBS</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> M28/ 5&#215; 10<sup>5</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947; &#8593; <break/>IL-4&#8593;<break/>IL12p70&#8593; <break/>TNF&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B96" ref-type="bibr">96</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins</td><td valign="top" align="left" rowspan="1" colspan="1">1. rOMP25<break/>2. rHSP60<break/>3. rOMP25+BLS<break/>4. rOMP25-BLS+ hsP60</td><td valign="top" align="left" rowspan="1" colspan="1">25 kD OMP, enzyme, heat shock protein 60 kDa</td><td valign="top" align="left" rowspan="1" colspan="1">20 &#956;g, 40 &#956;g, 30 &#956;g/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">Rev1 / 1&#8211;4&#215; 10<sup>9</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">IFA <break/>AH<break/>CS-NPs</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947; &#8593; <break/>TNF-&#945;&#8593;<break/>IL-4&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B82" ref-type="bibr">82</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Protein</td><td valign="top" align="left" rowspan="1" colspan="1">S19-OMP-liposome</td><td valign="top" align="left" rowspan="1" colspan="1">OMP of <italic toggle="yes">B. abortus</italic> strain S19, vaccine delivery system</td><td valign="top" align="left" rowspan="1" colspan="1">50 &#956;g/s.c</td><td valign="top" align="left" rowspan="1" colspan="1">S19/1.1 &#215; 10<sup>5</sup></td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/ 2.2 &#215; 10<sup>5</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B97" ref-type="bibr">97</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Multi-epitope subunit (gene code)</td><td valign="top" align="left" rowspan="1" colspan="1">1- FliC +7&#945;-HSDH + BhuA<break/>2- FliC + 7&#945;-HSDH + BhuA without Adjuant</td><td valign="top" align="left" rowspan="1" colspan="1">Flagellin <break/>Enzyme <break/>Heme transporter</td><td valign="top" align="left" rowspan="1" colspan="1">Poly B= B cell and T CD4+ epitopes/ Poly T=T CD8+ and T CD4+ cell epitopes Dose (N.D)</td><td valign="top" align="left" rowspan="1" colspan="1">RB51 <break/>Rev1</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M <italic toggle="yes">B. abortus</italic> 544/ 2&#215;10<sup>7</sup>/ i.p</td><td valign="top" align="left" rowspan="1" colspan="1">Poly I:C</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947; &#8593; <break/>IL-2&#8593; <break/>IL-10</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B87" ref-type="bibr">87</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Protein</td><td valign="top" align="left" rowspan="1" colspan="1">1- OMVs only<break/>2- OMVs + Poly(I:C)<break/>3- OMVs + CpG ODN + Montanide ISA 70VG</td><td valign="top" align="left" rowspan="1" colspan="1">OMV of B. <italic toggle="yes">melitensis strain</italic> 16 M</td><td valign="top" align="left" rowspan="1" colspan="1">5 &#956;g/s.c</td><td valign="top" align="left" rowspan="1" colspan="1">Rev1/ 2 &#215; 10<sup>8</sup>/ i.p</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> / 2 &#215; 10<sup>4</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">Poly(I:C)/CpG ODN 1826/Montanide ISA 70VG</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">3 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG2a &#8593; <break/>IgG1&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947; &#8593; <break/>IL-2&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B88" ref-type="bibr">88</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNA vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">1- pCIOmp31<break/>2- pCIOmp31 + adjuvant</td><td valign="top" align="left" rowspan="1" colspan="1">31 kDa Omp Enzyme</td><td valign="top" align="left" rowspan="1" colspan="1">100 &#956;g/i.m</td><td valign="top" align="left" rowspan="1" colspan="1">HKBC <italic toggle="yes">B. canis</italic> /1 &#215; 10<sup>9</sup>/s.c</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. canis</italic> RM6/66/ 5.5 &#215; 10<sup>5</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">IFA<break/>AH <break/>Montanide <break/>Quil A</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947; <break/>IL-4</td><td valign="top" align="left" rowspan="1" colspan="1">Mixed Th1&#8211;Th2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B98" ref-type="bibr">98</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gene cod (recombinant proteins)</td><td valign="top" align="left" rowspan="1" colspan="1">RHspA</td><td valign="top" align="left" rowspan="1" colspan="1">Heat shock proteins</td><td valign="top" align="left" rowspan="1" colspan="1">30 &#956;g/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">Rev1 /8 &#215; 10<sup>8</sup>/ s.c</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16 M/ 1 &#215; 10<sup>4</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">CFA/IFA</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947;&#8593; <break/>IL-12&#8593; <break/>IL-6 &#8593; <break/>IL-10&#8593; <break/>IL-4&#8593; <break/>IL-5&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Th2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B81" ref-type="bibr">81</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins</td><td valign="top" align="left" rowspan="1" colspan="1">ROmpA</td><td valign="top" align="left" rowspan="1" colspan="1">66.5 kDa omp</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g/ip</td><td valign="top" align="left" rowspan="1" colspan="1">MBP</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/ 2 &#215; 10<sup>4</sup>/ i.p</td><td valign="top" align="left" rowspan="1" colspan="1">IFA</td><td valign="top" align="left" rowspan="1" colspan="1">-(<xref rid="B3" ref-type="bibr">3</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1"> IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">TNF-&#945;&#8593; <break/>IFN-&#947;&#8593;<break/>MCP&#8593; <break/>IL-12p70&#8593; <break/>IL-10&#8593;<break/>IL-6&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Th2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B99" ref-type="bibr">99</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins</td><td valign="top" align="left" rowspan="1" colspan="1">1- rAspC+rDps rInpB +rNdk<break/>2- MBP</td><td valign="top" align="left" rowspan="1" colspan="1">Protein enzyme</td><td valign="top" align="left" rowspan="1" colspan="1">20 &#956;g/ip</td><td valign="top" align="left" rowspan="1" colspan="1">RB51/ 5&#215; 10<sup>6</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/ 5&#215; 10<sup>5</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">IFA</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG2a &#8593; <break/>IgG1&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IL-10&#8593; <break/>IL-12p70&#8593;<break/>IFN-&#947;&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B84" ref-type="bibr">84</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gene cod (recombinant proteins)</td><td valign="top" align="left" rowspan="1" colspan="1">1- rDnaK<break/>2- rTF<break/>3- rOmp31<break/>4- rDnaK+rOmp31<break/>5- rDnaK+rTF</td><td valign="top" align="left" rowspan="1" colspan="1">Molecular chaperon, Trigger factor, 31 kDa Omp</td><td valign="top" align="left" rowspan="1" colspan="1">30 &#956;g of each/i.p.</td><td valign="top" align="left" rowspan="1" colspan="1">Rev1i / 8 &#215; 10<sup>8</sup>/ s.c</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16 M / 1 &#215; 10<sup>4</sup>/ i.p</td><td valign="top" align="left" rowspan="1" colspan="1">CFA/IFA</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG2a&#8593; <break/>IgG1&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947;&#8593; <break/>IL-12&#8593; <break/>IL-6 &#8593; <break/>IL-10&#8595; <break/>IL-5&#8595;</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B69" ref-type="bibr">69</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins</td><td valign="top" align="left" rowspan="1" colspan="1">Rohr</td><td valign="top" align="left" rowspan="1" colspan="1">Peroxiredoxin protein</td><td valign="top" align="left" rowspan="1" colspan="1">20 &#956;g, i.p</td><td valign="top" align="left" rowspan="1" colspan="1">MBP</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/<break/> 5 &#215; 10<sup>4</sup>/ i.p</td><td valign="top" align="left" rowspan="1" colspan="1">IFA</td><td valign="top" align="left" rowspan="1" colspan="1">(-)</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG2a &#8593; <break/>IgG1&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IL-10&#8593; <break/>TNF&#8593; <break/>IL-12p70 &#8593;<break/>IFN-&#947;&#8593; <break/>IL-6&#8593; <break/>IL-10&#8593; <break/>MCP-1&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B67" ref-type="bibr">67</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins</td><td valign="top" align="left" rowspan="1" colspan="1">1- CobB<break/>2- AsnC<break/>3- Cu-Zn SOD</td><td valign="top" align="left" rowspan="1" colspan="1">Pathogenesis-associated proteins</td><td valign="top" align="left" rowspan="1" colspan="1">30 &#956;g, i.p</td><td valign="top" align="left" rowspan="1" colspan="1">S19 / 1&#215; 10<sup>6</sup>/ i.p</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544 /2&#215; 10<sup>4</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">CFA/IFA</td><td valign="top" align="left" rowspan="1" colspan="1">(-)</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">N.D</td><td valign="top" align="left" rowspan="1" colspan="1">N.D</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B100" ref-type="bibr">100</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins</td><td valign="top" align="left" rowspan="1" colspan="1">1- rOmp16+rOmp19+ rOmp28+ rL7/L12<break/>2- pCold-TF</td><td valign="top" align="left" rowspan="1" colspan="1">16 kDa Omp <break/>19 kDa Omp <break/>28 kDa Omp <break/>Ribosomal protein <break/>pCold-trigger factor vector</td><td valign="top" align="left" rowspan="1" colspan="1">Protein:100 &#956;g,<break/> i.p <break/>Vector: 100 &#956;g,<break/> i.p</td><td valign="top" align="left" rowspan="1" colspan="1">RB51/ 1&#215; 10<sup>6</sup>/ i.p</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/<break/> 2&#215; 10<sup>5</sup>/<break/> i.p</td><td valign="top" align="left" rowspan="1" colspan="1">IFA</td><td valign="top" align="left" rowspan="1" colspan="1">(-)</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG2a &#8593; <break/>IgG1&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947;&#8593; <break/>TNF &#8593; <break/>IL-6 &#8593; <break/>MCP-1&#8593; <break/>IL-12p70&#8593; <break/>IL-10&#8595;</td><td valign="top" align="left" rowspan="1" colspan="1">Mixed Th1&#8211;Th2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B101" ref-type="bibr">101</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins</td><td valign="top" align="left" rowspan="1" colspan="1">1- BMEI0357<break/>2- BMEI1098<break/>3- BMEI1845<break/>4- BMEII0346<break/>5- BMEII0375<break/>6- BMEII0395</td><td valign="top" align="left" rowspan="1" colspan="1">Regulatory proteins of Lrp/AsnC family</td><td valign="top" align="left" rowspan="1" colspan="1">30 &#956;g, i.p</td><td valign="top" align="left" rowspan="1" colspan="1">S19</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M/ 1&#215; 10<sup>5</sup>/ i.p</td><td valign="top" align="left" rowspan="1" colspan="1">CFA/IFA</td><td valign="top" align="left" rowspan="1" colspan="1">(-)</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">N.D</td><td valign="top" align="left" rowspan="1" colspan="1">N.D</td><td valign="top" align="left" rowspan="1" colspan="1">N.D</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B76" ref-type="bibr">76</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins</td><td valign="top" align="left" rowspan="1" colspan="1">1- rL7/L12<break/>2- rBLS<break/>3- L7/L12-B</td><td valign="top" align="left" rowspan="1" colspan="1">Ribosomal protein enzyme</td><td valign="top" align="left" rowspan="1" colspan="1">-/ s.c, vein of ear</td><td valign="top" align="left" rowspan="1" colspan="1">PBS</td><td valign="top" align="left" rowspan="1" colspan="1">N.D</td><td valign="top" align="left" rowspan="1" colspan="1">Freund's adjuvant</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">1 wk</td><td valign="top" align="left" rowspan="1" colspan="1">IgG &#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947;&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">N.D</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B102" ref-type="bibr">102</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins (gen cod)</td><td valign="top" align="left" rowspan="1" colspan="1">RNdk</td><td valign="top" align="left" rowspan="1" colspan="1">Nucleoside diphosphate kinase</td><td valign="top" align="left" rowspan="1" colspan="1">20 &#956;g,i.p</td><td valign="top" align="left" rowspan="1" colspan="1">MBP</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544 /<break/> 5 &#215; 10<sup>4</sup>/ i.p</td><td valign="top" align="left" rowspan="1" colspan="1">IFA</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1"> IgG2a &#8593; <break/>IgG1&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947;&#8593; <break/>TNF&#8593;<break/>MCP1&#8593; <break/>IL-6&#8593; <break/>IL-12p70&#8593;<break/>IL-10&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Mixed Th1&#8211;Th2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B103" ref-type="bibr">103</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins (title)</td><td valign="top" align="left" rowspan="1" colspan="1">1- Omp19<break/>2- P39<break/>3- Omp19+ P39</td><td valign="top" align="left" rowspan="1" colspan="1">19 kDa Omp periplasmic-binding protein</td><td valign="top" align="left" rowspan="1" colspan="1">50 &#956;g,i.p</td><td valign="top" align="left" rowspan="1" colspan="1">S19 / 1 &#215; 10<sup>4</sup>/</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544 <italic toggle="yes">B. melitensis</italic> 16M /5 &#215; 10<sup>4</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">CFA/IFA</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG2a &#8593; <break/>IgG1&#8593;<break/>IgG2b &#8593; <break/>IgG3 &#8593; <break/>IgM &#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947;&#8593; <break/>IL-2 &#8593;<break/>IL-12&#8593; <break/>IL-4&#8595;</td><td valign="top" align="left" rowspan="1" colspan="1">Mixed Th1&#8211;Th2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B75" ref-type="bibr">75</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins (TEXT)</td><td valign="top" align="left" rowspan="1" colspan="1">1- rAdk<break/>2- rSecB<break/>3- pcold-TF<break/>4- rAdk+ rSecB</td><td valign="top" align="left" rowspan="1" colspan="1">Adenylate kinase <break/>Preprotein translocase subunit</td><td valign="top" align="left" rowspan="1" colspan="1">50 &#956;g of each /i.p <break/>100 &#956;g/i.p: combined</td><td valign="top" align="left" rowspan="1" colspan="1">RB51/ 1 &#215; 10<sup>6</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/10<sup>5</sup></td><td valign="top" align="left" rowspan="1" colspan="1">IFA</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG2a &#8593; <break/>IgG1&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IL-10&#8593; <break/>IFN-&#947; &#8593; <break/>TNF &#8593; <break/>IL-6&#8593; <break/>MCP-1 &#8593;<break/>IL-12p70&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Mixed Th1&#8211;Th2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B104" ref-type="bibr">104</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant protein (text)</td><td valign="top" align="left" rowspan="1" colspan="1">1- rE2o-FA<break/>2- rE2o-Alum</td><td valign="top" align="left" rowspan="1" colspan="1">Dihydrolipoamide succinyltransferase</td><td valign="top" align="left" rowspan="1" colspan="1">Group1:25 &#956;g/s.c<break/>Group2:100 &#956;l/-</td><td valign="top" align="left" rowspan="1" colspan="1">S19/1 &#215; 10<sup>4</sup>/ i.p</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/<break/> 2 &#215; 10<sup>5</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">CFA/IFA <break/>AH</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">1 wk</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593; <break/>IgG2b &#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IL-4 &#8593; <break/>IL-10&#8593; <break/>IFN-&#947; &#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Th2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B79" ref-type="bibr">79</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant protein (text)</td><td valign="top" align="left" rowspan="1" colspan="1">1- rCysK group)<break/>2- rCysK-FA group<break/>3- rCysK-Al</td><td valign="top" align="left" rowspan="1" colspan="1">Enzyme</td><td valign="top" align="left" rowspan="1" colspan="1">25 &#956;g of each /s.c</td><td valign="top" align="left" rowspan="1" colspan="1">S19 / 5 &#215; 10<sup>4</sup>/ i.p</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/<break/> 2 &#215; 10<sup>5</sup>/ i.p</td><td valign="top" align="left" rowspan="1" colspan="1">CFA/IFA <break/>AH</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947; &#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Th2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B80" ref-type="bibr">80</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant protein</td><td valign="top" align="left" rowspan="1" colspan="1">1- rRS-<break/>2- rLS-2</td><td valign="top" align="left" rowspan="1" colspan="1">Enzyme</td><td valign="top" align="left" rowspan="1" colspan="1">100 &#956;g/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">Rev1/ 5 &#215; 10<sup>5</sup></td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16 M/ 5 &#215; 10<sup>5</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">IFA</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG &#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN&#8593; <break/>IL-2&#8593; <break/>IL-4 <break/>IL-10</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B78" ref-type="bibr">78</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Epitopic (recombinant proteins)</td><td valign="top" align="left" rowspan="1" colspan="1">1- r3E-rIL2<break/>2- rOMP31<break/>3- r3E<break/>4- rIL2<break/>5- chimeric proteins rOMP31-rIL2</td><td valign="top" align="left" rowspan="1" colspan="1">Immunogenic epitope of omp31</td><td valign="top" align="left" rowspan="1" colspan="1">30 &#956;g,i.p</td><td valign="top" align="left" rowspan="1" colspan="1">Rev1/ 1&#8211;4&#215; 10<sup>9</sup> /-</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> M16/ 1 &#215; 10<sup>4</sup><italic toggle="yes">/i.p</italic></td><td valign="top" align="left" rowspan="1" colspan="1">IFA <break/>IL-2</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN&#947; &#8593; <break/>IL-2&#8593; <break/>IL-4&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B89" ref-type="bibr">89</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins</td><td valign="top" align="left" rowspan="1" colspan="1">1- rOmp25 (40 &#956;g) IP<break/>2- rOmp25 (40 &#956;g) ID</td><td valign="top" align="left" rowspan="1" colspan="1">19 kDa Omp</td><td valign="top" align="left" rowspan="1" colspan="1">20&#8211;30 &#956;g / i.p,id</td><td valign="top" align="left" rowspan="1" colspan="1">S19</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/10 <sup>9</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">CFA/IFA</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IL-6&#8593; <break/>IL-12&#8593; <break/>TNF&#8593;<break/>IFN-&#947;&#8593; <break/>IL-4</td><td valign="top" align="left" rowspan="1" colspan="1">Th2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B105" ref-type="bibr">105</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gene cod (Dna)</td><td valign="top" align="left" rowspan="1" colspan="1">SodC+omp19+BLS+ PrpA</td><td valign="top" align="left" rowspan="1" colspan="1">Protein enzyme</td><td valign="top" align="left" rowspan="1" colspan="1">20 &#956;l / i.n</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/<break/> 2&#215; 10<sup>4</sup>/</td><td valign="top" align="left" rowspan="1" colspan="1">LPS</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">IgG &#8593; <break/>IgA&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947;&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B86" ref-type="bibr">86</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gene cod (recombinant proteins)</td><td valign="top" align="left" rowspan="1" colspan="1">1- chimeric protein of Omp19-P39 (rOP)</td><td valign="top" align="left" rowspan="1" colspan="1">Truncated 19 kDa Omp <break/>Truncated periplasmic-binding protein</td><td valign="top" align="left" rowspan="1" colspan="1">50 &#956;l / i.p</td><td valign="top" align="left" rowspan="1" colspan="1">S19/ 1&#215; 10<sup>4</sup>/-</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M <break/><italic toggle="yes">B. abortus</italic> 544/ 5 &#215; 10<sup>4</sup> /i.p</td><td valign="top" align="left" rowspan="1" colspan="1">Al CFA/IFA</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947;&#8593; <break/>IL-2 &#8593;<break/>IL-12p70&#8593; <break/>IL-10 <break/>IL-4</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B74" ref-type="bibr">74</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins</td><td valign="top" align="left" rowspan="1" colspan="1">1- rBLSOmp31-ChM<break/>2- rBLSOmp31-P407-Ch gel<break/>3- rBLSOmp31-IFA</td><td valign="top" align="left" rowspan="1" colspan="1">Epitope of 19 kDa Omp <break/>Enzyme</td><td valign="top" align="left" rowspan="1" colspan="1">500 &#956;g/I.N/CONJ/I.M <break/>0.5 ml/I.N <break/>0.05 ml/CONJ <break/>2 mL/I.M</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. ovis</italic> PA/ 1.09&#215; 10<sup>9</sup>/CONJ, preputial</td><td valign="top" align="left" rowspan="1" colspan="1">IFA</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">3 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG&#8593; <break/>IgA&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947;&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B106" ref-type="bibr">106</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Protein</td><td valign="top" align="left" rowspan="1" colspan="1">1- OMVs S19<break/>2- OMVs S19 &#916;<italic toggle="yes">per</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Protein</td><td valign="top" align="left" rowspan="1" colspan="1">15 &#956;g/s.c</td><td valign="top" align="left" rowspan="1" colspan="1">S19 /1 &#215; 10<sup>5</sup>/s.c</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/<break/> 2 &#215; 10<sup>/</sup> i.p</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593;<break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IL-2&#8593; <break/>IFN-&#947;&#8593; <break/>TNF &#8593; <break/>IL-4 &#8593; <break/>IL-6 &#8593; <break/>IL-10&#8593;<break/>IL-17A&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Th2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B107" ref-type="bibr">107</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNA vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">1- EPLG-Pep<break/>2- APLG-Pep<break/>3- Pep-Ad+ IFA<break/>4- EPLG-NP<break/>5- APLG-NP</td><td valign="top" align="left" rowspan="1" colspan="1">MHC-I- andMHC-II-restricted Tcell epitopes formulated by PLG</td><td valign="top" align="left" rowspan="1" colspan="1">Group1:50 &#956;g/s.c <break/>Group2:100 &#956;g/s.c</td><td valign="top" align="left" rowspan="1" colspan="1">DNA vaccine groups: PBS <break/>PLG groups: S19/ 5&#215;10<sup>4</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">Group 1: <italic toggle="yes">B.abortus</italic> 544/2&#215; 10/ i.p <break/>Group 2: <italic toggle="yes">B. abortus</italic> DB79BRAB4</td><td valign="top" align="left" rowspan="1" colspan="1">IFA <break/>PLG</td><td valign="top" align="left" rowspan="1" colspan="1">Group2: Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Group2: 1 wk</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947;&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B108" ref-type="bibr">108</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins</td><td valign="top" align="left" rowspan="1" colspan="1">rL7/L12-Omp25 <break/>rL7/L12-Omp25+ rIFN-&#947;</td><td valign="top" align="left" rowspan="1" colspan="1">Fusion protein <break/>ribosomal protein + <break/>25 kDa Omp</td><td valign="top" align="left" rowspan="1" colspan="1">Protein:30 &#956;g/i.p <break/>Cytokine: 10 &#956;g</td><td valign="top" align="left" rowspan="1" colspan="1">S19 / 5 &#215; 10<sup>5</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/ 5 &#215; 10<sup>7</sup>/ i.p</td><td valign="top" align="left" rowspan="1" colspan="1">Alum</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;<break/>IgG2b&#8593; <break/>IgG3&#8593; <break/>IgM&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947;&#8593; <break/>TNF-&#945;&#8593;<break/>GM-CSF&#8593; <break/>IL-2&#8593; <break/>IL-12&#8593;<break/>IL-5&#8593; <break/>IL-4&#8595; <break/>IL-10&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B85" ref-type="bibr">85</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins</td><td valign="top" align="left" rowspan="1" colspan="1">rOmp28</td><td valign="top" align="left" rowspan="1" colspan="1">28 kDa Omp</td><td valign="top" align="left" rowspan="1" colspan="1">100 &#956;g/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">B. abortus (10<sup>4</sup>)</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">IFA</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593;<break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B109" ref-type="bibr">109</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins</td><td valign="top" align="left" rowspan="1" colspan="1">rL7/L12</td><td valign="top" align="left" rowspan="1" colspan="1">Ribosomal protein entrapped by PLGA</td><td valign="top" align="left" rowspan="1" colspan="1">40 &#956;g/i.p <break/>Microparticles: 16 mg</td><td valign="top" align="left" rowspan="1" colspan="1">S19/10<sup>5</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/<break/> 2 &#215; 10<sup>7</sup>/ i.p</td><td valign="top" align="left" rowspan="1" colspan="1">Alum MF59</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IL-4&#8593; <break/>IFN-&#947;&#8593; <break/>TNF&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Mixed Th1&#8211;Th2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B110" ref-type="bibr">110</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins (gene cod text)</td><td valign="top" align="left" rowspan="1" colspan="1">1- rOmp25c</td><td valign="top" align="left" rowspan="1" colspan="1">Recombinant unlipidated porin protein</td><td valign="top" align="left" rowspan="1" colspan="1">20 &#956;g/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">S19/ 5&#215;10<sup>5</sup>/ i.p</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/ 5&#215;10<sup>5</sup>/i.p, <break/><italic toggle="yes">B. melitensis</italic> 16M, <break/><italic toggle="yes">B. suis</italic> 1330</td><td valign="top" align="left" rowspan="1" colspan="1">CFA/IFA</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;<break/>IgG2b&#8593; <break/>IgG3&#8593; <break/>IgM&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947;&#8593; <break/>TNF-&#945;&#8593;<break/>GM-CSF&#8593; <break/>IL-2&#8593; <break/>IL-4&#8593;<break/>IL-5&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Th2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B83" ref-type="bibr">83</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins</td><td valign="top" align="left" rowspan="1" colspan="1">r-glk</td><td valign="top" align="left" rowspan="1" colspan="1">Enzyme</td><td valign="top" align="left" rowspan="1" colspan="1">50 &#956;g/i.m</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/ 4 &#215; 10<sup>6</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">CFA/IFA</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593;<break/>IgG2a&#8593; <break/>IgG2b&#8593; <break/>IgG3&#8593;<break/>IgM&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B111" ref-type="bibr">111</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gene code</td><td valign="top" align="left" rowspan="1" colspan="1">rUrease</td><td valign="top" align="left" rowspan="1" colspan="1">Enzyme</td><td valign="top" align="left" rowspan="1" colspan="1">20, 30/ i.p., s.c.</td><td valign="top" align="left" rowspan="1" colspan="1">S19/10<sup>5</sup><break/>Rev.1./10<sup>5</sup></td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M, <break/><italic toggle="yes">B. abortus</italic> 544, <break/><italic toggle="yes">B. suis</italic> 1,330/<break/> 2&#215; 10<sup>7</sup></td><td valign="top" align="left" rowspan="1" colspan="1">CFA/IFA</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947;&#8593; <break/>IL-12&#8593; <break/>IL-4&#8595;</td><td valign="top" align="left" rowspan="1" colspan="1">Mixed Th1&#8211;Th2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B112" ref-type="bibr">112</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins (title)</td><td valign="top" align="left" rowspan="1" colspan="1">1- rSodC+<break/> rRibH+<break/> rNdk+rL7/<break/> L12+rMDH<break/>2- MBP</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">RB51/1 &#215; 10<sup>6</sup></td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/ 5 &#215; 10<sup>4</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">IFA</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">1 wk</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947;&#8593; <break/>IL-10&#8595; IL-12p70 <break/>TNF MCP-1 <break/>IL-6</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B113" ref-type="bibr">113</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Epitope (DNA vaccine)</td><td valign="top" align="left" rowspan="1" colspan="1">1- T epitopes<break/>3- B epitopes<break/>3- TB epitopes</td><td valign="top" align="left" rowspan="1" colspan="1">T cell and B cell epitopes of OMP31</td><td valign="top" align="left" rowspan="1" colspan="1">30 &#956;g/i.n</td><td valign="top" align="left" rowspan="1" colspan="1">PBS</td><td valign="top" align="left" rowspan="1" colspan="1">Live <italic toggle="yes">B. melitensis</italic> (5 &#215; 10<sup>5</sup>, i.n)</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">sIgA&#8593; <break/>IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947;</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B114" ref-type="bibr">114</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNA vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">pCIBLSOmp31</td><td valign="top" align="left" rowspan="1" colspan="1">1- 31 kDa Omp<break/>2- Enzyme</td><td valign="top" align="left" rowspan="1" colspan="1">100 &#956;g/i.m</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. ovis</italic> PA76250 /1 &#215; 10<sup>9</sup>,<break/><italic toggle="yes">B. canis</italic> M/ 6.3 &#215; 10<sup>8</sup>/</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. canis</italic> RM6/66/ 5.5 &#215; 10<sup>5</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">IFA <break/>AH<break/>Montanide <break/>Quil A</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947;&#8593; <break/>IL-4 &#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Mixed Th1&#8211;Th2</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B115" ref-type="bibr">115</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">1- Fractions B1<break/>2- Fractions B2<break/>3- Fractions B3<break/>4- Fractions B1+B2+B3</td><td valign="top" align="left" rowspan="1" colspan="1">Polysaccharide <break/>Protein</td><td valign="top" align="left" rowspan="1" colspan="1">Group1: 1 &#956;g/i.p <break/>Group2: 1 &#956;g/i.m</td><td valign="top" align="left" rowspan="1" colspan="1">PBS</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. suis 145</italic>/ 5 &#215; 10<sup>5</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">1 wk</td><td valign="top" align="left" rowspan="1" colspan="1"> IgM &#8593; <break/>IgG &#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B116" ref-type="bibr">116</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant proteins (title)</td><td valign="top" align="left" rowspan="1" colspan="1">FlgJ FliN</td><td valign="top" align="left" rowspan="1" colspan="1">Protein</td><td valign="top" align="left" rowspan="1" colspan="1">30 &#956;g/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">S19 /1 &#215; 10<sup>5</sup> /i.p</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544/<break/> 2&#215; 10<sup>5</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">CFA/IFA</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">2 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947;&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B117" ref-type="bibr">117</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Recombinant fusion</td><td valign="top" align="left" rowspan="1" colspan="1">1- rL7/L12<break/>2- TOmp31<break/>3- rL7/L12+ TOmp31</td><td valign="top" align="left" rowspan="1" colspan="1">Ribosomal protein <break/>Truncated 31 kDa<break/> Omp</td><td valign="top" align="left" rowspan="1" colspan="1">Fusion protein: 30 &#956;g/s.c <break/>Protein:15 &#956;g/s.c</td><td valign="top" align="left" rowspan="1" colspan="1">RB51/ 2 &#215; 10<sup>8</sup>/i.p, <break/>Rev1 / 2 &#215; 10<sup>8</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544 /<break/> 4 &#215; 10<sup>4</sup>/i.p, <break/><italic toggle="yes">B. melitensis</italic> 16M / 2 &#215; 10<sup>4</sup>/i.p</td><td valign="top" align="left" rowspan="1" colspan="1">CpG ODN <break/>Montanide ISA 50 V</td><td valign="top" align="left" rowspan="1" colspan="1">-</td><td valign="top" align="left" rowspan="1" colspan="1">3 wks</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1&#8593; <break/>IgG2a&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">IL-2&#8593; <break/>IL-10&#8593; <break/>IFN-&#947;&#8593;</td><td valign="top" align="left" rowspan="1" colspan="1">Th1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B118" ref-type="bibr">118</xref>)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">r, recombinant; BP26, recombinant BP26 protein; Omp, outer membrane protein; rMEP, multi-epitope protein; TF, trigger factor; BLS, Brucella lumazine synthase; DnaK, molecular chaperone; Bp26, periplasmic immunogenic protein; p39, sugar-binding 39-kDa protein; L, ribosomal protein; SodC, superoxide dismutase; rPGM, phosphoglucomutase; DapB, dihydrodipicolinate reductase; OMV, Outer membrane vesicle; TOmp2b, truncated outer membrane protein 2b; Th1, T helper1; SOmp2b, short form of Omp2b; BCG, Bacillus Calmette-Guerin; rHSP60, recombinant heat shock protein 60; BLS, Brucella lumazine synthase; FliC, flagellin C; HSDH, hydroxysteroid dehydrogenase; BhuA, outer membrane heme transporter; CpG ODN, CpG oligodeoxynucleotides; pCIOmp31, Omp31 gene cloned in the pCI plasmid; AspC, Aspartate Aminotransferase; Dps, DNA protection during starvation; Ndk, nucleoside diphosphate kinase; DnaK, a cytoplasmic protein; Ohr, hydroperoxide resistance protein; Adk, Adenylate kinase; SecB, a cytoplasmic chaperone; E2o, dihydrolipoamide succinyltransferase; CysK, Cysteine synthase K; FA, Freund's Adjuvant; AL, Alum; RS, riboflavin synthase; LS-2, Loraine synthase; 3E, immunogenic epitope derived from OMP31 antigen; PrpA, proline racemase subunit A; EPLG-Pep, peptides either entrapped in PLG microparticles; Ch, chitosan; APLG-Pep, peptides adsorbed on PLG particles; Pep-Ad, pool of peptides; r-glk, recombinant glucokinase; rRibH, riboflavin synthase subunit beta; rSodC, superoxide dismutase; MDH, malate dehydrogenase protein; OPS, O Polysaccharide; CTB, cholera toxin B subunit; LPS, lipopolysaccharide; CagA, cytotoxin-associated gene A; GI24, 24 amino acids compose the N-terminal &#945;-helical domain; B. melitensis, Brucella melitensis; B. canis, Brucella canis; B. ovis, Brucella ovis; B. suis, Brucella suis; PBS, Phosphate-buffered saline; I.p, Intraperitoneal; S.c, subcutaneous; I.m, intramuscular; CFA/IFA, Complete freund's adjuvant/ Incomplete Freund's adjuvant; TPPPS, Taishan Pinus massoniana pollen polysaccharide; Rev1, Brucella melitensis Rev 1; AH, Antigen-Aluminum Adjuvant; CS-NPs, chitosan nanoparticles; HKBC, heat-killed Brucella canis; B. canis, Brucella canis; MBP, Maltose binding protein; B. abortus, Brucella abortus; MHC, Major histocompatibility complex; Wks, weeks; Ig, immunoglobin; TNF-&#945;, Tumor necrosis factor- &#945;; IFN-&#947;, Interferon gamma-&#947;; Th1, T helper type 1; MCP-1, Monocyte chemoattractant protein-1; GM-CSF, Granulocyte-macrophage colony-stimulating factor</italic>.</p></table-wrap-foot></table-wrap></sec><sec id="s5"><title>DNA Vaccines</title><p>DNA-based <italic toggle="yes">Brucella</italic> vaccines are a kind of subunit vaccine which stimulated immune responses following multiple doses (<xref rid="T5" ref-type="table">Table 5</xref>) (<xref rid="B18" ref-type="bibr">18</xref>). These vaccines are safe and efficient brucellosis vaccines due to the stimulation of strong cellular immune responses, expression of several antigens, the existence of CpG motifs, and simple storage conditions (<xref rid="B139" ref-type="bibr">139</xref>). DNA-based vaccines contain gene sequences of pathogens, which are essential for intracellular survival of <italic toggle="yes">Brucella</italic> spp. The immunogenicity and efficacy of these virulence genes used in DNA vaccines have been demonstrated in animal studies, including the two-component BvrR/BvrS system (<xref rid="B119" ref-type="bibr">119</xref>), Cu-Zn superoxide dismutase (SOD) (<xref rid="B126" ref-type="bibr">126</xref>, <xref rid="B140" ref-type="bibr">140</xref>), ribosomal L7/L12 or <italic toggle="yes">Brucella</italic> lumazine synthase (BLS) (<xref rid="B139" ref-type="bibr">139</xref>, <xref rid="B141" ref-type="bibr">141</xref>), <italic toggle="yes">B. melitensis</italic> omp31 and omp25 genes (<xref rid="B125" ref-type="bibr">125</xref>, <xref rid="B142" ref-type="bibr">142</xref>), antigenic surface protein (BCSP31) gene (<xref rid="B120" ref-type="bibr">120</xref>), SP41 (<xref rid="B143" ref-type="bibr">143</xref>), and ribosomal protein L9 (rL9) (<xref rid="B122" ref-type="bibr">122</xref>). According to the studies that have been done, DNA vaccines may have the ability to resolve the disadvantages of other brucellosis vaccines (<xref rid="B119" ref-type="bibr">119</xref>, <xref rid="B120" ref-type="bibr">120</xref>, <xref rid="B144" ref-type="bibr">144</xref>). In most studies, animals vaccinated with different types of DNA vaccines have shown full protection against virulent strains (e.g., <italic toggle="yes">B. abortus S19, B. abortus 2308, B. melitensis 16M</italic>, and <italic toggle="yes">B. melitensis Rev1</italic>) (<xref rid="B120" ref-type="bibr">120</xref>, <xref rid="B143" ref-type="bibr">143</xref>).</p><table-wrap position="float" id="T5" orientation="portrait"><label>Table 5</label><caption><p>DNA and nanoparticle- based vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Name of vaccine</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Type of vaccine</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Structure of vaccine</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Advantage</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Disadvantage</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>References</bold>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">B. abortus S19</td><td valign="top" align="left" rowspan="1" colspan="1">DNA-based</td><td valign="top" align="left" rowspan="1" colspan="1">pCDNA-BvrR (plasmid pCDNA-BvrR)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Conferring a significant level of protection in animals due to inducting a specific Th1 response (antibody), increased IFN-&#947; expression level compared with IL-4, and a strong T cell-proliferative response<break/>&#8226; BvrR is a promising candidate for studies on DNA vaccines against brucellosis in the future.</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Lower antibody titers in pCDNA-BvrR vaccine group compared with other constructed DNA vaccines against <italic toggle="yes">Brucella</italic></td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B119" ref-type="bibr">119</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">B. abortus</td><td valign="top" align="left" rowspan="1" colspan="1">DNA-based</td><td valign="top" align="left" rowspan="1" colspan="1">DNA encoding antigenic surface protein (BCSP31)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Exhibiting a protective efficacy in rabbit models due to inducting appropriate cellular immune responses</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B120" ref-type="bibr">120</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 2308</td><td valign="top" align="left" rowspan="1" colspan="1">DNA-based</td><td valign="top" align="left" rowspan="1" colspan="1">DNA encoding the BAB1 0263 (pVF263) and BAB1 0278 (pVF278)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; In animals, both vaccines elicit a T-cell response (cellular immunity) and a dominant IgG2a response (humoral responses).<break/>&#8226; Only pVF263 induces significant levels of INF-&#947;.<break/>&#8226; None of them induce IL-10 and IL-4.<break/>&#8226; A significant protection is induced by BAB1 0278 antigen.</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Inability of pVF278 to stimulate significantly the production of cytokines, particularly IFN-&#945;<break/>&#8226; Inability of pVF263 plasmid to confer a significant level of protection compared to pVF278 DNA</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B121" ref-type="bibr">121</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M</td><td valign="top" align="left" rowspan="1" colspan="1">DNA-based</td><td valign="top" align="left" rowspan="1" colspan="1">DNA-SP41 vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Inducing SP41-specific serum IgG antibodies<break/>&#8226; Inducing a T-cell proliferative response and IFN-&#947; production (Th1) but not IL-5</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Vaccination with Rev1 induces better and sufficient protection levels than SP41 DNA vaccine against <italic toggle="yes">B. melitensis</italic> 16M in mice</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B120" ref-type="bibr">120</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">B. abortus</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">DNA-based</td><td valign="top" align="left" rowspan="1" colspan="1">Plasmid DNA vaccine encoding ribosomal protein L9</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Increasing IgG antibody responses (both IgG1 and IgG2a isotypes)<break/>&#8226; Inducing the secretion of Th1-type cytokines: IFN-&#947; by CD4+ and CD8+ T cells as well as TNF-&#945; and IL-2 but not IL-4<break/>&#8226; Following the EP and prime/boost strategy induces protection against <italic toggle="yes">B. abortus</italic> infection compared to S19 vaccine.</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B122" ref-type="bibr">122</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Wild-type <italic toggle="yes">B. abortus</italic></td><td valign="top" align="left" rowspan="1" colspan="1">DNA-based</td><td valign="top" align="left" rowspan="1" colspan="1">Recombinant GntR plasmid (pVGntR)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Inducing more significant protection compared to conventional RB51 vaccine by increasing IgG as well as IFN-&#947; and IL-4 (Th1- and Th2- immune responses)</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B123" ref-type="bibr">123</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 2308</td><td valign="top" align="left" rowspan="1" colspan="1">DNA-based</td><td valign="top" align="left" rowspan="1" colspan="1">Recombinant plasmid based on BAB1-0267 and BAB1-270 ORFs (encodes protein with SH3 domain and Zn dependent metalloproteinase)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; BAB1_0267 ORF: significantly increases the production of IgG1 and IFN-&#947; as well as Th1-type immune responses.<break/>&#8226; BAB1_0270 ORF: is considered as an effective candidate due to significantly increasing the production of IgG2a, IFN-&#947;, and TNF-&#945; as well as Th1-type immune responses.</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; BAB1_0267 does not provide significant levels of protection</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B124" ref-type="bibr">124</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> Rev1</td><td valign="top" align="left" rowspan="1" colspan="1">DNA-based</td><td valign="top" align="left" rowspan="1" colspan="1">pcDNA3.1-Omp25-31</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Increasing the levels of IgG and IFN-&#947; as well as inducing a T-cell-proliferative response<break/>&#8226; Eliciting strong and protective humoral and cellular immunity</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B125" ref-type="bibr">125</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 2308</td><td valign="top" align="left" rowspan="1" colspan="1">DNA-based</td><td valign="top" align="left" rowspan="1" colspan="1">Multi-epitope DNA vaccine encoding epitopes from Cu-Zn SOD</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Eliciting IgG, IFN-&#947;, and Th1 responses but no IL-4<break/>&#8226; Inducing humoral and cellular immune responses in animals</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; The production of IL-4 as an indicator of Th2 activation is not detected</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B126" ref-type="bibr">126</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 2308</td><td valign="top" align="left" rowspan="1" colspan="1">DNA-based</td><td valign="top" align="left" rowspan="1" colspan="1">Multivalent DNA vaccines by fusion of BAB1 0273 and/or BAB1 0278 of ORF from GI-3 and <italic toggle="yes">B. abortus</italic> 2308 <italic toggle="yes">sodC</italic></td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Inducing both humoral and cellular immune responses<break/>&#8226; Inducing a significant increase in the production of IgM, IgG, IgG2a, and IFN-&#947;, as well as Th1-type immune responses</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Inducing low protection levels in mice challenged with <italic toggle="yes">B. abortus</italic> 2308</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B126" ref-type="bibr">126</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 2308</td><td valign="top" align="left" rowspan="1" colspan="1">DNA-based</td><td valign="top" align="left" rowspan="1" colspan="1">DNA vaccine containing ORF of GI-3 with ABC-type transporter (pV278a)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Conferring protection in animals due to increasing the secretion of dominant IgG2a and INF-&#947; but not IL-4</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B127" ref-type="bibr">127</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">B. ovis</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Nanoparticle- based</td><td valign="top" align="left" rowspan="1" colspan="1">Mannosylated nanoparticles (MAN-NP-HS)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Significantly conferring a higher protection level than Rev1 due to eliciting a more intense mucosal IgA response and elevating IL-2, IL-4, and IFN-&#947; levels.<break/>&#8226; MAN-NP-HS is distributed from palpebral area to the nasal region and the GI tract.<break/>&#8226; As a safe and suitable adjuvant for conjunctival vaccination</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B128" ref-type="bibr">128</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">B. abortus</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Nanoparticle- based</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Malate dehydrogenase (rMdh), rOmp 10 and 19 loaded in mucoadhesive<break/>&#8226; CNs</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Inducing an increase in IgG especially IgG1, IFN-&#947;, and IL-4 (Th1-Th2 response) levels<break/>&#8226; Significantly increasing anti-Mdh IgA in nasal and fecal excretions, and anti-Omps IgA in sera, nasal, and genital secretions and fecal excretions<break/>&#8226; Increasing anti-Mdh IgA antibody level but not anti-Omps IgA<break/>&#8226; Inducting antigen-specific IgA, Th2-polarized immune responses, and highly specific IgG</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B129" ref-type="bibr">129</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16 M and <italic toggle="yes">B. abortus</italic> 544</td><td valign="top" align="left" rowspan="1" colspan="1">Nanoparticle- based</td><td valign="top" align="left" rowspan="1" colspan="1">Chimeric antigen TF/Bp26/Omp31 (TBO) loaded glycine nanoparticles</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Inducing high levels of IgG and IgA in immunized mice sera and mouth<break/>&#8226; Inducing both cellular and humoral immune responses<break/>&#8226; i.p administration could generate a better immune response in comparison with oral and nasal administration as well as antigens-Freund adjuvant administration.</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Oral administration fails to induce the highest level of protection against <italic toggle="yes">B. melitensis</italic> 16 M and <italic toggle="yes">B. abortus</italic> 544 in comparison with i.p injection of nanovaccine</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B130" ref-type="bibr">130</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544</td><td valign="top" align="left" rowspan="1" colspan="1">Nanoparticle- based</td><td valign="top" align="left" rowspan="1" colspan="1">OPS and LPS antigens conjugated with PLGA nanoparticles<break/> (LPS-PLGA and OPS-PLGA)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Both improve the immunization process in animals and humans against brucellosis due to inducing IgM and IgG secretion and more protection than pure antigens (OPS and LPS).<break/>&#8226; LPS-PLGA conjugate vaccine induces more immunogenicity compared to OPS-PLGA nanovaccines.</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B131" ref-type="bibr">131</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">B. abortus</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Nanoparticle- based</td><td valign="top" align="left" rowspan="1" colspan="1">Malate dehydrogenase (Mdh), loaded in mucoadhesive CNs (CNs-Mdh)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Inducing higher IL-6 production than unloaded antigens and TF loaded CNs (CNs-TF)<break/>&#8226; Significantly increasing IL-4 and IgG-secreting cells after 4W<break/>&#8226; Increasing Mdh-specific IgG levels after 6W (IgG1 and IgG2a but with the predominance of IgG1 response)<break/>&#8226; Inducing a significant increase in Mdh-specific IgA and total IgA in secretions and sera of immunized group<break/>&#8226; Intranasal immunization effectively induces antigen-specific mucosal immune responses through the elicitation of Th2-related immune responses.</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B132" ref-type="bibr">132</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> and <italic toggle="yes">B. abortus</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Nanoparticle- based</td><td valign="top" align="left" rowspan="1" colspan="1">Trimethyl chitosan nanoparticles of Urease (TMC/Urease)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Eliciting low titers of specific IgG following i.p injection of urease alone and oral administration of both TMC/Urease and urease alone<break/>&#8226; Inducing high levels of specific IgG following i.p administration of TMC/Urease<break/>&#8226; Eliciting a Th1-Th2 immune response following i.p administration of urease alone and TMC/Urease<break/>&#8226; Eliciting a Th1-Th17 immune response following oral administration of urease alone and TMC/Urease<break/>&#8226; Inducing a cell proliferative response in spleen cells of i.p vaccinated mice with TMC/Urease nanoparticles<break/>&#8226; i.p vaccination with TMC/Urease nanoparticles results in a high degree of protection.</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Failing to induce the highest level of protection against virulent strains of <italic toggle="yes">Brucella</italic> spp. due to not eliciting a detectable specific IgA immune response<break/>&#8226; Inducing a lower degree of protection than i.p. immunization</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B133" ref-type="bibr">133</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16 M and <italic toggle="yes">B. abortus</italic> 544</td><td valign="top" align="left" rowspan="1" colspan="1">Nanoparticle- based</td><td valign="top" align="left" rowspan="1" colspan="1">Mannosylated Chitosan Nanoparticles (MCN) loaded with <italic toggle="yes">FliC</italic> protein</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Inducing a significant increase in specific IgG (higher IgG2a titers), IgM, and IgA levels; high levels of IFN-&#947; and IL-2; but low levels of IL-10 following FliC and FliC-MCN challenges<break/>&#8226; Conferring a significant level of protection due to humoral and cellular responses of Th1-dominant type as well as cross protection against <italic toggle="yes">B. melitensis</italic> and <italic toggle="yes">B. abortus</italic> infections</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Conferring less protection than live attenuated <italic toggle="yes">B. melitensis</italic> Rev1 and <italic toggle="yes">B. abortus</italic> RB51 vaccines against <italic toggle="yes">B. melitensis</italic> 16 M and <italic toggle="yes">B. abortus</italic> 544</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B134" ref-type="bibr">134</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16 M and <italic toggle="yes">B. abortus</italic> 544</td><td valign="top" align="left" rowspan="1" colspan="1">Nanoparticle- based</td><td valign="top" align="left" rowspan="1" colspan="1">Calcium phosphate nanoparticles (CaPNs)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Eliciting increased ratio of specific IgG2a to specific IgG1, high levels of IFN-&#947; and IL-12 (cellular and humoral immune responses), and low levels of IL-10<break/>&#8226; Conferring protection against <italic toggle="yes">B. melitensis</italic> 16M and <italic toggle="yes">B. abortus</italic> 544<break/>&#8226; All antigens used in the vaccine formulations are conserved between <italic toggle="yes">B. melitensis</italic> 16M and <italic toggle="yes">B. abortus</italic> 544; therefore, cross protection could be obtained by a single vaccine.</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B135" ref-type="bibr">135</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M</td><td valign="top" align="left" rowspan="1" colspan="1">Nanoparticle- based</td><td valign="top" align="left" rowspan="1" colspan="1">Omp31-loaded N-trimethyl chitosan nanoparticles (TMC/Omp31)</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Oral immunization induces a Th1&#8211;Th17 immune response but lower antibody titer.<break/>&#8226; i.p immunization by Omp31-IFA and TMC/Omp31 NPs induces Th1 and Th1&#8211;Th2 immune responses and high IgG titer (IFN-&#947; and IL-12).<break/>&#8226; Only in i.p administration route of TMC/Omp31, high IL-4 production vaccination with Omp31 stimulates a vigorous cell proliferative response which could further be increased with oral immunization with TMC/Omp31 NPs.<break/>&#8226; Conferring a significant level of protection in the orally administered group in comparison with the i.p immunized mice due to Th17 response</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B136" ref-type="bibr">136</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. abortus</italic> 544</td><td valign="top" align="left" rowspan="1" colspan="1">Nanoparticle- based</td><td valign="top" align="left" rowspan="1" colspan="1">L7/L12 entrapping PLGA nanoparticles</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Inducing high IgG antibody titers (predominant IgG1; however, IgG1/2a ratio shows a mixed profile of Th1/Th2 responses.)<break/>&#8226; Inducting high levels of Th1 cytokines, especially IFN-&#947;<break/>&#8226; Potently inducing an inflammatory cellular response<break/>&#8226; Inducing a significant reduction in CFU of splenic bacteria in the vaccinated mice against <italic toggle="yes">B. abortus</italic> 544<break/>&#8226; Inducing both humoral and cellular responses</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B137" ref-type="bibr">137</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic toggle="yes">B. melitensis</italic> 16M</td><td valign="top" align="left" rowspan="1" colspan="1">Nanoparticle- based</td><td valign="top" align="left" rowspan="1" colspan="1">Nanovaccines against based on PLGA nanoparticles and oligopolysaccharide antigen</td><td valign="top" align="left" rowspan="1" colspan="1">&#8226; Inducing a significant increase in IgG and IgM titers and efficient opsonophagocytosis of <italic toggle="yes">Brucella</italic> in the sera of immunized animals<break/>&#8226; Conferring a high level of protection<break/>&#8226; Could be considered as a candidate for immunization of animals and humans against the diseases caused by <italic toggle="yes">B. melitensis</italic> and needs further investigations</td><td valign="top" align="left" rowspan="1" colspan="1">NR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B138" ref-type="bibr">138</xref>)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">Introduced DNA vaccines</italic>.</p><p><italic toggle="yes">NR, not reported; IFN, interferon gamma &#947;; IL, interleukin; ORFs, open reading frames; GI-3, genomic island 3; Th1, T-helper 1; IgG, immunoglobulin G; SOD, superoxide dismutase; GI3, genomic island; rOmp, outer membrane proteins; CNs, chitosan nanoparticles; W, weeks; i.p, intraperitoneal</italic>.</p></table-wrap-foot></table-wrap><p>Intramuscular (i.m.) administration of DNA-based vaccine has been shown to induce a protective immune response as similar as Rev1 in different animal model studies (<xref rid="B125" ref-type="bibr">125</xref>, <xref rid="B143" ref-type="bibr">143</xref>, <xref rid="B145" ref-type="bibr">145</xref>, <xref rid="B146" ref-type="bibr">146</xref>). Jain et al. demonstrated that the electroporation (EP) approach induced further protective responses than the i.m. route (<xref rid="B122" ref-type="bibr">122</xref>). A combination of several suitable antigens, such as L7/L12, BCSP31, SOD, P39, and omp16, could be used to make a &#8220;divalent or poly-antigenic DNA vaccine,&#8221; which has been reported to be effective due to more antigenic components, induction of a wide range of humoral and cellular immune responses, and simulation of the most similar status to <italic toggle="yes">Brucella</italic> infection (<xref rid="B78" ref-type="bibr">78</xref>, <xref rid="B126" ref-type="bibr">126</xref>, <xref rid="B143" ref-type="bibr">143</xref>, <xref rid="B147" ref-type="bibr">147</xref>&#8211;<xref rid="B149" ref-type="bibr">149</xref>).</p><p>Same as subunit vaccines, DNA-based brucellosis vaccines can stimulate both humoral and cellular immune system arms, TCD4 and TCD8 helper cells, as well as a significant increase in IFN&#947;, TNF-&#945;, and IL-12 levels (<xref rid="B122" ref-type="bibr">122</xref>), which IFN&#947; exerts a protective effect by boosting macrophage activity (<xref rid="B150" ref-type="bibr">150</xref>).</p><p>However, several publications have shown no changes in the expression of IL-4, IL-10, and IFN-&#947; following DNA vaccine administration which may be related to the suppressive function of Treg in preventing IFN-&#947; development (<xref rid="B151" ref-type="bibr">151</xref>&#8211;<xref rid="B154" ref-type="bibr">154</xref>). DNA-based vaccines do not provide significant levels of protection compared to live-attenuated vaccines. This is consistent with the finding of Kurar et al., Leclerq et al., and Schurig et al. studies which indicated that a lower immune response and no protective response was observed following the administration of DNA based vaccine against <italic toggle="yes">Brucella</italic> challenge (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B155" ref-type="bibr">155</xref>, <xref rid="B156" ref-type="bibr">156</xref>). It may happen due to the inability of the vaccine to express specific antigens such as GroEL-Hsp antigen in PcDNA3-DNA vaccine (<xref rid="B7" ref-type="bibr">7</xref>). The need for repeated booster doses administration in response to the rapid silencing of genes, is the main reason for the loss of long-term protective response which could be improved using an adjuvant. This result is in line with the finding of a study by Velikovsky et al., demonstrating that following repeated vaccination with PcDNA3 containing the BLS gene, a protective response was induced in mice in addition to the production of IgG2a (<xref rid="B157" ref-type="bibr">157</xref>). Therefore, despite the expression of protective antigens, DNA-based vaccines may unable to express antigens in high amounts, and today efforts are made to delay gene silencing for a longer time.</p></sec><sec id="s6"><title>Nanoparticle Based Vaccines</title><p>Nanoparticles (NPs) containing <italic toggle="yes">Brucella</italic> vaccine induce antibody responses (IgM, mucosal IgA, and IgG) (<xref rid="B129" ref-type="bibr">129</xref>, <xref rid="B130" ref-type="bibr">130</xref>), increase IFN-&#947;, IL-12, IL-4, and IL-6 levels, and decrease IL-10 levels (<xref rid="B134" ref-type="bibr">134</xref>, <xref rid="B135" ref-type="bibr">135</xref>) in animal model studies (<xref rid="T5" ref-type="table">Table 5</xref>). Most studies have reported increased IgG1 level linked to the Th2 response, compared to IgG2 level (<xref rid="B129" ref-type="bibr">129</xref>, <xref rid="B134" ref-type="bibr">134</xref>, <xref rid="B135" ref-type="bibr">135</xref>, <xref rid="B137" ref-type="bibr">137</xref>) which is linked to the Th1 response (<xref rid="B135" ref-type="bibr">135</xref>). Nanoparticle-based vaccines cannot be used to vaccinate humans against brucellosis due to the risk of disease (<xref rid="B138" ref-type="bibr">138</xref>), however, oral vaccines show more benefits in an animal model study (<xref rid="B133" ref-type="bibr">133</xref>). In addition to a Th1-Th2 response (<xref rid="B129" ref-type="bibr">129</xref>, <xref rid="B130" ref-type="bibr">130</xref>, <xref rid="B132" ref-type="bibr">132</xref>), oral administration of NP-based vaccines induces a Th1-Th17 response which is stronger and suitable for controlling brucellosis. Despite many advantages of oral vaccines over intraperitoneal (i.p) vaccines, including ease of preparation, painless administration, and a stronger Th1-Th17 response induction (<xref rid="B133" ref-type="bibr">133</xref>, <xref rid="B158" ref-type="bibr">158</xref>), they are less effective in inducing antibody responses, especially IgA. Relative toxicity, limitation in both antigen loading and vaccine production as well as weak stimulation of the immune system are the most disadvantages of nanoparticle-based vaccines (<xref rid="B159" ref-type="bibr">159</xref>, <xref rid="B160" ref-type="bibr">160</xref>). According to animal model studies, a decrease in the number of CFUs of splenic bacteria is observed following NP-based vaccines administration, indicating that these vaccine have the potential to induce protection against brucellosis. The immune response induced by NPs depends on their uptake by antigen-presenting cells (APCs) and their particle size and charge (<xref rid="B137" ref-type="bibr">137</xref>). A powerful protective response needs a combination of Th1 and IgA responses (<xref rid="B135" ref-type="bibr">135</xref>).</p><p>Mannosylation of nanoparticles in the MAN-NP-HS vaccine candidate aids nanoparticles to reach directly mannose receptors that are abundantly expressed on the surface of immune cells and are important in antigen uptake. Following administration of the MAN-NP-HS vaccine, a mixture of mucosal IgA antibodies and Th1-Th2 cytokines including IL-12, IL-4, and IFN-&#947; is produced, of which IFN-&#947; plays a critical role in inducing cellular immunity. According to these findings, MAN-NP-HS provides even more protection than Rev1 due to the induction of more specific IgA (<xref rid="B131" ref-type="bibr">131</xref>). This vaccine, which is administered through the eye (palpebral), shows no side effects or inflammation. Moreover, the release of the MAN-NP-HS vaccine from the palpebral to the nasal mucosa and GI tract leads to greater protection (<xref rid="B36" ref-type="bibr">36</xref>). Another candidate is a combination of LPS and OPS antigens with PLGA nanoparticles, which has the potential to induce strong protection in animals and humans by producing IgM and IgG antibodies. These antigens alone are not effective in inducing immunity, but when combined with nanoparticles, they produce more antibodies (<xref rid="B156" ref-type="bibr">156</xref>). Most effective nanovaccine candidates induce a significant reduction in bacterial load in splenocytes, Th1 response, and antibody response, especially mucosal IgA. Choosing an antigen that is protected between two pathogenic strains is critical because it contributes to the induction of cross-protection against both strains following vaccination (<xref rid="B135" ref-type="bibr">135</xref>).</p></sec><sec id="s7"><title>Other Vaccines</title><p><italic toggle="yes">Brucella</italic> dual vaccine is a new approach to the development of a <italic toggle="yes">Brucella</italic>-based vaccine platform of immunogenic antigens, oriented to simultaneously control the transmission of two important bacterial pathogens from cattle to humans. In a study by Abedi et al., the use of a total TN-OMP (outer membrane vesicles of <italic toggle="yes">Brucella</italic>) conjugated with rCagA (recombinant protein of <italic toggle="yes">Helicobacter pylori</italic>) was evaluated, and the results revealed that rCagA as an adjuvant increased the immune response against TN-OMP. Thus, this combination vaccine was effective in inducing simultaneously serum bactericidal and splenic activities of <italic toggle="yes">B. abortus</italic> and <italic toggle="yes">H. pylori</italic> in BALB/c mouse model (<xref rid="B161" ref-type="bibr">161</xref>). Similarly, Bahador et al. showed that subcutaneous immunization of mice by conjugated rCagA with <italic toggle="yes">Brucella</italic> LPS (rCagA+ LPS) induced protective effects. Iannino et al. designed the Bab-pgm strain (genetically engineered live <italic toggle="yes">B. abortus</italic> vaccine) as a heterologous carrier for the recombinant chimeric antigen to deliver Shiga toxin-producing <italic toggle="yes">E. coli</italic> (STEC) in a mouse model, which resulted in the induction of a protective immune response against two very different pathogens (<xref rid="B162" ref-type="bibr">162</xref>). Another approach to vaccine development is the use of a modified <italic toggle="yes">Brucella</italic> immunodominant antigen instead of deleting <italic toggle="yes">Brucella</italic> antigens or epitopes or introducing a foreign antigen, which could induce differential antibodies against <italic toggle="yes">B. ovis</italic> (<xref rid="B163" ref-type="bibr">163</xref>). Another approach to vaccine production is polysaccharide conjugate vaccines which are produced <italic toggle="yes">via</italic> the covalent glycan-protein conjugation of bacterial surface; they have been proven to be cost-effective tools to prevent dramatic infectious diseases. It has been demonstrated that OPS of <italic toggle="yes">B. abortus</italic> could be expressed in <italic toggle="yes">Yersinia enterocolitica O:9</italic> and displayed on CTB <italic toggle="yes">via</italic> glycosylation, eliciting an antigen-specific immune response and a significant protection level against brucellosis (<xref rid="B164" ref-type="bibr">164</xref>). Antigen-delivery systems, such as attenuated viruses or bacteria, are essential for presenting <italic toggle="yes">B. abortus</italic> immunogenic antigens to the immune system cells. Recently, Lin et al. designed an adenoviral vector expressing both p39 and lumazine synthase proteins of <italic toggle="yes">B. abortus</italic>, which elicited significant humoral and cellular immune responses, although pre-existing immunity against adenovirus could prevent a vaccine from working (<xref rid="B165" ref-type="bibr">165</xref>). There are several studies using liposomes as <italic toggle="yes">Brucella</italic> antigen-delivery systems. Liposomes are not only widely used as a carrier to improve vaccine efficacy and efficiency in the transport of antigens to appropriate sites but also possess adjuvant properties against bacteria (<xref rid="B166" ref-type="bibr">166</xref>). Goel et al. showed that liposome-encapsulated recombinant Omp25 induced a protective immune response comparable to that induced by S19 in a mouse model (<xref rid="B167" ref-type="bibr">167</xref>). In another study, subcutaneous co-administration of <italic toggle="yes">Brucella</italic> Cu-Zn SOD recombinant protein with recombinant IL-18, encapsulated in <italic toggle="yes">E. coli</italic> lipid liposome (escheriosome), demonstrated a stronger IgG2a-type antibody response in immunized mice compared with free BaSOD DNA. Another approach to vaccine development against <italic toggle="yes">Brucella</italic> infection includes lysed <italic toggle="yes">B</italic>. <italic toggle="yes">abortus</italic> (<xref rid="B168" ref-type="bibr">168</xref>, <xref rid="B169" ref-type="bibr">169</xref>) or whole organism of <italic toggle="yes">Brucella</italic> spp. without cytoplasmic contents. The bacterial-ghost (BG) technology is the use of biologically killed Gram-negative bacterial cells produced <italic toggle="yes">via</italic> controlled expression of the cloned lysis gene <italic toggle="yes">E</italic> of X174 bacteriophage. BGs are potential envelope structures lacking cytoplasmic contents, which act as a delivery system and an efficient adjuvant for DNA- and protein-based vaccines. In the case of <italic toggle="yes">Brucella</italic>, it has been reported that <italic toggle="yes">Brucella S2</italic> ghosts effectively elicit a pathogen-specific antibody response, enhancing IgG antibody and T cell responses in mice compared to inactivated bacteria (<xref rid="B170" ref-type="bibr">170</xref>). Kwon et al. used a fragment of PMPA-36 (porcine myeloid antimicrobial peptide 36), named GI24, for <italic toggle="yes">B. abortus</italic> lysis and produced <italic toggle="yes">B. abortus</italic> ghosts, termed as <italic toggle="yes">B. abortus</italic> lysed cells (<xref rid="B171" ref-type="bibr">171</xref>). Due to the lack of genetic materials in BG vaccines, the horizontal transfer of antibiotic resistance genes or pathogenic islands to the resident gut flora does not occur.</p></sec><sec id="s8"><title>Future Trends of Brucellosis Vaccines</title><p>There are many efforts for the development of new vaccines, safer and more effective based on new technologies such as the engineered live-attenuated vaccines based on deletions in virulence genes, and viral or bacterial vector-based <italic toggle="yes">Brucella</italic> vaccines, subunit vaccines, DNA vaccines, Nanoparticle-based vaccines. The majority of these vaccines designed with regard to new technologies showed the enhanced immune responses and protective immunity against brucellosis in mice, livestock, and guinea pig models. For example, Bugybayeva et al. (<xref rid="B52" ref-type="bibr">52</xref>) indicated that the tetravalent vaccine formulation Flu-NS1-80-Omp16+Flu-NS1-80-L7/L12+Flu-NS1-80-Omp19+Flu-NS1-80-SOD protected guinea pigs from B. melitensis 16M infection at a significant level (<italic toggle="yes">P</italic> &lt; 0.05). Thus, this vaccine can be chosen as a potential vaccine candidate for further development of an effective human vaccine against brucellosis.</p><p>The subunit vaccines are promising vaccine candidates due to their safety profile, well-defined non-infectious nature, inability to revert to a virulent strain, non-viability unlike attenuated vaccines, and capability of manipulation to maximize desirable activities. However, they indicated some disadvantages such as the poor antigenicity, instability, and short half-life of recombinant subunit antigens. Hence, the use of adjuvants, immunomodulators, and antigen delivery systems, or is necessary to enhance immune responses. For these reasons, already despite many efforts, no successful subunit vaccine has been developed for brucellosis livestock (<xref rid="B172" ref-type="bibr">172</xref>). On the other hand, DNA vaccines are one of the methods employed for developing a safe and efficient brucellosis vaccine due to stimulation of cellular immune responses and expression of several antigens; however, they do not induce significant levels of protection due to the lack of a long-term protective response (<xref rid="B157" ref-type="bibr">157</xref>).</p><p>Out of vaccines with new technologies, the engineered live-attenuated vaccines based on deletions in virulence genes have accounted as the best approach for developing new vaccines with minimal residual virulence, due to the induction of high safety levels compared to classical live-attenuated vaccines. A variety of these vaccine types are under development based on different deletions in <italic toggle="yes">B. abortus</italic> or <italic toggle="yes">B. melitensis</italic> virulence genes, which eventually result in significant attenuation and increased production of T cells, pro-inflammatory cytokines, and antibodies (<xref rid="B19" ref-type="bibr">19</xref>). Hence, they can be considered a promising vaccine candidate for human use.</p></sec><sec sec-type="conclusions" id="s9"><title>Conclusion</title><p>To date, no vaccine licensed against human brucellosis is available. Hence, the control of human brucellosis has relied heavily on the control of animal brucellosis by vaccination. Live-attenuated vaccines such as <italic toggle="yes">B. abortus</italic> strains S19 and <italic toggle="yes">B. melitensis</italic> strain Rev1 as the two most common anti-brucellosis vaccines have been widely used in the world for the immunization of animals. However, they had some drawbacks, such as the induction of abortion in pregnant animals, the virulence for humans, the production of anti-<italic toggle="yes">Brucella</italic> antibodies interfering with serodiagnosis, and the antibiotic resistance against brucellosis treatment. Two factors should be considered in designing an effective brucellosis vaccine: the route of vaccine administration and the design of the vaccine to induce cell-mediated immunity which is the most important component of the immune system in inducing defense. It appears that of the brucellosis vaccines, the live attenuated vaccines that some of their genes have been deleted are more effective. They can increase the production of T cells, pro-inflammatory cytokines, and antibodies. Therefore, they can be considered a promising brucellosis vaccines.</p></sec><sec id="s10"><title>Author Contributions</title><p>MH, SD, RG, MM, NB, AD, TN, and MT contributed in revising and final approval of the version to be published. All authors agreed and confirmed the manuscript for publication.</p></sec><sec sec-type="COI-statement" id="conf1"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher's Note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Corbel</surname><given-names>MJ</given-names></name></person-group>. <source>Brucellosis in Humans and Animals</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name> (<year>2006</year>).</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boschiroli</surname><given-names>M-L</given-names></name><name name-style="western"><surname>Foulongne</surname><given-names>V</given-names></name><name name-style="western"><surname>O'Callaghan</surname><given-names>D</given-names></name></person-group>. <article-title>Brucellosis: a worldwide zoonosis</article-title>. <source>Curr Opin Microbiol.</source> (<year>2001</year>) <volume>4</volume>:<fpage>58</fpage>&#8211;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/S1369-5274(00)00165-X</pub-id><pub-id pub-id-type="pmid">11173035</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vershilova</surname><given-names>P</given-names></name></person-group>. <article-title>The use of live vaccine for vaccination of human beings against brucellosis in the USSR</article-title>. <source>Bull World Health Organ.</source> (<year>1961</year>) <volume>24</volume>:<fpage>85</fpage>.<pub-id pub-id-type="pmid">13780996</pub-id><pub-id pub-id-type="pmcid">PMC2555373</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pappas</surname><given-names>G</given-names></name></person-group>. <article-title>The changing <italic toggle="yes">Brucella</italic> ecology: novel reservoirs, new threats</article-title>. <source>Int J Antimicrob Agents.</source> (<year>2010</year>) <volume>36</volume>:<fpage>S8</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2010.06.013</pub-id><pub-id pub-id-type="pmid">20696557</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stear</surname><given-names>MJ</given-names></name></person-group>. <article-title>OIE manual of diagnostic tests and vaccines for terrestrial animals (mammals, birds and bees) 5th edn. Volumes 1 &amp; 2. World Organization for Animal Health 2004. ISBN 92 9044 622 6.80 140</article-title>. <source>Parasitology</source>. (<year>2005</year>) <volume>130</volume>:<fpage>727</fpage>. <pub-id pub-id-type="doi">10.1017/S0031182005007699</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montaraz</surname><given-names>J</given-names></name><name name-style="western"><surname>Winter</surname><given-names>A</given-names></name></person-group>. <article-title>Comparison of living and nonliving vaccines for <italic toggle="yes">Brucella abortus</italic> in BALB/c mice</article-title>. <source>Infect Immun.</source> (<year>1986</year>) <volume>53</volume>:<fpage>245</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1128/iai.53.2.245-251.1986</pub-id><pub-id pub-id-type="pmid">3089933</pub-id><pub-id pub-id-type="pmcid">PMC260865</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Corbel</surname><given-names>MJ</given-names></name></person-group>. <article-title>Brucellosis vaccines: past, present and future</article-title>. <source>Vet Microbiol.</source> (<year>2002</year>) <volume>90</volume>:<fpage>479</fpage>&#8211;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/S0378-1135(02)00255-9</pub-id><pub-id pub-id-type="pmid">12414166</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Skyberg</surname><given-names>JA</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L</given-names></name><name name-style="western"><surname>Clapp</surname><given-names>B</given-names></name><name name-style="western"><surname>Thornburg</surname><given-names>T</given-names></name><name name-style="western"><surname>Pascual</surname><given-names>DW</given-names></name></person-group>. <article-title>Progress in <italic toggle="yes">Brucella</italic> vaccine development</article-title>. <source>Front Biol.</source> (<year>2013</year>) <volume>8</volume>:<fpage>60</fpage>&#8211;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1007/s11515-012-1196-0</pub-id><pub-id pub-id-type="pmid">23730309</pub-id><pub-id pub-id-type="pmcid">PMC3666581</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansoori</surname><given-names>N</given-names></name><name name-style="western"><surname>Pourmand</surname><given-names>MR</given-names></name></person-group>. <article-title>Vaccines and vaccine candidates against brucellosis</article-title>. <source>Infect Epidemiol Microbiol.</source> (<year>2016</year>) <volume>2</volume>:<fpage>32</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.18869/modares.iem.2.4.32</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z-Q</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J-X</given-names></name><name name-style="western"><surname>Fu</surname><given-names>W-D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>A <italic toggle="yes">Brucella melitensis</italic> M5-90 wboA deletion strain is attenuated and enhances vaccine efficacy</article-title>. <source>Mol Immunol.</source> (<year>2015</year>) <volume>66</volume>:<fpage>276</fpage>&#8211;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2015.04.004</pub-id><pub-id pub-id-type="pmid">25899866</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Truong</surname><given-names>QL</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y</given-names></name><name name-style="western"><surname>Park</surname><given-names>S</given-names></name><name name-style="western"><surname>Park</surname><given-names>B-K</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>T-W</given-names></name></person-group>. <article-title><italic toggle="yes">Brucella abortus</italic> mutants lacking ATP-binding cassette transporter proteins are highly attenuated in virulence and confer protective immunity against virulent <italic toggle="yes">B. abortus</italic> challenge in BALB/c mice</article-title>. <source>Microbial Pathogenesis.</source> (<year>2016</year>) <volume>95</volume>:<fpage>175</fpage>&#8211;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2016.04.009</pub-id><pub-id pub-id-type="pmid">27057678</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tian</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Ding</surname><given-names>C</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name></person-group>. <article-title>Characterization of <italic toggle="yes">Brucella abortus</italic> mutant strain &#916;22915, a potential vaccine candidate</article-title>. <source>Vet Res.</source> (<year>2017</year>) <volume>48</volume>:<fpage>1</fpage>&#8211;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1186/s13567-017-0422-9</pub-id><pub-id pub-id-type="pmid">28376905</pub-id><pub-id pub-id-type="pmcid">PMC5381064</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Truong</surname><given-names>QL</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K</given-names></name><name name-style="western"><surname>Park</surname><given-names>B-K</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>T-W</given-names></name></person-group>. <article-title>Booster vaccination with safe, modified, live-attenuated mutants of <italic toggle="yes">Brucella abortus</italic> strain RB51 vaccine confers protective immunity against virulent strains of <italic toggle="yes">B. abortus</italic> and <italic toggle="yes">Brucella canis</italic> in BALB/c mice</article-title>. <source>Microbiology.</source> (<year>2015</year>) <volume>161</volume>:<fpage>2137</fpage>&#8211;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1099/mic.0.000170</pub-id><pub-id pub-id-type="pmid">26341622</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name></person-group>. <article-title>Research progress in live attenuated <italic toggle="yes">Brucella</italic> vaccine development</article-title>. <source>Curr Pharm Biotechnol.</source> (<year>2013</year>) <volume>14</volume>:<fpage>887</fpage>&#8211;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.2174/1389201014666131226123016</pub-id><pub-id pub-id-type="pmid">24372253</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horwell</surname><given-names>F</given-names></name><name name-style="western"><surname>Van Drimmelen</surname><given-names>G</given-names></name></person-group>. <article-title><italic toggle="yes">Brucella melitensis</italic> strain Rev I as a vaccine for cattle</article-title>. <source>J S Afr Vet Assoc.</source> (<year>1971</year>) <volume>42</volume>:<fpage>233</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="pmid">5005602</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><etal/></person-group>. <article-title><italic toggle="yes">Brucella suis</italic> strain 2 vaccine is safe and protective against heterologous <italic toggle="yes">Brucella</italic> spp. infections</article-title>. <source>Vaccine.</source> (<year>2016</year>) <volume>34</volume>:<fpage>395</fpage>&#8211;<lpage>400</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.116</pub-id><pub-id pub-id-type="pmid">26626213</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verger</surname><given-names>J-M</given-names></name><name name-style="western"><surname>Grayon</surname><given-names>M</given-names></name><name name-style="western"><surname>Zundel</surname><given-names>E</given-names></name><name name-style="western"><surname>Lechopier</surname><given-names>P</given-names></name><name name-style="western"><surname>Olivier-Bernardin</surname><given-names>V</given-names></name></person-group>. <article-title>Comparison of the efficacy of <italic toggle="yes">Brucella suis</italic> strain 2 and <italic toggle="yes">Brucella melitensis</italic> Rev. 1 live vaccines against a <italic toggle="yes">Brucella melitensis</italic> experimental infection in pregnant ewes</article-title>. <source>Vaccine.</source> (<year>1995</year>) <volume>13</volume>:<fpage>191</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/0264-410X(95)93135-V</pub-id><pub-id pub-id-type="pmid">7625115</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gheibi</surname><given-names>A</given-names></name><name name-style="western"><surname>Khanahmad</surname><given-names>H</given-names></name><name name-style="western"><surname>Kashfi</surname><given-names>K</given-names></name><name name-style="western"><surname>Sarmadi</surname><given-names>M</given-names></name><name name-style="western"><surname>Khorramizadeh</surname><given-names>MR</given-names></name></person-group>. <article-title>Development of new generation of vaccines for <italic toggle="yes">Brucella abortus</italic></article-title>. <source>Heliyon</source>. (<year>2018</year>) <volume>4</volume>:<fpage>e01079</fpage>. <pub-id pub-id-type="doi">10.1016/j.heliyon.2018.e01079</pub-id><pub-id pub-id-type="pmid">30603712</pub-id><pub-id pub-id-type="pmcid">PMC6307385</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Truong</surname><given-names>QL</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y</given-names></name><name name-style="western"><surname>Park</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>T-W</given-names></name></person-group>. <source>Brucella abortus</source> &#916;cydC&#916;cydD and &#916;cydC&#916;purD double-mutants are highly attenuated and confer long-term protective immunity against virulent <italic toggle="yes">Brucella abortus. Vaccine</italic>. (<year>2016</year>) <volume>34</volume>:<fpage>237</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.11.030</pub-id><pub-id pub-id-type="pmid">26616550</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title><italic toggle="yes">Brucella melitensis</italic> 16 M &#916;hfq attenuation confers protection against wild-type challenge in BALB/c mice</article-title>. <source>Microbiol Immunol.</source> (<year>2013</year>) <volume>57</volume>:<fpage>502</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1111/1348-0421.12065</pub-id><pub-id pub-id-type="pmid">23647412</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yin</surname><given-names>S</given-names></name><name name-style="western"><surname>Yi</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Guo</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>The <italic toggle="yes">Brucella melitensis</italic> M5-90&#916;manB live vaccine candidate is safer than M5-90 and confers protection against wild-type challenge in BALB/c mice</article-title>. <source>Microb Pathog.</source> (<year>2017</year>) <volume>112</volume>:<fpage>148</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2017.09.016</pub-id><pub-id pub-id-type="pmid">28916316</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verdiguel-Fern&#225;ndez</surname><given-names>L</given-names></name><name name-style="western"><surname>Oropeza-Navarro</surname><given-names>R</given-names></name><name name-style="western"><surname>Ortiz</surname><given-names>A</given-names></name><name name-style="western"><surname>Robles-Pesina</surname><given-names>M</given-names></name><name name-style="western"><surname>Ram&#237;rez-Lezama</surname><given-names>J</given-names></name><name name-style="western"><surname>Casta&#241;eda-Ram&#237;rez</surname><given-names>A</given-names></name><etal/></person-group>. <article-title><italic toggle="yes">Brucella melitensis</italic> omp31 mutant is attenuated and confers protection against virulent <italic toggle="yes">Brucella melitensis</italic> challenge in BALB/c mice</article-title>. <source>J Microbiol Biotechnol.</source> (<year>2020</year>) <volume>30</volume>:<fpage>497</fpage>&#8211;<lpage>504</lpage>. <pub-id pub-id-type="doi">10.4014/jmb.1908.08056</pub-id><pub-id pub-id-type="pmid">31986561</pub-id><pub-id pub-id-type="pmcid">PMC9728373</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Xi</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Development and evaluation of in murine model, of an improved live-vaccine candidate against brucellosis from to <italic toggle="yes">Brucella melitensis</italic> vjbR deletion mutant</article-title>. <source>Microb Pathog.</source> (<year>2018</year>) <volume>124</volume>:<fpage>250</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2018.08.052</pub-id><pub-id pub-id-type="pmid">30149131</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stranahan</surname><given-names>LW</given-names></name><name name-style="western"><surname>Chaki</surname><given-names>SP</given-names></name><name name-style="western"><surname>Garcia-Gonzalez</surname><given-names>DG</given-names></name><name name-style="western"><surname>Khalaf</surname><given-names>OH</given-names></name><name name-style="western"><surname>Arenas-Gamboa</surname><given-names>AM</given-names></name></person-group>. <article-title>Evaluation of the efficacy of the <italic toggle="yes">Brucella canis</italic> RM6/66 &#916;vjbR vaccine candidate for protection against <italic toggle="yes">B. canis</italic> infection in mice</article-title>. <source>Msphere</source>. (<year>2020</year>) <volume>5</volume>:<fpage>20</fpage>. <pub-id pub-id-type="doi">10.1128/mSphere.00172-20</pub-id><pub-id pub-id-type="pmid">32434839</pub-id><pub-id pub-id-type="pmcid">PMC7380573</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arenas-Gamboa</surname><given-names>A</given-names></name><name name-style="western"><surname>Rice-Ficht</surname><given-names>A</given-names></name><name name-style="western"><surname>Kahl-McDonagh</surname><given-names>M</given-names></name><name name-style="western"><surname>Ficht</surname><given-names>T</given-names></name></person-group>. <article-title>Protective efficacy and safety of <italic toggle="yes">Brucella melitensis</italic> 16M&#916;mucR against intraperitoneal and aerosol challenge in BALB/c mice</article-title>. <source>Infect Immun.</source> (<year>2011</year>) <volume>79</volume>:<fpage>3653</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.05330-11</pub-id><pub-id pub-id-type="pmid">21708998</pub-id><pub-id pub-id-type="pmcid">PMC3165458</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clapp</surname><given-names>B</given-names></name><name name-style="western"><surname>Skyberg</surname><given-names>JA</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Thornburg</surname><given-names>T</given-names></name><name name-style="western"><surname>Walters</surname><given-names>N</given-names></name><name name-style="western"><surname>Pascual</surname><given-names>DW</given-names></name></person-group>. <article-title>Protective live oral brucellosis vaccines stimulate Th1 and Th17 cell responses</article-title>. <source>Infect Immun.</source> (<year>2011</year>) <volume>79</volume>:<fpage>4165</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.05080-11</pub-id><pub-id pub-id-type="pmid">21768283</pub-id><pub-id pub-id-type="pmcid">PMC3187253</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>The <italic toggle="yes">Brucella melitensis</italic> M5-90 phosphoglucomutase (PGM) mutant is attenuated and confers protection against wild-type challenge in BALB/c mice</article-title>. <source>World J Microbiol Biotechnol.</source> (<year>2016</year>) <volume>32</volume>:<fpage>58</fpage>. <pub-id pub-id-type="doi">10.1007/s11274-016-2015-6</pub-id><pub-id pub-id-type="pmid">26925620</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><etal/></person-group>. <article-title><italic toggle="yes">Brucella melitensis</italic> 16M&#916;TcfSR as a potential live vaccine allows for the differentiation between natural and vaccinated infection</article-title>. <source>Exp Ther Med.</source> (<year>2015</year>) <volume>10</volume>:<fpage>1182</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.3892/etm.2015.2619</pub-id><pub-id pub-id-type="pmid">26622461</pub-id><pub-id pub-id-type="pmcid">PMC4533132</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Niu</surname><given-names>JR</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XL</given-names></name><name name-style="western"><surname>Wu</surname><given-names>TL</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Evaluation of a <italic toggle="yes">Brucella melitensis</italic> mutant deficient in O-polysaccharide export system ATP-binding protein as a rough vaccine candidate</article-title>. <source>Microbes Infection.</source> (<year>2014</year>) <volume>16</volume>:<fpage>633</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.micinf.2014.06.013</pub-id><pub-id pub-id-type="pmid">25043564</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Peng</surname><given-names>X</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J</given-names></name></person-group>. <article-title>Rough <italic toggle="yes">Brucella</italic> strain RM57 is attenuated and confers protection against <italic toggle="yes">Brucella melitensis</italic></article-title>. <source>Microb Pathog</source>. (<year>2017</year>) <volume>107</volume>:<fpage>270</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2017.03.045</pub-id><pub-id pub-id-type="pmid">28390976</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costa</surname><given-names>LF</given-names></name><name name-style="western"><surname>Cabello</surname><given-names>AL</given-names></name><name name-style="western"><surname>Batista</surname><given-names>DFA</given-names></name><name name-style="western"><surname>Chaki</surname><given-names>SP</given-names></name><name name-style="western"><surname>de Figueiredo</surname><given-names>P</given-names></name><name name-style="western"><surname>da Paix&#227;o</surname><given-names>TA</given-names></name><etal/></person-group>. <article-title>The candidate vaccine strain <italic toggle="yes">Brucella ovis</italic> &#916; abcBA is protective against <italic toggle="yes">Brucella melitensis</italic> infection in mice</article-title>. <source>Microbiol Immunol.</source> (<year>2020</year>) <volume>64</volume>:<fpage>730</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/1348-0421.12850</pub-id><pub-id pub-id-type="pmid">32965738</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>APC</given-names></name><name name-style="western"><surname>Mac&#234;do</surname><given-names>AA</given-names></name><name name-style="western"><surname>Costa</surname><given-names>LF</given-names></name><name name-style="western"><surname>Rocha</surname><given-names>CE</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>LN</given-names></name><name name-style="western"><surname>Farias</surname><given-names>JR</given-names></name><etal/></person-group>. <article-title>Encapsulated <italic toggle="yes">Brucella ovis</italic> lacking a putative ATP-binding cassette transporter (&#916; abcBA) protects against wild type <italic toggle="yes">Brucella ovis</italic> in rams</article-title>. <source>PLoS ONE.</source> (<year>2015</year>) <volume>10</volume>:<fpage>e0136865</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0136865</pub-id><pub-id pub-id-type="pmid">26317399</pub-id><pub-id pub-id-type="pmcid">PMC4552948</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sancho</surname><given-names>P</given-names></name><name name-style="western"><surname>Tejedor</surname><given-names>C</given-names></name><name name-style="western"><surname>Sidhu-Mu&#241;oz</surname><given-names>RS</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Lago</surname><given-names>L</given-names></name><name name-style="western"><surname>Vizca&#237;no</surname><given-names>N</given-names></name></person-group>. <article-title>Evaluation in mice of <italic toggle="yes">Brucella ovis</italic> attenuated mutants for use as live vaccines against <italic toggle="yes">B. ovis</italic> infection</article-title>. <source>Vet Res.</source> (<year>2014</year>) <volume>45</volume>:<fpage>1</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1186/1297-9716-45-61</pub-id><pub-id pub-id-type="pmid">24898325</pub-id><pub-id pub-id-type="pmcid">PMC4057616</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>G</given-names></name><name name-style="western"><surname>Jain-Gupta</surname><given-names>N</given-names></name><name name-style="western"><surname>Alqublan</surname><given-names>H</given-names></name><name name-style="western"><surname>Dorneles</surname><given-names>E</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>S</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name></person-group>. <article-title>Development of an auxotrophic, live-attenuated <italic toggle="yes">Brucella suis</italic> vaccine strain capable of expressing multimeric GnRH</article-title>. <source>Vaccine.</source> (<year>2019</year>) <volume>37</volume>:<fpage>910</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2018.12.070</pub-id><pub-id pub-id-type="pmid">30655173</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Czibener</surname><given-names>C</given-names></name><name name-style="western"><surname>Del Giudice</surname><given-names>MG</given-names></name><name name-style="western"><surname>Spera</surname><given-names>JM</given-names></name><name name-style="western"><surname>Fulgenzi</surname><given-names>FR</given-names></name><name name-style="western"><surname>Ugalde</surname><given-names>JE</given-names></name></person-group>. <article-title>Delta-pgm, a new live-attenuated vaccine against <italic toggle="yes">Brucella suis</italic></article-title>. <source>Vaccine</source>. (<year>2016</year>) <volume>34</volume>:<fpage>1524</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.02.025</pub-id><pub-id pub-id-type="pmid">26899373</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain-Gupta</surname><given-names>N</given-names></name><name name-style="western"><surname>Waldrop</surname><given-names>SG</given-names></name><name name-style="western"><surname>Tenpenny</surname><given-names>NM</given-names></name><name name-style="western"><surname>Witonsky</surname><given-names>SG</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name></person-group>. <article-title>Rough Brucella neotomae provides protection against <italic toggle="yes">Brucella suis</italic> challenge in mice</article-title>. <source>Vet Microbiol.</source> (<year>2019</year>) <volume>239</volume>:<fpage>108447</fpage>. <pub-id pub-id-type="doi">10.1016/j.vetmic.2019.108447</pub-id><pub-id pub-id-type="pmid">31767087</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yin</surname><given-names>S</given-names></name><name name-style="western"><surname>Guo</surname><given-names>F</given-names></name><name name-style="western"><surname>Meng</surname><given-names>R</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>A potent <italic toggle="yes">Brucella abortus</italic> 2308 &#916;ery live vaccine allows for the differentiation between natural and vaccinated infection</article-title>. <source>J Microbiol.</source> (<year>2014</year>) <volume>52</volume>:<fpage>681</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s12275-014-3689-9</pub-id><pub-id pub-id-type="pmid">24994009</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Truong</surname><given-names>QL</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y</given-names></name><name name-style="western"><surname>Barate</surname><given-names>AK</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>T-W</given-names></name></person-group>. <article-title>Characterization and protective property of <italic toggle="yes">Brucella abortus</italic> cydC and looP mutants</article-title>. <source>Clin Vaccine Immunol.</source> (<year>2014</year>) <volume>21</volume>:<fpage>1573</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00164-14</pub-id><pub-id pub-id-type="pmid">25253663</pub-id><pub-id pub-id-type="pmcid">PMC4248770</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ke</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Ren</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Deletion of the small RNA chaperone protein Hfq down regulates genes related to virulence and confers protection against wild-type <italic toggle="yes">Brucella</italic> challenge in mice</article-title>. <source>Front Microbiol.</source> (<year>2016</year>) <volume>6</volume>:<fpage>1570</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2015.01570</pub-id><pub-id pub-id-type="pmid">26834720</pub-id><pub-id pub-id-type="pmcid">PMC4718986</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Clapp</surname><given-names>B</given-names></name><name name-style="western"><surname>Thornburg</surname><given-names>T</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>C</given-names></name><name name-style="western"><surname>Pascual</surname><given-names>DW</given-names></name></person-group>. <article-title>Vaccination with a &#916;norD &#916;znuA <italic toggle="yes">Brucella abortus</italic> mutant confers potent protection against virulent challenge</article-title>. <source>Vaccine.</source> (<year>2016</year>) <volume>34</volume>:<fpage>5290</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.09.004</pub-id><pub-id pub-id-type="pmid">27639282</pub-id><pub-id pub-id-type="pmcid">PMC5053898</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>B</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title><italic toggle="yes">Brucella abortus</italic> 2308&#916;NodV&#916;NodW double-mutant is highly attenuated and confers protection against wild-type challenge in BALB/c mice</article-title>. <source>Microb Pathog.</source> (<year>2017</year>) <volume>106</volume>:<fpage>30</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2017.01.043</pub-id><pub-id pub-id-type="pmid">28131952</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>X</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Deletion of the LuxR-type regulator VjbR in <italic toggle="yes">Brucella canis</italic> affects expression of type IV secretion system and bacterial virulence, and the mutant strain confers protection against <italic toggle="yes">Brucella canis</italic> challenge in mice</article-title>. <source>Microb Pathog.</source> (<year>2020</year>) <volume>139</volume>:<fpage>103865</fpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2019.103865</pub-id><pub-id pub-id-type="pmid">31715318</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z-Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J-L</given-names></name><name name-style="western"><surname>Xi</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G-L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S-L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X-G</given-names></name><etal/></person-group>. <article-title>Deletion of the transcriptional regulator GntR down regulated the expression of genes related to virulence and conferred protection against wild-type <italic toggle="yes">Brucella</italic> challenge in BALB/c mice</article-title>. <source>Mol Immunol.</source> (<year>2017</year>) <volume>92</volume>:<fpage>99</fpage>&#8211;<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2017.10.011</pub-id><pub-id pub-id-type="pmid">29055858</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perkins</surname><given-names>SD</given-names></name><name name-style="western"><surname>Smither</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>HS</given-names></name></person-group>. <article-title>Towards a <italic toggle="yes">Brucella</italic> vaccine for humans</article-title>. <source>FEMS Microbiol Rev.</source> (<year>2010</year>) <volume>34</volume>:<fpage>379</fpage>&#8211;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1111/j.1574-6976.2010.00211.x</pub-id><pub-id pub-id-type="pmid">20180858</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorneles</surname><given-names>EM</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Lage</surname><given-names>AP</given-names></name></person-group>. <article-title>Recent advances in <italic toggle="yes">Brucella abortus</italic> vaccines</article-title>. <source>Vet Res.</source> (<year>2015</year>) <volume>46</volume>:<fpage>1</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1186/s13567-015-0199-7</pub-id><pub-id pub-id-type="pmid">26155935</pub-id><pub-id pub-id-type="pmcid">PMC4495609</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Mariri</surname><given-names>A</given-names></name><name name-style="western"><surname>Mahmoud</surname><given-names>NH</given-names></name><name name-style="western"><surname>Hammoud</surname><given-names>R</given-names></name></person-group>. <article-title>Efficacy evaluation of live <italic toggle="yes">Escherichia coli</italic> expression <italic toggle="yes">Brucella</italic> P39 protein combined with CpG oligodeoxynucleotides vaccine against <italic toggle="yes">Brucella melitensis</italic> 16M, in BALB/c mice</article-title>. <source>Biologicals.</source> (<year>2012</year>) <volume>40</volume>:<fpage>140</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.biologicals.2012.01.002</pub-id><pub-id pub-id-type="pmid">22296786</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bugybayeva</surname><given-names>D</given-names></name><name name-style="western"><surname>Kydyrbayev</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zinina</surname><given-names>N</given-names></name><name name-style="western"><surname>Assanzhanova</surname><given-names>N</given-names></name><name name-style="western"><surname>Yespembetov</surname><given-names>B</given-names></name><name name-style="western"><surname>Kozhamkulov</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>A new candidate vaccine for human brucellosis based on influenza viral vectors: a preliminary investigation for the development of an immunization schedule in a guinea pig model</article-title>. <source>Infect Dis Poverty.</source> (<year>2021</year>) <volume>10</volume>:<fpage>1</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1186/s40249-021-00801-y</pub-id><pub-id pub-id-type="pmid">33593447</pub-id><pub-id pub-id-type="pmcid">PMC7886305</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabynov</surname><given-names>K</given-names></name></person-group>. <article-title>Influenza viral vector based <italic toggle="yes">Brucella abortus</italic> vaccine: a novel vaccine candidate for veterinary practice</article-title>. <source>Expert Rev Vaccines.</source> (<year>2016</year>) <volume>15</volume>:<fpage>1237</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1080/14760584.2016.1208089</pub-id><pub-id pub-id-type="pmid">27356589</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Mariri</surname><given-names>A</given-names></name><name name-style="western"><surname>Tibor</surname><given-names>A</given-names></name><name name-style="western"><surname>Lestrate</surname><given-names>P</given-names></name><name name-style="western"><surname>Mertens</surname><given-names>P</given-names></name><name name-style="western"><surname>De Bolle</surname><given-names>X</given-names></name><name name-style="western"><surname>Letesson</surname><given-names>J-J</given-names></name></person-group>. <article-title>Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding <italic toggle="yes">Brucella abortus</italic> bacterioferritin or P39 antigen</article-title>. <source>Infect Immun.</source> (<year>2002</year>) <volume>70</volume>:<fpage>1915</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.70.4.1915-1923.2002</pub-id><pub-id pub-id-type="pmid">11895955</pub-id><pub-id pub-id-type="pmcid">PMC127831</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mailybayeva</surname><given-names>A</given-names></name><name name-style="western"><surname>Ryskeldinova</surname><given-names>S</given-names></name><name name-style="western"><surname>Zinina</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>E-M</given-names></name><name name-style="western"><surname>Renukaradhya</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Tabynov</surname><given-names>K</given-names></name></person-group>. <article-title>Evaluation of duration of immunogenicity and protective efficacy of improved influenza viral vector&#8211;based <italic toggle="yes">Brucella abortus</italic> vaccine against <italic toggle="yes">Brucella melitensis</italic> infection in sheep and goats</article-title>. <source>Front Vet Sci</source>. (<year>2020</year>) <volume>7</volume>:<fpage>58</fpage>. <pub-id pub-id-type="doi">10.3389/fvets.2020.00058</pub-id><pub-id pub-id-type="pmid">32175335</pub-id><pub-id pub-id-type="pmcid">PMC7056664</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senevirathne</surname><given-names>A</given-names></name><name name-style="western"><surname>Hewawaduge</surname><given-names>C</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name></person-group>. <article-title>Attenuated Salmonella secreting <italic toggle="yes">Brucella</italic> protective antigens confer dual-faceted protection against brucellosis and salmonellosis in a mouse model</article-title>. <source>Vet Immunol Immunopathol.</source> (<year>2019</year>) <volume>209</volume>:<fpage>31</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetimm.2019.02.001</pub-id><pub-id pub-id-type="pmid">30885303</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bugybayeva</surname><given-names>D</given-names></name><name name-style="western"><surname>Ryskeldinova</surname><given-names>S</given-names></name><name name-style="western"><surname>Zinina</surname><given-names>N</given-names></name><name name-style="western"><surname>Sarmykova</surname><given-names>M</given-names></name><name name-style="western"><surname>Assanzhanova</surname><given-names>N</given-names></name><name name-style="western"><surname>Kydyrbayev</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Development of human vectored brucellosis vaccine formulation: assessment of safety and protectiveness of influenza viral vectors expressing <italic toggle="yes">Brucella</italic> immunodominant proteins in mice and guinea pigs</article-title>. <source>BioMed Res Int</source>. (<year>2020</year>) <volume>2020</volume>:<fpage>1438929</fpage>. <pub-id pub-id-type="doi">10.1155/2020/1438928</pub-id><pub-id pub-id-type="pmid">33274194</pub-id><pub-id pub-id-type="pmcid">PMC7695499</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohammadi</surname><given-names>E</given-names></name><name name-style="western"><surname>Golchin</surname><given-names>M</given-names></name></person-group>. <article-title>High protection of mice against <italic toggle="yes">Brucella abortus</italic> by oral immunization with recombinant probiotic <italic toggle="yes">Lactobacillus casei</italic> vector vaccine, expressing the outer membrane protein OMP19 of <italic toggle="yes">Brucella</italic> species</article-title>. <source>Comp Immunol Microbiol Infect Dis.</source> (<year>2020</year>) <volume>70</volume>:<fpage>101470</fpage>. <pub-id pub-id-type="doi">10.1016/j.cimid.2020.101470</pub-id><pub-id pub-id-type="pmid">32208191</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rezaei</surname><given-names>M</given-names></name><name name-style="western"><surname>Rabbani Khorasgani</surname><given-names>M</given-names></name><name name-style="western"><surname>Zarkesh Esfahani</surname><given-names>SH</given-names></name><name name-style="western"><surname>Emamzadeh</surname><given-names>R</given-names></name><name name-style="western"><surname>Abtahi</surname><given-names>H</given-names></name></person-group>. <article-title>Production of <italic toggle="yes">Brucella melitensis</italic> Omp16 protein fused to the human interleukin 2 in <italic toggle="yes">Lactococcus lactis</italic> MG1363 toward developing a Lactococcus-based vaccine against brucellosis</article-title>. <source>Can J Microbiol.</source> (<year>2020</year>) <volume>66</volume>:<fpage>39</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1139/cjm-2019-0261</pub-id><pub-id pub-id-type="pmid">31574230</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo-Zhen</surname><given-names>L</given-names></name><name name-style="western"><surname>Yi-Zhong</surname><given-names>L</given-names></name><name name-style="western"><surname>Kui-Zheng</surname><given-names>C</given-names></name><name name-style="western"><surname>Jun-Lin</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhong-Ren</surname><given-names>M</given-names></name></person-group>. <article-title>Immunogenicity of recombinant adenovirus co-expressing the L7/L12 and BCSP31 proteins of <italic toggle="yes">Brucella abortus</italic></article-title>. <source>Kafkas &#220;niversitesi Veteriner Fak&#252;ltesi Dergisi</source>. (<year>2018</year>) <volume>24</volume>:<fpage>211</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.9775/kvfd.2017.18644</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vellinga</surname><given-names>J</given-names></name><name name-style="western"><surname>Smith</surname><given-names>JP</given-names></name><name name-style="western"><surname>Lipiec</surname><given-names>A</given-names></name><name name-style="western"><surname>Majhen</surname><given-names>D</given-names></name><name name-style="western"><surname>Lemckert</surname><given-names>A</given-names></name><name name-style="western"><surname>van Ooij</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Challenges in manufacturing adenoviral vectors for global vaccine product deployment</article-title>. <source>Hum Gene Ther.</source> (<year>2014</year>) <volume>25</volume>:<fpage>318</fpage>&#8211;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1089/hum.2014.007</pub-id><pub-id pub-id-type="pmid">24593243</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leya</surname><given-names>M</given-names></name><name name-style="western"><surname>Kim</surname><given-names>WK</given-names></name><name name-style="western"><surname>Ochirkhuyag</surname><given-names>E</given-names></name><name name-style="western"><surname>Yu</surname><given-names>E-C</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y-J</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Protective efficacy of attenuated Salmonella Typhimurium strain expressing BLS, Omp19, PrpA, or SOD of <italic toggle="yes">Brucella abortus</italic> in goats</article-title>. <source>J Vet Sci</source>. (<year>2021</year>) <volume>22</volume>:<fpage>e15</fpage>. <pub-id pub-id-type="doi">10.4142/jvs.2021.22.e15</pub-id><pub-id pub-id-type="pmid">33774931</pub-id><pub-id pub-id-type="pmcid">PMC8007450</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senevirathne</surname><given-names>A</given-names></name><name name-style="western"><surname>Hewawaduge</surname><given-names>C</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name></person-group>. <article-title>Live vaccine consisting of attenuated Salmonella secreting and delivering <italic toggle="yes">Brucella</italic> ribosomal protein L7/L12 induces humoral and cellular immune responses and protects mice against virulent <italic toggle="yes">Brucella abortus</italic> 544 challenge</article-title>. <source>Vet Res.</source> (<year>2020</year>) <volume>51</volume>:<fpage>1</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1186/s13567-020-0735-y</pub-id><pub-id pub-id-type="pmid">31973749</pub-id><pub-id pub-id-type="pmcid">PMC6979349</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hewawaduge</surname><given-names>C</given-names></name><name name-style="western"><surname>Senevirathne</surname><given-names>A</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name></person-group>. <article-title>Enhancement of host infectivity, immunity, and protective efficacy by addition of sodium bicarbonate antacid to oral vaccine formulation of live attenuated <italic toggle="yes">Salmonella</italic> secreting <italic toggle="yes">Brucella</italic> antigens</article-title>. <source>Microb Pathog.</source> (<year>2020</year>) <volume>138</volume>:<fpage>103857</fpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2019.103857</pub-id><pub-id pub-id-type="pmid">31705999</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>WK</given-names></name><name name-style="western"><surname>Moon</surname><given-names>JY</given-names></name><name name-style="western"><surname>Cho</surname><given-names>JS</given-names></name><name name-style="western"><surname>Hur</surname><given-names>J</given-names></name></person-group>. <article-title>Protective efficacy by various doses of a new brucellosis vaccine candidate based on <italic toggle="yes">Salmonella</italic> strains expressing <italic toggle="yes">Brucella abortus</italic> BSCP31, Omp3b and superoxide dismutase against brucellosis in murine model</article-title>. <source>Pathogens Dis</source>. (<year>2017</year>) <volume>75</volume>:<fpage>ftx094</fpage>. <pub-id pub-id-type="doi">10.1093/femspd/ftx094</pub-id><pub-id pub-id-type="pmid">28873944</pub-id><pub-id pub-id-type="pmcid">PMC5808651</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabynov</surname><given-names>K</given-names></name><name name-style="western"><surname>Sansyzbay</surname><given-names>A</given-names></name><name name-style="western"><surname>Kydyrbayev</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yespembetov</surname><given-names>B</given-names></name><name name-style="western"><surname>Ryskeldinova</surname><given-names>S</given-names></name><name name-style="western"><surname>Zinina</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Influenza viral vectors expressing the <italic toggle="yes">Brucella</italic> OMP16 or L7/L12 proteins as vaccines against <italic toggle="yes">B. abortus</italic> infection</article-title>. <source>Virol J.</source> (<year>2014</year>) <volume>11</volume>:<fpage>1</fpage>&#8211;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1186/1743-422X-11-69</pub-id><pub-id pub-id-type="pmid">24716528</pub-id><pub-id pub-id-type="pmcid">PMC3997475</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C-X</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>K</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X-J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C-F</given-names></name><etal/></person-group>. <article-title>Immunogenic response to a recombinant pseudorabies virus carrying bp26 gene of <italic toggle="yes">Brucella melitensis</italic> in mice</article-title>. <source>Res Vet Sci.</source> (<year>2015</year>) <volume>100</volume>:<fpage>61</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.rvsc.2015.03.030</pub-id><pub-id pub-id-type="pmid">25890577</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;ez</surname><given-names>D</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>P</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>A</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>E</given-names></name><name name-style="western"><surname>O&#241;ate</surname><given-names>A</given-names></name></person-group>. <article-title>Oral immunization of mice with recombinant <italic toggle="yes">Lactococcus lactis</italic> expressing Cu, Zn superoxide dismutase of <italic toggle="yes">Brucella abortus</italic> triggers protective immunity</article-title>. <source>Vaccine.</source> (<year>2012</year>) <volume>30</volume>:<fpage>1283</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.12.088</pub-id><pub-id pub-id-type="pmid">22222868</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno</surname><given-names>E</given-names></name><name name-style="western"><surname>Barquero-Calvo</surname><given-names>E</given-names></name></person-group>. <article-title>The role of neutrophils in brucellosis</article-title>. <source>Microbiol Mol Biol Rev.</source> (<year>2020</year>) <volume>84</volume>:<fpage>e00048</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1128/MMBR.00048-20</pub-id><pub-id pub-id-type="pmid">33055283</pub-id><pub-id pub-id-type="pmcid">PMC7567297</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ficht</surname><given-names>TA</given-names></name><name name-style="western"><surname>Kahl-McDonagh</surname><given-names>MM</given-names></name><name name-style="western"><surname>Arenas-Gamboa</surname><given-names>AM</given-names></name><name name-style="western"><surname>Rice-Ficht</surname><given-names>AC</given-names></name></person-group>. <article-title>Brucellosis: the case for live, attenuated vaccines</article-title>. <source>Vaccine.</source> (<year>2009</year>) <volume>27</volume>:<fpage>D40</fpage>&#8211;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.08.058</pub-id><pub-id pub-id-type="pmid">19837284</pub-id><pub-id pub-id-type="pmcid">PMC2780424</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singha</surname><given-names>H</given-names></name><name name-style="western"><surname>Mallick</surname><given-names>AI</given-names></name><name name-style="western"><surname>Jana</surname><given-names>C</given-names></name><name name-style="western"><surname>Fatima</surname><given-names>N</given-names></name><name name-style="western"><surname>Owais</surname><given-names>M</given-names></name><name name-style="western"><surname>Chaudhuri</surname><given-names>P</given-names></name></person-group>. <article-title>Co-immunization with interlukin-18 enhances the protective efficacy of liposomes encapsulated recombinant Cu&#8211;Zn superoxide dismutase protein against <italic toggle="yes">Brucella abortus</italic></article-title>. <source>Vaccine</source>. (<year>2011</year>) <volume>29</volume>:<fpage>4720</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.04.088</pub-id><pub-id pub-id-type="pmid">21565241</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hop</surname><given-names>HT</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>AWB</given-names></name><name name-style="western"><surname>Simborio</surname><given-names>HLT</given-names></name><name name-style="western"><surname>Arayan</surname><given-names>LT</given-names></name><name name-style="western"><surname>Min</surname><given-names>WG</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name><etal/></person-group>. <article-title>Immunization of mice with recombinant <italic toggle="yes">Brucella abortus</italic> organic hydroperoxide resistance (Ohr) protein protects against a virulent <italic toggle="yes">Brucella abortus</italic> 544 Infection</article-title>. <source>J Microbiol Biotechnol.</source> (<year>2016</year>) <volume>26</volume>:<fpage>190</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.4014/jmb.1505.05028</pub-id><pub-id pub-id-type="pmid">26464379</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasquevich</surname><given-names>KA</given-names></name><name name-style="western"><surname>Estein</surname><given-names>SM</given-names></name><name name-style="western"><surname>Samartino</surname><given-names>CG</given-names></name><name name-style="western"><surname>Zwerdling</surname><given-names>A</given-names></name><name name-style="western"><surname>Coria</surname><given-names>LM</given-names></name><name name-style="western"><surname>Barrionuevo</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Immunization with recombinant <italic toggle="yes">Brucella</italic> species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against <italic toggle="yes">Brucella abortus</italic> infection</article-title>. <source>Infect Immun.</source> (<year>2009</year>) <volume>77</volume>:<fpage>436</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.00123-09</pub-id><pub-id pub-id-type="pmid">18981242</pub-id><pub-id pub-id-type="pmcid">PMC2612246</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghasemi</surname><given-names>A</given-names></name><name name-style="western"><surname>Jeddi-Tehrani</surname><given-names>M</given-names></name><name name-style="western"><surname>Mautner</surname><given-names>J</given-names></name><name name-style="western"><surname>Salari</surname><given-names>MH</given-names></name><name name-style="western"><surname>Zarnani</surname><given-names>A-H</given-names></name></person-group>. <article-title>Immunization of mice with a novel recombinant molecular chaperon confers protection against <italic toggle="yes">Brucella melitensis</italic> infection</article-title>. <source>Vaccine.</source> (<year>2014</year>) <volume>32</volume>:<fpage>6659</fpage>&#8211;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.09.013</pub-id><pub-id pub-id-type="pmid">25240754</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Peng</surname><given-names>D</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Comparison of immune effects between <italic toggle="yes">Brucella</italic> recombinant Omp10-Omp28-L7/L12 proteins expressed in eukaryotic and prokaryotic systems</article-title>. <source>Front Vet Sci.</source> (<year>2020</year>) <volume>7</volume>:<fpage>576</fpage>. <pub-id pub-id-type="doi">10.3389/fvets.2020.00576</pub-id><pub-id pub-id-type="pmid">33195494</pub-id><pub-id pub-id-type="pmcid">PMC7531237</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Singh</surname><given-names>D</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>M</given-names></name><name name-style="western"><surname>Bhatnagar</surname><given-names>R</given-names></name></person-group>. <article-title>A combined subunit vaccine comprising BP26, Omp25 and L7/L12 against brucellosis</article-title>. <source>Pathogens Dis</source>. (<year>2019</year>) <volume>77</volume>:<fpage>ftaa002</fpage>. <pub-id pub-id-type="doi">10.1093/femspd/ftaa002</pub-id><pub-id pub-id-type="pmid">31971564</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golshani</surname><given-names>M</given-names></name><name name-style="western"><surname>Amani</surname><given-names>M</given-names></name><name name-style="western"><surname>Siadat</surname><given-names>SD</given-names></name><name name-style="western"><surname>Nejati-Moheimani</surname><given-names>M</given-names></name><name name-style="western"><surname>Arsang</surname><given-names>A</given-names></name><name name-style="western"><surname>Bouzari</surname><given-names>S</given-names></name></person-group>. <article-title>Comparison of the protective immunity elicited by a <italic toggle="yes">Brucella</italic> cocktail protein vaccine (rL7/L12+ rTOmp31+ rSOmp2b) in two different adjuvant formulations in BALB/c mice</article-title>. <source>Mol Immunol.</source> (<year>2018</year>) <volume>103</volume>:<fpage>306</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2018.10.002</pub-id><pub-id pub-id-type="pmid">30343119</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdollahi</surname><given-names>A</given-names></name><name name-style="western"><surname>Mansouri</surname><given-names>S</given-names></name><name name-style="western"><surname>Amani</surname><given-names>J</given-names></name><name name-style="western"><surname>Fasihi-Ramandi</surname><given-names>M</given-names></name><name name-style="western"><surname>Ranjbar</surname><given-names>R</given-names></name><name name-style="western"><surname>Ghasemi</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>A recombinant chimera protein as a novel <italic toggle="yes">Brucella</italic> subunit vaccine: protective efficacy and induced immune response in BALB/c mice</article-title>. <source>Jundishapur J Microbiol</source>. (<year>2018</year>) <fpage>11</fpage>.</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tadepalli</surname><given-names>G</given-names></name><name name-style="western"><surname>Konduru</surname><given-names>B</given-names></name><name name-style="western"><surname>Murali</surname><given-names>HS</given-names></name><name name-style="western"><surname>Batra</surname><given-names>HV</given-names></name></person-group>. <article-title>Intraperitoneal administration of a novel chimeric immunogen (rOP) elicits IFN-&#947; and IL-12p70 protective immune response in BALB/c mice against virulent <italic toggle="yes">Brucella</italic></article-title>. <source>Immunol Lett</source>. (<year>2017</year>) <volume>192</volume>:<fpage>79</fpage>&#8211;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1016/j.imlet.2017.10.013</pub-id><pub-id pub-id-type="pmid">29106986</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tadepalli</surname><given-names>G</given-names></name><name name-style="western"><surname>Singh</surname><given-names>AK</given-names></name><name name-style="western"><surname>Balakrishna</surname><given-names>K</given-names></name><name name-style="western"><surname>Murali</surname><given-names>HS</given-names></name><name name-style="western"><surname>Batra</surname><given-names>HV</given-names></name></person-group>. <article-title>Immunogenicity and protective efficacy of <italic toggle="yes">Brucella abortus</italic> recombinant protein cocktail (rOmp19+ rP39) against <italic toggle="yes">B. abortus</italic> 544 and <italic toggle="yes">B. melitensis</italic> 16M infection in murine model</article-title>. <source>Mol Immunol.</source> (<year>2016</year>) <volume>71</volume>:<fpage>34</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2016.01.001</pub-id><pub-id pub-id-type="pmid">26826463</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>An</surname><given-names>C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Ke</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lei</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Immunization with individual proteins of the Lrp/AsnC family induces protection against <italic toggle="yes">Brucella melitensis</italic> 16M challenges in mice</article-title>. <source>Front Microbiol.</source> (<year>2015</year>) <volume>6</volume>:<fpage>1193</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2015.01193</pub-id><pub-id pub-id-type="pmid">26579099</pub-id><pub-id pub-id-type="pmcid">PMC4625564</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Song</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ju</surname><given-names>W</given-names></name><name name-style="western"><surname>Song</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>A novel recombinant multi-epitope protein against <italic toggle="yes">Brucella melitensis</italic> infection</article-title>. <source>Immunol Lett.</source> (<year>2016</year>) <volume>175</volume>:<fpage>1</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.imlet.2016.04.016</pub-id><pub-id pub-id-type="pmid">27133932</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Yin</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S</given-names></name><name name-style="western"><surname>Lang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Immunoproteomic analysis of <italic toggle="yes">Brucella melitensis</italic> and identification of a new immunogenic candidate protein for the development of brucellosis subunit vaccine</article-title>. <source>Mol Immunol.</source> (<year>2011</year>) <volume>49</volume>:<fpage>175</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2011.08.009</pub-id><pub-id pub-id-type="pmid">21943783</pub-id></mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>SK</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name></person-group>. <article-title>Immunogenicity and protective potential of a bacterially expressed recombinant dihydrolipoamide succinyltransferase (rE2o) of <italic toggle="yes">Brucella abortus</italic> in BALB/c mice</article-title>. <source>World J Microbiol Biotechnol.</source> (<year>2012</year>) <volume>28</volume>:<fpage>2487</fpage>&#8211;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1007/s11274-012-1056-8</pub-id><pub-id pub-id-type="pmid">22806154</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>S</given-names></name><name name-style="western"><surname>Afley</surname><given-names>P</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name></person-group>. <article-title>Immunological responses to recombinant cysteine synthase A of <italic toggle="yes">Brucella abortus</italic> in BALB/c mice</article-title>. <source>World J Microbiol Biotechnol.</source> (<year>2013</year>) <volume>29</volume>:<fpage>907</fpage>&#8211;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1007/s11274-012-1247-3</pub-id><pub-id pub-id-type="pmid">23269507</pub-id></mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghasemi</surname><given-names>A</given-names></name><name name-style="western"><surname>Zarnani</surname><given-names>A-H</given-names></name><name name-style="western"><surname>Ghoodjani</surname><given-names>A</given-names></name><name name-style="western"><surname>Rezania</surname><given-names>S</given-names></name><name name-style="western"><surname>Salari</surname><given-names>MH</given-names></name><name name-style="western"><surname>Jeddi-Tehrani</surname><given-names>M</given-names></name></person-group>. <article-title>Identification of a new immunogenic candidate conferring protection against <italic toggle="yes">Brucella melitensis</italic> infection in mice</article-title>. <source>Mol Immunol.</source> (<year>2014</year>) <volume>62</volume>:<fpage>142</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2014.06.017</pub-id><pub-id pub-id-type="pmid">24995396</pub-id></mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yousefi</surname><given-names>S</given-names></name><name name-style="western"><surname>Abbassi-Daloii</surname><given-names>T</given-names></name><name name-style="western"><surname>Sekhavati</surname><given-names>MH</given-names></name><name name-style="western"><surname>Tahmoorespur</surname><given-names>M</given-names></name></person-group>. <article-title>Evaluation of immune responses induced by polymeric OMP25-BLS <italic toggle="yes">Brucella</italic> antigen</article-title>. <source>Microb Pathog.</source> (<year>2018</year>) <volume>115</volume>:<fpage>50</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2017.12.045</pub-id><pub-id pub-id-type="pmid">29253594</pub-id></mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>S</given-names></name><name name-style="western"><surname>Peddayelachagiri</surname><given-names>BV</given-names></name><name name-style="western"><surname>Nagaraj</surname><given-names>S</given-names></name><name name-style="western"><surname>Kingston</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Batra</surname><given-names>HV</given-names></name></person-group>. <article-title>Recombinant outer membrane protein 25c from <italic toggle="yes">Brucella abortus</italic> induces Th1 and Th2 mediated protection against <italic toggle="yes">Brucella abortus</italic> infection in mouse model</article-title>. <source>Mol Immunol.</source> (<year>2018</year>) <volume>99</volume>:<fpage>9</fpage>&#8211;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2018.04.002</pub-id><pub-id pub-id-type="pmid">29649688</pub-id></mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hop</surname><given-names>HT</given-names></name><name name-style="western"><surname>Arayan</surname><given-names>LT</given-names></name><name name-style="western"><surname>Huy</surname><given-names>TXN</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>AWB</given-names></name><name name-style="western"><surname>Min</surname><given-names>W</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name><etal/></person-group>. <article-title>Immunization of BALB/c mice with a combination of four recombinant <italic toggle="yes">Brucella abortus</italic> proteins, AspC, Dps, InpB and Ndk, confers a marked protection against a virulent strain of <italic toggle="yes">Brucella abortus</italic></article-title>. <source>Vaccine</source>. (<year>2018</year>) <volume>36</volume>:<fpage>3027</fpage>&#8211;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2018.04.019</pub-id><pub-id pub-id-type="pmid">29678458</pub-id></mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>S</given-names></name><name name-style="western"><surname>Peddayelachagiri</surname><given-names>BV</given-names></name><name name-style="western"><surname>Nagaraj</surname><given-names>S</given-names></name><name name-style="western"><surname>Konduru</surname><given-names>B</given-names></name><name name-style="western"><surname>Batra</surname><given-names>HV</given-names></name></person-group>. <article-title>Protective and therapeutic efficacy study of divalent fusion protein rL7/L12-Omp25 against <italic toggle="yes">B. abortus</italic> 544 in presence of IFN&#947;</article-title>. <source>Appl Microbiol Biotechnol.</source> (<year>2018</year>) <volume>102</volume>:<fpage>8895</fpage>&#8211;<lpage>907</lpage>. <pub-id pub-id-type="doi">10.1007/s00253-018-9314-9</pub-id><pub-id pub-id-type="pmid">30136204</pub-id></mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senevirathne</surname><given-names>A</given-names></name><name name-style="western"><surname>Hewawaduge</surname><given-names>C</given-names></name><name name-style="western"><surname>Hajam</surname><given-names>IA</given-names></name><name name-style="western"><surname>Lalsiamthara</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name></person-group>. <article-title>Intranasally administered anti-<italic toggle="yes">Brucella</italic> subunit vaccine formulation induces protective immune responses against nasal <italic toggle="yes">Brucella</italic> challenge</article-title>. <source>Vet Microbiol.</source> (<year>2019</year>) <volume>228</volume>:<fpage>112</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetmic.2018.11.022</pub-id><pub-id pub-id-type="pmid">30593355</pub-id></mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadeghi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Fasihi-Ramandi</surname><given-names>M</given-names></name><name name-style="western"><surname>Bouzari</surname><given-names>S</given-names></name></person-group>. <article-title>Evaluation of immunogenicity of novel multi-epitope subunit vaccines in combination with poly I: C against <italic toggle="yes">Brucella melitensis</italic> and <italic toggle="yes">Brucella abortus</italic> infection</article-title>. <source>Int Immunopharmacol.</source> (<year>2019</year>) <volume>75</volume>:<fpage>105829</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2019.105829</pub-id><pub-id pub-id-type="pmid">31437796</pub-id></mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golshani</surname><given-names>M</given-names></name><name name-style="western"><surname>Amani</surname><given-names>M</given-names></name><name name-style="western"><surname>Amirzadeh</surname><given-names>F</given-names></name><name name-style="western"><surname>Nazeri</surname><given-names>E</given-names></name><name name-style="western"><surname>Siadat</surname><given-names>SD</given-names></name><name name-style="western"><surname>Nejati-Moheimani</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Evaluation of Poly (I: C) and combination of CpG ODN plus Montanide ISA adjuvants to enhance the efficacy of outer membrane vesicles as an acellular vaccine against <italic toggle="yes">Brucella melitensis</italic> infection in mice</article-title>. <source>Int Immunopharmacol.</source> (<year>2020</year>) <volume>84</volume>:<fpage>106573</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2020.106573</pub-id><pub-id pub-id-type="pmid">32454410</pub-id></mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nazifi</surname><given-names>N</given-names></name><name name-style="western"><surname>Tahmoorespur</surname><given-names>M</given-names></name><name name-style="western"><surname>Sekhavati</surname><given-names>MH</given-names></name><name name-style="western"><surname>Haghparast</surname><given-names>A</given-names></name><name name-style="western"><surname>Behroozikhah</surname><given-names>AM</given-names></name></person-group>. <article-title><italic toggle="yes">In vivo</italic> immunogenicity assessment and vaccine efficacy evaluation of a chimeric tandem repeat of epitopic region of OMP31 antigen fused to interleukin 2 (IL-2) against <italic toggle="yes">Brucella melitensis</italic> in BALB/c mice</article-title>. <source>BMC Vet Res.</source> (<year>2019</year>) <volume>15</volume>:<fpage>402</fpage>. <pub-id pub-id-type="doi">10.1186/s12917-019-2074-7</pub-id><pub-id pub-id-type="pmid">31703683</pub-id><pub-id pub-id-type="pmcid">PMC6842255</pub-id></mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delpino</surname><given-names>MV</given-names></name><name name-style="western"><surname>Estein</surname><given-names>SM</given-names></name><name name-style="western"><surname>Fossati</surname><given-names>CA</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>PC</given-names></name><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name></person-group>. <article-title>Vaccination with <italic toggle="yes">Brucella</italic> recombinant DnaK and SurA proteins induces protection against <italic toggle="yes">Brucella abortus</italic> infection in BALB/c mice</article-title>. <source>Vaccine.</source> (<year>2007</year>) <volume>25</volume>:<fpage>6721</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2007.07.002</pub-id><pub-id pub-id-type="pmid">17686554</pub-id></mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>P</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>N</given-names></name></person-group>. <article-title>Factors that influence the immune response to vaccination</article-title>. <source>Clin Microbiol Rev.</source> (<year>2019</year>) <volume>32</volume>:<fpage>e00084</fpage>&#8211;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.00084-18</pub-id><pub-id pub-id-type="pmid">30867162</pub-id><pub-id pub-id-type="pmcid">PMC6431125</pub-id></mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliveira</surname><given-names>SC</given-names></name><name name-style="western"><surname>Splitter</surname><given-names>GA</given-names></name></person-group>. <article-title>Immunization of mice with recombinant L7L12 ribosomal protein confers protection against <italic toggle="yes">Brucella abortus</italic> infection</article-title>. <source>Vaccine.</source> (<year>1996</year>) <volume>14</volume>:<fpage>959</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/0264-410X(96)00018-7</pub-id><pub-id pub-id-type="pmid">8873388</pub-id></mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Xi</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group>. <article-title><italic toggle="yes">Brucella abortus</italic> phosphoglyceromutase and dihydrodipicolinate reductase induce Th1 and Th2-related immune responses</article-title>. <source>World J Microbiol Biotechnol.</source> (<year>2018</year>) <volume>34</volume>:<fpage>1</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s11274-017-2405-4</pub-id><pub-id pub-id-type="pmid">29302824</pub-id></mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>G</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Sunil Kumar</surname><given-names>B</given-names></name><name name-style="western"><surname>Mahajan</surname><given-names>K</given-names></name><name name-style="western"><surname>Verma</surname><given-names>R</given-names></name></person-group>. <article-title>Characterization and immunogenicity of outer membrane vesicles from <italic toggle="yes">Brucella abortus</italic></article-title>. <source>J Immunoassay Immunochem</source>. (<year>2016</year>) <volume>37</volume>:<fpage>261</fpage>&#8211;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1080/15321819.2015.1132231</pub-id><pub-id pub-id-type="pmid">26684926</pub-id></mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golshani</surname><given-names>M</given-names></name><name name-style="western"><surname>Rafati</surname><given-names>S</given-names></name><name name-style="western"><surname>Nejati-Moheimani</surname><given-names>M</given-names></name><name name-style="western"><surname>Ghasemian</surname><given-names>M</given-names></name><name name-style="western"><surname>Bouzari</surname><given-names>S</given-names></name></person-group>. <article-title>Comparison of potential protection conferred by three immunization strategies (protein/protein, DNA/DNA, and DNA/protein) against <italic toggle="yes">Brucella</italic> infection using Omp2b in BALB/c Mice</article-title>. <source>Vet Microbiol.</source> (<year>2016</year>) <volume>197</volume>:<fpage>47</fpage>&#8211;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetmic.2016.10.027</pub-id><pub-id pub-id-type="pmid">27938682</pub-id></mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Huo</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Evaluation of a recombinant bacillus calmette-gu&#233;rin vaccine expressing P39-L7/L12 of <italic toggle="yes">Brucella melitensis</italic>: an immunization strategy against brucellosis in BALB/c mice</article-title>. <source>Materials Express.</source> (<year>2020</year>) <volume>10</volume>:<fpage>350</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1166/mex.2020.1645</pub-id></mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukherjee</surname><given-names>F</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>A</given-names></name><name name-style="western"><surname>Bahekar</surname><given-names>VS</given-names></name><name name-style="western"><surname>Rana</surname><given-names>SK</given-names></name><name name-style="western"><surname>Rajendra</surname><given-names>L</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>GK</given-names></name><etal/></person-group>. <article-title>Evaluation of immunogenicity and protective efficacy of a liposome containing <italic toggle="yes">Brucella abortus</italic> S19 outer membrane protein in BALB/c mice</article-title>. <source>Iran J Vet Res.</source> (<year>2016</year>) <volume>17</volume>:<fpage>1</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">27656221</pub-id><pub-id pub-id-type="pmcid">PMC4898012</pub-id></mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clausse</surname><given-names>M</given-names></name><name name-style="western"><surname>D&#237;az</surname><given-names>AG</given-names></name><name name-style="western"><surname>Iba&#241;ez</surname><given-names>AE</given-names></name><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name><name name-style="western"><surname>Giambartolomei</surname><given-names>GH</given-names></name><name name-style="western"><surname>Estein</surname><given-names>SM</given-names></name></person-group>. <article-title>Evaluation of the efficacy of outer membrane protein 31 vaccine formulations for protection against <italic toggle="yes">Brucella canis</italic> in BALB/c mice</article-title>. <source>Clin Vaccine Immunol.</source> (<year>2014</year>) <volume>21</volume>:<fpage>1689</fpage>&#8211;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00527-14</pub-id><pub-id pub-id-type="pmid">25339409</pub-id><pub-id pub-id-type="pmcid">PMC4248782</pub-id></mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simborio</surname><given-names>HLT</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>AWB</given-names></name><name name-style="western"><surname>Hop</surname><given-names>HT</given-names></name><name name-style="western"><surname>Arayan</surname><given-names>LT</given-names></name><name name-style="western"><surname>Min</surname><given-names>W</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name><etal/></person-group>. <article-title>Immune modulation of recombinant OmpA against <italic toggle="yes">Brucella abortus</italic> 544 infection in mice</article-title>. <source>J Microbiol Biotechnol.</source> (<year>2016</year>) <volume>26</volume>:<fpage>603</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4014/jmb.1509.09061</pub-id><pub-id pub-id-type="pmid">26699748</pub-id></mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Du</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Immunization of mice with recombinant protein CobB or AsnC confers protection against <italic toggle="yes">Brucella abortus</italic> infection</article-title>. <source>PLoS ONE.</source> (<year>2012</year>) <volume>7</volume>:<fpage>e29552</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0029552</pub-id><pub-id pub-id-type="pmid">22383953</pub-id><pub-id pub-id-type="pmcid">PMC3286461</pub-id></mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huy</surname><given-names>TXN</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>TT</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>AWB</given-names></name><name name-style="western"><surname>Vu</surname><given-names>SH</given-names></name><name name-style="western"><surname>Min</surname><given-names>W</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name><etal/></person-group>. <article-title>Immunization with a combination of four recombinant <italic toggle="yes">Brucella abortus</italic> Proteins Omp16, Omp19, Omp28, and L7/L12 induces T helper 1 immune response against virulent <italic toggle="yes">B. abortus</italic> 544 infection in BALB/c mice</article-title>. <source>Front Vet Sci.</source> (<year>2021</year>) <volume>7</volume>:<fpage>1221</fpage>. <pub-id pub-id-type="doi">10.3389/fvets.2020.577026</pub-id><pub-id pub-id-type="pmid">33553273</pub-id><pub-id pub-id-type="pmcid">PMC7854899</pub-id></mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Z-Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J-Y</given-names></name></person-group>. <article-title>Immunogenicity analysis of a novel subunit vaccine candidate molecule&#8212;recombinant L7/L12 ribosomal protein of <italic toggle="yes">Brucella suis</italic></article-title>. <source>Appl Biochem Biotechnol</source>. (<year>2016</year>) <volume>179</volume>:<fpage>1445</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1007/s12010-016-2076-x</pub-id><pub-id pub-id-type="pmid">27075455</pub-id></mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hop</surname><given-names>HT</given-names></name><name name-style="western"><surname>Simborio</surname><given-names>HL</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>AWB</given-names></name><name name-style="western"><surname>Arayan</surname><given-names>LT</given-names></name><name name-style="western"><surname>Min</surname><given-names>W</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name><etal/></person-group>. <article-title>Immunogenicity and protective effect of recombinant <italic toggle="yes">Brucella abortus</italic> Ndk (rNdk) against a virulent strain <italic toggle="yes">B. abortus</italic> 544 infection in BALB/c mice</article-title>. <source>FEMS Microbiol Lett.</source> (<year>2015</year>) <volume>362</volume>:<fpage>1</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1093/femsle/fnv003</pub-id><pub-id pub-id-type="pmid">25724777</pub-id></mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huy</surname><given-names>TXN</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>AWB</given-names></name><name name-style="western"><surname>Vu</surname><given-names>SH</given-names></name><name name-style="western"><surname>Arayan</surname><given-names>LT</given-names></name><name name-style="western"><surname>Hop</surname><given-names>HT</given-names></name><name name-style="western"><surname>Min</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Immunogenicity and protective response induced by recombinant <italic toggle="yes">Brucella abortus</italic> proteins Adk, SecB and combination of these two recombinant proteins against a virulent strain <italic toggle="yes">B. abortus</italic> 544 infection in BALB/c mice</article-title>. <source>Microbial Pathogen.</source> (<year>2020</year>) <volume>143</volume>:<fpage>104137</fpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2020.104137</pub-id><pub-id pub-id-type="pmid">32169487</pub-id></mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goel</surname><given-names>D</given-names></name><name name-style="western"><surname>Bhatnagar</surname><given-names>R</given-names></name></person-group>. <article-title>Intradermal immunization with outer membrane protein 25 protects Balb/c mice from virulent <italic toggle="yes">B. abortus</italic> 544</article-title>. <source>Mol Immunol.</source> (<year>2012</year>) <volume>51</volume>:<fpage>159</fpage>&#8211;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2012.02.126</pub-id><pub-id pub-id-type="pmid">22464098</pub-id></mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#237;az</surname><given-names>AG</given-names></name><name name-style="western"><surname>Quinteros</surname><given-names>DA</given-names></name><name name-style="western"><surname>Paolicchi</surname><given-names>FA</given-names></name><name name-style="western"><surname>Rivero</surname><given-names>MA</given-names></name><name name-style="western"><surname>Palma</surname><given-names>SD</given-names></name><name name-style="western"><surname>Pardo</surname><given-names>RP</given-names></name><etal/></person-group>. <article-title>Mucosal immunization with polymeric antigen BLSOmp31 using alternative delivery systems against <italic toggle="yes">Brucella ovis</italic> in rams</article-title>. <source>Vet Immunol Immunopathol.</source> (<year>2019</year>) <volume>209</volume>:<fpage>70</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetimm.2019.02.005</pub-id><pub-id pub-id-type="pmid">30885309</pub-id></mixed-citation></ref><ref id="B107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solanki</surname><given-names>KS</given-names></name><name name-style="western"><surname>Varshney</surname><given-names>R</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>S</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>P</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Non-infectious outer membrane vesicles derived from <italic toggle="yes">Brucella abortus</italic> S19&#916;per as an alternative acellular vaccine protects mice against virulent challenge</article-title>. <source>Int Immunopharmacol.</source> (<year>2021</year>) <volume>90</volume>:<fpage>107148</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2020.107148</pub-id><pub-id pub-id-type="pmid">33189614</pub-id></mixed-citation></ref><ref id="B108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Afley</surname><given-names>P</given-names></name><name name-style="western"><surname>Dohre</surname><given-names>SK</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>G</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name></person-group>. <article-title>Prediction of T cell epitopes of <italic toggle="yes">Brucella abortus</italic> and evaluation of their protective role in mice</article-title>. <source>Appl Microbiol Biotechnol.</source> (<year>2015</year>) <volume>99</volume>:<fpage>7625</fpage>&#8211;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1007/s00253-015-6787-7</pub-id><pub-id pub-id-type="pmid">26150246</pub-id></mixed-citation></ref><ref id="B109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DG</given-names></name><name name-style="western"><surname>Min</surname><given-names>W</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name><etal/></person-group>. <article-title>Protective effects of recombinant <italic toggle="yes">Brucella abortus</italic> Omp28 against infection with a virulent strain of <italic toggle="yes">Brucella abortus</italic> 544 in mice</article-title>. <source>J Vet Sci.</source> (<year>2012</year>) <volume>13</volume>:<fpage>287</fpage>. <pub-id pub-id-type="doi">10.4142/jvs.2012.13.3.287</pub-id><pub-id pub-id-type="pmid">23000585</pub-id><pub-id pub-id-type="pmcid">PMC3467404</pub-id></mixed-citation></ref><ref id="B110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>D</given-names></name><name name-style="western"><surname>Goel</surname><given-names>D</given-names></name><name name-style="western"><surname>Bhatnagar</surname><given-names>R</given-names></name></person-group>. <article-title>Recombinant L7/L12 protein entrapping PLGA (poly lactide-co-glycolide) micro particles protect BALB/c mice against the virulent <italic toggle="yes">B. abortus</italic> 544 infection</article-title>. <source>Vaccine.</source> (<year>2015</year>) <volume>33</volume>:<fpage>2786</fpage>&#8211;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.04.030</pub-id><pub-id pub-id-type="pmid">25930114</pub-id></mixed-citation></ref><ref id="B111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>AK</given-names></name><name name-style="western"><surname>Balakrishna</surname><given-names>K</given-names></name><name name-style="western"><surname>Sripathy</surname><given-names>MH</given-names></name><name name-style="western"><surname>Batra</surname><given-names>HV</given-names></name></person-group>. <article-title>Studies on recombinant glucokinase (r-glk) protein of <italic toggle="yes">Brucella abortus</italic> as a candidate vaccine molecule for brucellosis</article-title>. <source>Vaccine.</source> (<year>2014</year>) <volume>32</volume>:<fpage>5600</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.07.106</pub-id><pub-id pub-id-type="pmid">25131740</pub-id></mixed-citation></ref><ref id="B112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abkar</surname><given-names>M</given-names></name><name name-style="western"><surname>Amani</surname><given-names>J</given-names></name><name name-style="western"><surname>Sahebghadam Lotfi</surname><given-names>A</given-names></name><name name-style="western"><surname>Nikbakht Brujeni</surname><given-names>G</given-names></name><name name-style="western"><surname>Alamian</surname><given-names>S</given-names></name><name name-style="western"><surname>Kamali</surname><given-names>M</given-names></name></person-group>. <article-title>Subcutaneous immunization with a novel immunogenic candidate (urease) confers protection against <italic toggle="yes">Brucella abortus</italic> and <italic toggle="yes">Brucella melitensis</italic> infections</article-title>. <source>Apmis.</source> (<year>2015</year>) <volume>123</volume>:<fpage>667</fpage>&#8211;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1111/apm.12400</pub-id><pub-id pub-id-type="pmid">25939375</pub-id></mixed-citation></ref><ref id="B113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arayan</surname><given-names>LT</given-names></name><name name-style="western"><surname>Huy</surname><given-names>TXN</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>AWB</given-names></name><name name-style="western"><surname>Hop</surname><given-names>HT</given-names></name><name name-style="western"><surname>Son</surname><given-names>VH</given-names></name><name name-style="western"><surname>Min</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Substantial protective immunity conferred by a combination of <italic toggle="yes">Brucella abortus</italic> recombinant proteins against <italic toggle="yes">Brucella abortus</italic> 544 infection in BALB/c mice</article-title>. <source>J Microbiol Biotechnol</source>. (<year>2019</year>) <volume>29</volume>:<fpage>330</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.4014/jmb.1811.10066</pub-id><pub-id pub-id-type="pmid">30609879</pub-id></mixed-citation></ref><ref id="B114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jia</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pang</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>The immunogenicity of OMP31 peptides and its protection against <italic toggle="yes">Brucella melitensis</italic> infection in mice</article-title>. <source>Sci Rep.</source> (<year>2019</year>) <volume>9</volume>:<fpage>1</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/s41598-019-40084-w</pub-id><pub-id pub-id-type="pmid">30837598</pub-id><pub-id pub-id-type="pmcid">PMC6401381</pub-id></mixed-citation></ref><ref id="B115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clausse</surname><given-names>M</given-names></name><name name-style="western"><surname>D&#237;az</surname><given-names>AG</given-names></name><name name-style="western"><surname>Ghersi</surname><given-names>G</given-names></name><name name-style="western"><surname>Zylberman</surname><given-names>V</given-names></name><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name><name name-style="western"><surname>Giambartolomei</surname><given-names>GH</given-names></name><etal/></person-group>. <article-title>The vaccine candidate BLSOmp31 protects mice against <italic toggle="yes">Brucella canis</italic> infection</article-title>. <source>Vaccine.</source> (<year>2013</year>) <volume>31</volume>:<fpage>6129</fpage>&#8211;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.07.041</pub-id><pub-id pub-id-type="pmid">23906889</pub-id></mixed-citation></ref><ref id="B116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cherwonogrodzky</surname><given-names>JW</given-names></name><name name-style="western"><surname>Barab&#233;</surname><given-names>ND</given-names></name><name name-style="western"><surname>Grigat</surname><given-names>ML</given-names></name><name name-style="western"><surname>Lee</surname><given-names>WE</given-names></name><name name-style="western"><surname>Poirier</surname><given-names>RT</given-names></name><name name-style="western"><surname>Jager</surname><given-names>SJ</given-names></name><etal/></person-group>. <article-title>Thermostable cross-protective subunit vaccine against <italic toggle="yes">Brucella</italic> species</article-title>. <source>Clin Vaccine Immunol.</source> (<year>2014</year>) <volume>21</volume>:<fpage>1681</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00447-14</pub-id><pub-id pub-id-type="pmid">25320267</pub-id><pub-id pub-id-type="pmcid">PMC4248776</pub-id></mixed-citation></ref><ref id="B117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Vaccination with recombinant flagellar proteins FlgJ and FliN induce protection against <italic toggle="yes">Brucella abortus</italic> 544 infection in BALB/c mice</article-title>. <source>Vet Microbiol.</source> (<year>2012</year>) <volume>161</volume>:<fpage>137</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetmic.2012.07.016</pub-id><pub-id pub-id-type="pmid">22854331</pub-id></mixed-citation></ref><ref id="B118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golshani</surname><given-names>M</given-names></name><name name-style="western"><surname>Rafati</surname><given-names>S</given-names></name><name name-style="western"><surname>Dashti</surname><given-names>A</given-names></name><name name-style="western"><surname>Gholami</surname><given-names>E</given-names></name><name name-style="western"><surname>Siadat</surname><given-names>SD</given-names></name><name name-style="western"><surname>Oloomi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Vaccination with recombinant L7/L12-truncated Omp31 protein induces protection against <italic toggle="yes">Brucella</italic> infection in BALB/c mice</article-title>. <source>Mol Immunol.</source> (<year>2015</year>) <volume>65</volume>:<fpage>287</fpage>&#8211;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2015.01.009</pub-id><pub-id pub-id-type="pmid">25723468</pub-id></mixed-citation></ref><ref id="B119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name></person-group>. <article-title>Evaluation of a DNA vaccine encoding <italic toggle="yes">Brucella</italic> BvrR in BALB/c mice</article-title>. <source>Mol Med Rep.</source> (<year>2019</year>) <volume>19</volume>:<fpage>1302</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2018.9735</pub-id><pub-id pub-id-type="pmid">30569140</pub-id></mixed-citation></ref><ref id="B120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imtiaz</surname><given-names>W</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A</given-names></name><name name-style="western"><surname>Gul</surname><given-names>ST</given-names></name><name name-style="western"><surname>Saqib</surname><given-names>M</given-names></name><name name-style="western"><surname>Saleemi</surname><given-names>MK</given-names></name><name name-style="western"><surname>Shahzad</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Evaluation of DNA vaccine encoding BCSP31 surface protein of <italic toggle="yes">Brucella abortus</italic> for protective immunity</article-title>. <source>Microb Pathog.</source> (<year>2018</year>) <volume>125</volume>:<fpage>514</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2018.10.016</pub-id><pub-id pub-id-type="pmid">30321591</pub-id></mixed-citation></ref><ref id="B121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riquelme-Neira</surname><given-names>R</given-names></name><name name-style="western"><surname>Retamal-D&#237;az</surname><given-names>A</given-names></name><name name-style="western"><surname>Acu&#241;a</surname><given-names>F</given-names></name><name name-style="western"><surname>Riquelme</surname><given-names>P</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>A</given-names></name><name name-style="western"><surname>S&#225;ez</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Protective effect of a DNA vaccine containing an open reading frame with homology to an ABC-type transporter present in the genomic island 3 of <italic toggle="yes">Brucella abortus</italic> in BALB/c mice</article-title>. <source>Vaccine.</source> (<year>2013</year>) <volume>31</volume>:<fpage>3663</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.06.013</pub-id><pub-id pub-id-type="pmid">23834811</pub-id></mixed-citation></ref><ref id="B122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>S</given-names></name><name name-style="western"><surname>Afley</surname><given-names>P</given-names></name><name name-style="western"><surname>Dohre</surname><given-names>SK</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>N</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name></person-group>. <article-title>Evaluation of immunogenicity and protective efficacy of a plasmid DNA vaccine encoding ribosomal protein L9 of <italic toggle="yes">Brucella abortus</italic> in BALB/c mice</article-title>. <source>Vaccine.</source> (<year>2014</year>) <volume>32</volume>:<fpage>4537</fpage>&#8211;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.06.012</pub-id><pub-id pub-id-type="pmid">24950353</pub-id></mixed-citation></ref><ref id="B123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Xi</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Immunization with recombinant GntR plasmid confers protection against <italic toggle="yes">Brucella</italic> challenge in BALB/c mice</article-title>. <source>Microb Pathog.</source> (<year>2017</year>) <volume>111</volume>:<fpage>357</fpage>&#8211;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2017.09.010</pub-id><pub-id pub-id-type="pmid">28916314</pub-id></mixed-citation></ref><ref id="B124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#243;mez</surname><given-names>LA</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>FI</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>PA</given-names></name><name name-style="western"><surname>Flores</surname><given-names>MR</given-names></name><name name-style="western"><surname>Molina</surname><given-names>RE</given-names></name><name name-style="western"><surname>Coloma</surname><given-names>RF</given-names></name><etal/></person-group>. <article-title>Immunogenicity and protective response induced by recombinant plasmids based on the BAB1_0267 and BAB1_0270 open reading frames of <italic toggle="yes">Brucella abortus</italic> 2308 in BALB/c mice</article-title>. <source>Front Cell Infect Microbiol.</source> (<year>2016</year>) <volume>6</volume>:<fpage>117</fpage>. <pub-id pub-id-type="doi">10.3389/fcimb.2016.00117</pub-id><pub-id pub-id-type="pmid">27747197</pub-id><pub-id pub-id-type="pmcid">PMC5041321</pub-id></mixed-citation></ref><ref id="B125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shojaei</surname><given-names>M</given-names></name><name name-style="western"><surname>Tahmoorespur</surname><given-names>M</given-names></name><name name-style="western"><surname>Soltani</surname><given-names>M</given-names></name><name name-style="western"><surname>Sekhavati</surname><given-names>MH</given-names></name></person-group>. <article-title>Immunogenicity evaluation of plasmids encoding <italic toggle="yes">Brucella melitensis</italic> Omp25 and Omp31 antigens in BALB/c mice</article-title>. <source>Iran J Basic Med Sci.</source> (<year>2018</year>) <volume>21</volume>:<fpage>957</fpage>. <pub-id pub-id-type="doi">10.22038/IJBMS.2018.27540.6722</pub-id><pub-id pub-id-type="pmid">30524697</pub-id><pub-id pub-id-type="pmcid">PMC6272067</pub-id></mixed-citation></ref><ref id="B126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Escalona</surname><given-names>E</given-names></name><name name-style="western"><surname>S&#225;ez</surname><given-names>D</given-names></name><name name-style="western"><surname>O&#241;ate</surname><given-names>A</given-names></name></person-group>. <article-title>Immunogenicity of a multi-epitope dna vaccine encoding epitopes from Cu&#8211;Zn superoxide dismutase and open reading Frames of <italic toggle="yes">Brucella abortus</italic> in mice</article-title>. <source>Front Immunol.</source> (<year>2017</year>) <volume>8</volume>:<fpage>125</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2017.00125</pub-id><pub-id pub-id-type="pmid">28232837</pub-id><pub-id pub-id-type="pmcid">PMC5298974</pub-id></mixed-citation></ref><ref id="B127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sislema-Egas</surname><given-names>F</given-names></name><name name-style="western"><surname>C&#233;spedes</surname><given-names>S</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>P</given-names></name><name name-style="western"><surname>Retamal-D&#237;az</surname><given-names>A</given-names></name><name name-style="western"><surname>S&#225;ez</surname><given-names>D</given-names></name><name name-style="western"><surname>O&#241;ate</surname><given-names>A</given-names></name></person-group>. <article-title>Evaluation of protective effect of DNA vaccines encoding the BAB1_0263 and BAB1_0278 open reading frames of <italic toggle="yes">Brucella abortus</italic> in BALB/c mice</article-title>. <source>Vaccine.</source> (<year>2012</year>) <volume>30</volume>:<fpage>7286</fpage>&#8211;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.09.039</pub-id><pub-id pub-id-type="pmid">23026687</pub-id></mixed-citation></ref><ref id="B128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Da Costa Martins</surname><given-names>R</given-names></name><name name-style="western"><surname>Gamazo</surname><given-names>C</given-names></name><name name-style="western"><surname>S&#225;nchez-Mart&#237;nez</surname><given-names>M</given-names></name><name name-style="western"><surname>Barber&#225;n</surname><given-names>M</given-names></name><name name-style="western"><surname>Pe&#241;uelas</surname><given-names>I</given-names></name><name name-style="western"><surname>Irache</surname><given-names>JM</given-names></name></person-group>. <article-title>Conjunctival vaccination against <italic toggle="yes">Brucella ovis</italic> in mice with mannosylated nanoparticles</article-title>. <source>J Control Release.</source> (<year>2012</year>) <volume>162</volume>:<fpage>553</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2012.07.030</pub-id><pub-id pub-id-type="pmid">22846987</pub-id></mixed-citation></ref><ref id="B129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shim</surname><given-names>S</given-names></name><name name-style="western"><surname>Soh</surname><given-names>SH</given-names></name><name name-style="western"><surname>Im</surname><given-names>YB</given-names></name><name name-style="western"><surname>Park</surname><given-names>H-E</given-names></name><name name-style="western"><surname>Cho</surname><given-names>C-S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Elicitation of Th1/Th2 related responses in mice by chitosan nanoparticles loaded with <italic toggle="yes">Brucella abortus</italic> malate dehydrogenase, outer membrane proteins 10 and 19</article-title>. <source>Int J Medical Microbiol.</source> (<year>2020</year>) <volume>310</volume>:<fpage>151362</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijmm.2019.151362</pub-id><pub-id pub-id-type="pmid">31676233</pub-id></mixed-citation></ref><ref id="B130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karevan</surname><given-names>G</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>K</given-names></name><name name-style="western"><surname>Taheri</surname><given-names>RA</given-names></name><name name-style="western"><surname>Fasihi-Ramandi</surname><given-names>M</given-names></name></person-group>. <article-title>Immunogenicity of glycine nanoparticles containing a chimeric antigen as <italic toggle="yes">Brucella</italic> vaccine candidate</article-title>. <source>Clin Exp Vaccine Res.</source> (<year>2021</year>) <volume>10</volume>:<fpage>35</fpage>. <pub-id pub-id-type="doi">10.7774/cevr.2021.10.1.35</pub-id><pub-id pub-id-type="pmid">33628752</pub-id><pub-id pub-id-type="pmcid">PMC7892938</pub-id></mixed-citation></ref><ref id="B131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Afshari</surname><given-names>H</given-names></name><name name-style="western"><surname>Maleki</surname><given-names>M</given-names></name><name name-style="western"><surname>Salouti</surname><given-names>M</given-names></name></person-group>. <article-title>Immunological effects of two new nanovaccines against <italic toggle="yes">Brucella</italic> based on OPS and LPS antigens conjugated with PLGA nanoparticles</article-title>. <source>Eur Polym J.</source> (<year>2020</year>) <volume>139</volume>:<fpage>110021</fpage>. <pub-id pub-id-type="doi">10.1016/j.eurpolymj.2020.110021</pub-id></mixed-citation></ref><ref id="B132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soh</surname><given-names>SH</given-names></name><name name-style="western"><surname>Shim</surname><given-names>S</given-names></name><name name-style="western"><surname>Im</surname><given-names>YB</given-names></name><name name-style="western"><surname>Park</surname><given-names>H-T</given-names></name><name name-style="western"><surname>Cho</surname><given-names>C-S</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>HS</given-names></name></person-group>. <article-title>Induction of Th2-related immune responses and production of systemic IgA in mice intranasally immunized with <italic toggle="yes">Brucella abortus</italic> malate dehydrogenase loaded chitosan nanoparticles</article-title>. <source>Vaccine.</source> (<year>2019</year>) <volume>37</volume>:<fpage>1554</fpage>&#8211;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2019.02.005</pub-id><pub-id pub-id-type="pmid">30792035</pub-id></mixed-citation></ref><ref id="B133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abkar</surname><given-names>M</given-names></name><name name-style="western"><surname>Fasihi-Ramandi</surname><given-names>M</given-names></name><name name-style="western"><surname>Kooshki</surname><given-names>H</given-names></name><name name-style="western"><surname>Lotfi</surname><given-names>AS</given-names></name></person-group>. <article-title>Oral immunization of mice with Omp31-loaded N-trimethyl chitosan nanoparticles induces high protection against <italic toggle="yes">Brucella melitensis</italic> infection</article-title>. <source>Int J Nanomed.</source> (<year>2017</year>) <volume>12</volume>:<fpage>8769</fpage>. <pub-id pub-id-type="doi">10.2147/IJN.S149774</pub-id><pub-id pub-id-type="pmid">29263667</pub-id><pub-id pub-id-type="pmcid">PMC5732559</pub-id></mixed-citation></ref><ref id="B134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadeghi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Fasihi-Ramandi</surname><given-names>M</given-names></name><name name-style="western"><surname>Azizi</surname><given-names>M</given-names></name><name name-style="western"><surname>Bouzari</surname><given-names>S</given-names></name></person-group>. <article-title>Mannosylated chitosan nanoparticles loaded with FliC antigen as a novel vaccine candidate against <italic toggle="yes">Brucella melitensis</italic> and <italic toggle="yes">Brucella abortus</italic> infection</article-title>. <source>J Biotechnol.</source> (<year>2020</year>) <volume>310</volume>:<fpage>89</fpage>&#8211;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/j.jbiotec.2020.01.016</pub-id><pub-id pub-id-type="pmid">32017955</pub-id></mixed-citation></ref><ref id="B135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadeghi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Fasihi-Ramandi</surname><given-names>M</given-names></name><name name-style="western"><surname>Bouzari</surname><given-names>S</given-names></name></person-group>. <article-title>Nanoparticle-based vaccines for brucellosis: calcium phosphate nanoparticles-adsorbed antigens induce cross protective response in mice</article-title>. <source>Int J Nanomed.</source> (<year>2020</year>) <volume>15</volume>:<fpage>3877</fpage>. <pub-id pub-id-type="doi">10.2147/IJN.S249942</pub-id><pub-id pub-id-type="pmid">32581535</pub-id><pub-id pub-id-type="pmcid">PMC7269176</pub-id></mixed-citation></ref><ref id="B136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abkar</surname><given-names>M</given-names></name><name name-style="western"><surname>Fasihi-Ramandi</surname><given-names>M</given-names></name><name name-style="western"><surname>Kooshki</surname><given-names>H</given-names></name><name name-style="western"><surname>Lotfi</surname><given-names>AS</given-names></name></person-group>. <article-title>Intraperitoneal immunization with Urease loaded N-trimethyl Chitosan nanoparticles elicits high protection against <italic toggle="yes">Brucella melitensis</italic> and <italic toggle="yes">Brucella abortus</italic> infections</article-title>. <source>Immunol Lett.</source> (<year>2018</year>) <volume>199</volume>:<fpage>53</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.imlet.2018.03.004</pub-id><pub-id pub-id-type="pmid">29548705</pub-id></mixed-citation></ref><ref id="B137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>D</given-names></name><name name-style="western"><surname>Somani</surname><given-names>VK</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>S</given-names></name><name name-style="western"><surname>Bhatnagar</surname><given-names>R</given-names></name></person-group>. <article-title>PLGA (85: 15) nanoparticle based delivery of rL7/L12 ribosomal protein in mice protects against <italic toggle="yes">Brucella abortus</italic> 544 infection: a promising alternate to traditional adjuvants</article-title>. <source>Mol Immunol.</source> (<year>2015</year>) <volume>68</volume>:<fpage>272</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2015.09.011</pub-id><pub-id pub-id-type="pmid">26442664</pub-id></mixed-citation></ref><ref id="B138"><label>138.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maleki</surname><given-names>M</given-names></name><name name-style="western"><surname>Salouti</surname><given-names>M</given-names></name><name name-style="western"><surname>Shafiee Ardestani</surname><given-names>M</given-names></name><name name-style="western"><surname>Talebzadeh</surname><given-names>A</given-names></name></person-group>. <article-title>Preparation of a nanovaccine against <italic toggle="yes">Brucella melitensis</italic> M16 based on PLGA nanoparticles and oligopolysaccharide antigen</article-title>. <source>Artif Cells Nanomed Biotechnol.</source> (<year>2019</year>) <volume>47</volume>:<fpage>4248</fpage>&#8211;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1080/21691401.2019.1687490</pub-id><pub-id pub-id-type="pmid">31718300</pub-id></mixed-citation></ref><ref id="B139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>X-D</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D-H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S-T</given-names></name><name name-style="western"><surname>Li</surname><given-names>S-X</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name></person-group>. <article-title>A combined DNA vaccine provides protective immunity against Mycobacterium bovis and <italic toggle="yes">Brucella abortus</italic> in cattle</article-title>. <source>DNA Cell Biol.</source> (<year>2009</year>) <volume>28</volume>:<fpage>191</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1089/dna.2008.0790</pub-id><pub-id pub-id-type="pmid">19364278</pub-id></mixed-citation></ref><ref id="B140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Smith</surname><given-names>A</given-names></name><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>E</given-names></name><name name-style="western"><surname>O&#241;ate</surname><given-names>A</given-names></name></person-group>. <article-title>Evaluation of <italic toggle="yes">Brucella abortus</italic> DNA vaccine by expression of Cu&#8211;Zn superoxide dismutase antigen fused to IL-2</article-title>. <source>Immunobiology.</source> (<year>2006</year>) <volume>211</volume>:<fpage>65</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.imbio.2005.09.004</pub-id><pub-id pub-id-type="pmid">16446171</pub-id></mixed-citation></ref><ref id="B141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Velikovsky</surname><given-names>CA</given-names></name><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name><name name-style="western"><surname>Giambartolomei</surname><given-names>GH</given-names></name><name name-style="western"><surname>Goldbaum</surname><given-names>FA</given-names></name><name name-style="western"><surname>Estein</surname><given-names>S</given-names></name><name name-style="western"><surname>Bowden</surname><given-names>RA</given-names></name><etal/></person-group>. <article-title>A DNA vaccine encoding lumazine synthase from <italic toggle="yes">Brucella abortus</italic> induces protective immunity in BALB/c mice</article-title>. <source>Infect Immun.</source> (<year>2002</year>) <volume>70</volume>:<fpage>2507</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.70.5.2507-2511.2002</pub-id><pub-id pub-id-type="pmid">11953389</pub-id><pub-id pub-id-type="pmcid">PMC127889</pub-id></mixed-citation></ref><ref id="B142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ranjbar</surname><given-names>R</given-names></name><name name-style="western"><surname>Sharifimoghadam</surname><given-names>S</given-names></name><name name-style="western"><surname>Saeidi</surname><given-names>E</given-names></name><name name-style="western"><surname>Jonaidi</surname><given-names>N</given-names></name><name name-style="western"><surname>Sheikhshahrokh</surname><given-names>A</given-names></name></person-group>. <article-title>Induction of protective immune responses in mice by double DNA vaccine encoding of <italic toggle="yes">Brucella melitensis</italic> Omp31 and <italic toggle="yes">Escherichia coli</italic> Eae genes</article-title>. <source>Trop J Pharmaceut Res.</source> (<year>2016</year>) <volume>15</volume>:<fpage>2077</fpage>&#8211;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.4314/tjpr.v15i10.4</pub-id></mixed-citation></ref><ref id="B143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Mariri</surname><given-names>A</given-names></name><name name-style="western"><surname>Abbady</surname><given-names>AQ</given-names></name></person-group>. <article-title>Evaluation of the immunogenicity and the protective efficacy in mice of a DNA vaccine encoding SP41 from <italic toggle="yes">Brucella melitensis</italic></article-title>. <source>J Infect Develop Countr</source>. (<year>2013</year>) <volume>7</volume>:<fpage>329</fpage>&#8211;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.3855/jidc.2296</pub-id><pub-id pub-id-type="pmid">23592643</pub-id></mixed-citation></ref><ref id="B144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donnelly</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Wahren</surname><given-names>B</given-names></name><name name-style="western"><surname>Liu</surname><given-names>MA</given-names></name></person-group>. <article-title>DNA vaccines: progress and challenges</article-title>. <source>J Immunol.</source> (<year>2005</year>) <volume>175</volume>:<fpage>633</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.175.2.633</pub-id><pub-id pub-id-type="pmid">16002657</pub-id></mixed-citation></ref><ref id="B145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name><name name-style="western"><surname>Velikovsky</surname><given-names>CA</given-names></name><name name-style="western"><surname>de la Barrera</surname><given-names>S</given-names></name><name name-style="western"><surname>Estein</surname><given-names>SM</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>L</given-names></name><name name-style="western"><surname>Bowden</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>A DNA vaccine coding for the <italic toggle="yes">Brucella</italic> outer membrane protein 31 confers protection against <italic toggle="yes">B. melitensis</italic> and <italic toggle="yes">B. ovis</italic> infection by eliciting a specific cytotoxic response</article-title>. <source>Infect Immunity.</source> (<year>2005</year>) <volume>73</volume>:<fpage>6537</fpage>&#8211;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.73.10.6537-6546.2005</pub-id><pub-id pub-id-type="pmid">16177328</pub-id><pub-id pub-id-type="pmcid">PMC1230944</pub-id></mixed-citation></ref><ref id="B146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Onate</surname><given-names>AA</given-names></name><name name-style="western"><surname>C&#233;spedes</surname><given-names>S</given-names></name><name name-style="western"><surname>Cabrera</surname><given-names>A</given-names></name><name name-style="western"><surname>Rivers</surname><given-names>R</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>A</given-names></name><name name-style="western"><surname>Mu&#241;oz</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>A DNA vaccine encoding Cu, Zn superoxide dismutase of <italic toggle="yes">Brucella abortus</italic> induces protective immunity in BALB/c mice</article-title>. <source>Infect Immun.</source> (<year>2003</year>) <volume>71</volume>:<fpage>4857</fpage>&#8211;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.71.9.4857-4861.2003</pub-id><pub-id pub-id-type="pmid">12933826</pub-id><pub-id pub-id-type="pmcid">PMC187304</pub-id></mixed-citation></ref><ref id="B147"><label>147.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>D</given-names></name><name name-style="western"><surname>Ni</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of <italic toggle="yes">Brucella abortus</italic> in BALB/c mice</article-title>. <source>Infect Immun.</source> (<year>2006</year>) <volume>74</volume>:<fpage>2734</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.74.5.2734-2741.2006</pub-id><pub-id pub-id-type="pmid">16622210</pub-id><pub-id pub-id-type="pmcid">PMC1459688</pub-id></mixed-citation></ref><ref id="B148"><label>148.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>D-H</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X-D</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name></person-group>. <article-title>A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against <italic toggle="yes">Brucella abortus</italic> 2308 by inducing specific CTL responses</article-title>. <source>DNA Cell Biol.</source> (<year>2007</year>) <volume>26</volume>:<fpage>435</fpage>&#8211;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1089/dna.2006.0552</pub-id><pub-id pub-id-type="pmid">17570767</pub-id></mixed-citation></ref><ref id="B149"><label>149.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>C</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T</given-names></name><name name-style="western"><surname>Du</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Immunogenicity of a multi-epitope DNA vaccine against hantavirus</article-title>. <source>Hum Vaccin Immunother.</source> (<year>2012</year>) <volume>8</volume>:<fpage>208</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.4161/hv.18389</pub-id><pub-id pub-id-type="pmid">22426376</pub-id></mixed-citation></ref><ref id="B150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paranavitana</surname><given-names>C</given-names></name><name name-style="western"><surname>Zelazowska</surname><given-names>E</given-names></name><name name-style="western"><surname>Izadjoo</surname><given-names>M</given-names></name><name name-style="western"><surname>Hoover</surname><given-names>D</given-names></name></person-group>. <article-title>Interferon-&#947; associated cytokines and chemokines produced by spleen cells from <italic toggle="yes">Brucella</italic>-immune mice</article-title>. <source>Cytokine.</source> (<year>2005</year>) <volume>30</volume>:<fpage>86</fpage>&#8211;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2004.12.009</pub-id><pub-id pub-id-type="pmid">15804600</pub-id></mixed-citation></ref><ref id="B151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name><name name-style="western"><surname>Velikovsky</surname><given-names>CA</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>L</given-names></name><name name-style="western"><surname>Estein</surname><given-names>SM</given-names></name><name name-style="western"><surname>de la Barrera</surname><given-names>S</given-names></name><name name-style="western"><surname>Bowden</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding <italic toggle="yes">Brucella melitensis</italic> outer membrane protein 31 (Omp31) and recombinant Omp31 boosting</article-title>. <source>Clin Vaccine Immunol.</source> (<year>2007</year>) <volume>14</volume>:<fpage>869</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00472-06</pub-id><pub-id pub-id-type="pmid">17428946</pub-id><pub-id pub-id-type="pmcid">PMC1951060</pub-id></mixed-citation></ref><ref id="B152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name></person-group>. <article-title><italic toggle="yes">Brucella abortus</italic> strain RB51 as a vector for heterologous protein expression and induction of specific Th1 type immune responses</article-title>. <source>Infect Immun.</source> (<year>2000</year>) <volume>68</volume>:<fpage>3290</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.68.6.3290-3296.2000</pub-id><pub-id pub-id-type="pmid">10816476</pub-id><pub-id pub-id-type="pmcid">PMC97584</pub-id></mixed-citation></ref><ref id="B153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sojka</surname><given-names>DK</given-names></name><name name-style="western"><surname>Fowell</surname><given-names>DJ</given-names></name></person-group>. <article-title>Regulatory T cells inhibit acute IFN-&#947; synthesis without blocking T-helper cell type 1 (Th1) differentiation <italic toggle="yes">via</italic> a compartmentalized requirement for IL-10</article-title>. <source>Proc Nat Acad Sci USA.</source> (<year>2011</year>) <volume>108</volume>:<fpage>18336</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1110566108</pub-id><pub-id pub-id-type="pmid">22025707</pub-id><pub-id pub-id-type="pmcid">PMC3215041</pub-id></mixed-citation></ref><ref id="B154"><label>154.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grivennikov</surname><given-names>SI</given-names></name><name name-style="western"><surname>Tumanov</surname><given-names>AV</given-names></name><name name-style="western"><surname>Liepinsh</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Kruglov</surname><given-names>AA</given-names></name><name name-style="western"><surname>Marakusha</surname><given-names>BI</given-names></name><name name-style="western"><surname>Shakhov</surname><given-names>AN</given-names></name><etal/></person-group>. <article-title>Distinct and nonredundant <italic toggle="yes">in vivo</italic> functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects</article-title>. <source>Immunity.</source> (<year>2005</year>) <volume>22</volume>:<fpage>93</fpage>&#8211;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2004.11.016</pub-id><pub-id pub-id-type="pmid">15664162</pub-id></mixed-citation></ref><ref id="B155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>DS</given-names></name><name name-style="western"><surname>Seo</surname><given-names>SI</given-names></name><name name-style="western"><surname>Shin</surname><given-names>WG</given-names></name><name name-style="western"><surname>Park</surname><given-names>CH</given-names></name></person-group>. <article-title>Risk for colorectal neoplasia in patients with <italic toggle="yes">Helicobacter pylori</italic> infection: a systematic review and meta-analysis</article-title>. <source>Clin Transl Gastroenterol.</source> (<year>2020</year>) <volume>11</volume>:<fpage>e00127</fpage>. <pub-id pub-id-type="doi">10.14309/ctg.0000000000000127</pub-id><pub-id pub-id-type="pmid">32032128</pub-id><pub-id pub-id-type="pmcid">PMC7145030</pub-id></mixed-citation></ref><ref id="B156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leclerq</surname><given-names>S</given-names></name><name name-style="western"><surname>Harms</surname><given-names>JS</given-names></name><name name-style="western"><surname>Rosinha</surname><given-names>GMS</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>V</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>SC</given-names></name></person-group>. <article-title>Induction of a th1-type of immune response but not protective immunity by intramuscular DNA immunisation with <italic toggle="yes">Brucella abortus</italic> GroEL heat-shock gene</article-title>. <source>J Med Microbiol.</source> (<year>2002</year>) <volume>51</volume>:<fpage>20</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1099/0022-1317-51-1-20</pub-id><pub-id pub-id-type="pmid">11803949</pub-id></mixed-citation></ref><ref id="B157"><label>157.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Velikovsky</surname><given-names>CA</given-names></name><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>M</given-names></name><name name-style="western"><surname>Fossati</surname><given-names>CA</given-names></name><name name-style="western"><surname>Fainboim</surname><given-names>L</given-names></name><name name-style="western"><surname>Spitz</surname><given-names>M</given-names></name></person-group>. <article-title>Single-shot plasmid DNA intrasplenic immunization for the production of monoclonal antibodies. Persistent expression of DNA</article-title>. <source>J Immunol Methods.</source> (<year>2000</year>) <volume>244</volume>:<fpage>1</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-1759(00)00244-1</pub-id><pub-id pub-id-type="pmid">11033013</pub-id></mixed-citation></ref><ref id="B158"><label>158.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abkar</surname><given-names>M</given-names></name><name name-style="western"><surname>Fasihi-Ramandi</surname><given-names>M</given-names></name><name name-style="western"><surname>Kooshki</surname><given-names>H</given-names></name><name name-style="western"><surname>Lotfi</surname><given-names>AS</given-names></name></person-group>. <article-title>Intraperitoneal immunization with Urease loaded N-trimethyl Chitosan nanoparticles elicits high protection against <italic toggle="yes">Brucella melitensis</italic> and <italic toggle="yes">Brucella abortus</italic> infections</article-title>. <source>Immunol Lett.</source> (<year>2018</year>) <volume>199</volume>:<fpage>53</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="pmid">29548705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.imlet.2018.03.004</pub-id></mixed-citation></ref><ref id="B159"><label>159.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Halifa</surname><given-names>S</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>L</given-names></name><name name-style="western"><surname>Arpin</surname><given-names>D</given-names></name><name name-style="western"><surname>Bourgault</surname><given-names>S</given-names></name><name name-style="western"><surname>Archambault</surname><given-names>D</given-names></name></person-group>. <article-title>Nanoparticle-based vaccines against respiratory viruses</article-title>. <source>Front Immunol.</source> (<year>2019</year>) <volume>10</volume>:<fpage>22</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.00022</pub-id><pub-id pub-id-type="pmid">30733717</pub-id><pub-id pub-id-type="pmcid">PMC6353795</pub-id></mixed-citation></ref><ref id="B160"><label>160.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gregory</surname><given-names>AE</given-names></name><name name-style="western"><surname>Titball</surname><given-names>R</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>D</given-names></name></person-group>. <article-title>Vaccine delivery using nanoparticles</article-title>. <source>Front Cell Infect Microbiol</source>. (<year>2013</year>) <volume>3</volume>:<fpage>13</fpage>. <pub-id pub-id-type="doi">10.3389/fcimb.2013.00013</pub-id><pub-id pub-id-type="pmid">23532930</pub-id><pub-id pub-id-type="pmcid">PMC3607064</pub-id></mixed-citation></ref><ref id="B161"><label>161.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abadi</surname><given-names>AH</given-names></name><name name-style="western"><surname>Mahdavi</surname><given-names>M</given-names></name><name name-style="western"><surname>Khaledi</surname><given-names>A</given-names></name><name name-style="western"><surname>Esmaeili</surname><given-names>S-A</given-names></name><name name-style="western"><surname>Esmaeili</surname><given-names>D</given-names></name><name name-style="western"><surname>Sahebkar</surname><given-names>A</given-names></name></person-group>. <article-title>Study of serum bactericidal and splenic activity of Total-OMP-CagA combination from <italic toggle="yes">Brucella abortus</italic> and <italic toggle="yes">Helicobacter pylori</italic> in BALB/c mouse model</article-title>. <source>Microb Pathog.</source> (<year>2018</year>) <volume>121</volume>:<fpage>100</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2018.04.050</pub-id><pub-id pub-id-type="pmid">29709690</pub-id></mixed-citation></ref><ref id="B162"><label>162.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iannino</surname><given-names>F</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>CK</given-names></name><name name-style="western"><surname>Roset</surname><given-names>MS</given-names></name><name name-style="western"><surname>Briones</surname><given-names>G</given-names></name></person-group>. <article-title>Development of a dual vaccine for prevention of <italic toggle="yes">Brucella abortus</italic> infection and <italic toggle="yes">Escherichia coli</italic> O157: H7 intestinal colonization</article-title>. <source>Vaccine.</source> (<year>2015</year>) <volume>33</volume>:<fpage>2248</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.03.033</pub-id><pub-id pub-id-type="pmid">25820069</pub-id></mixed-citation></ref><ref id="B163"><label>163.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arag&#243;n-Aranda</surname><given-names>B</given-names></name><name name-style="western"><surname>de Miguel</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Mart&#237;nez-G&#243;mez</surname><given-names>E</given-names></name><name name-style="western"><surname>Z&#250;&#241;iga-Ripa</surname><given-names>A</given-names></name><name name-style="western"><surname>Salvador-Besc&#243;s</surname><given-names>M</given-names></name><name name-style="western"><surname>Moriy&#243;n</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Rev1 wbdR tagged vaccines against <italic toggle="yes">Brucella ovis</italic></article-title>. <source>Vet Res</source>. (<year>2019</year>) <volume>50</volume>:<fpage>1</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1186/s13567-019-0714-3</pub-id><pub-id pub-id-type="pmid">31730501</pub-id><pub-id pub-id-type="pmcid">PMC6858679</pub-id></mixed-citation></ref><ref id="B164"><label>164.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Pan</surname><given-names>C</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P</given-names></name><name name-style="western"><surname>Feng</surname><given-names>E</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Application of an O-linked glycosylation system in <italic toggle="yes">Yersinia enterocolitica</italic> serotype O: 9 to generate a new candidate vaccine against <italic toggle="yes">Brucella abortus</italic></article-title>. <source>Microorganisms</source>. (<year>2020</year>) <volume>8</volume>:<fpage>436</fpage>. <pub-id pub-id-type="doi">10.3390/microorganisms8030436</pub-id><pub-id pub-id-type="pmid">32244903</pub-id><pub-id pub-id-type="pmcid">PMC7143757</pub-id></mixed-citation></ref><ref id="B165"><label>165.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>G-Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J-T</given-names></name><name name-style="western"><surname>Wei</surname><given-names>S-C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S-E</given-names></name><name name-style="western"><surname>Huo</surname><given-names>S-D</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z-R</given-names></name></person-group>. <article-title>Immunogenicity of adenovirus and DNA vaccines co-expressing P39 and lumazine synthase proteins of <italic toggle="yes">Brucella abortus</italic> in BALB/c mice</article-title>. <source>Trop Anim Health Prod.</source> (<year>2018</year>) <volume>50</volume>:<fpage>957</fpage>&#8211;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1007/s11250-018-1517-7</pub-id><pub-id pub-id-type="pmid">29492808</pub-id></mixed-citation></ref><ref id="B166"><label>166.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name></person-group>. <article-title>Liposomes used as a vaccine adjuvant-delivery system: from basics to clinical immunization</article-title>. <source>J Control Rel.</source> (<year>2019</year>) <volume>303</volume>:<fpage>130</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2019.04.025</pub-id><pub-id pub-id-type="pmid">31022431</pub-id><pub-id pub-id-type="pmcid">PMC7111479</pub-id></mixed-citation></ref><ref id="B167"><label>167.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goel</surname><given-names>D</given-names></name><name name-style="western"><surname>Rajendran</surname><given-names>V</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>PC</given-names></name><name name-style="western"><surname>Bhatnagar</surname><given-names>R</given-names></name></person-group>. <article-title>Cell mediated immune response after challenge in Omp25 liposome immunized mice contributes to protection against virulent <italic toggle="yes">Brucella abortus</italic> 544</article-title>. <source>Vaccine.</source> (<year>2013</year>) <volume>31</volume>:<fpage>1231</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.12.043</pub-id><pub-id pub-id-type="pmid">23273966</pub-id></mixed-citation></ref><ref id="B168"><label>168.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>WK</given-names></name><name name-style="western"><surname>Moon</surname><given-names>JY</given-names></name><name name-style="western"><surname>Cho</surname><given-names>JS</given-names></name><name name-style="western"><surname>Akanda</surname><given-names>MR</given-names></name><name name-style="western"><surname>Park</surname><given-names>BY</given-names></name><name name-style="western"><surname>Kug Eo</surname><given-names>S</given-names></name><etal/></person-group>. <article-title><italic toggle="yes">Brucella abortus</italic> lysed cells using GI24 induce robust immune response and provide effective protection in Beagles</article-title>. <source>Pathogens Dis</source>. (<year>2018</year>) <volume>76</volume>:<fpage>ftx124</fpage>. <pub-id pub-id-type="doi">10.1093/femspd/ftx124</pub-id><pub-id pub-id-type="pmid">29272378</pub-id></mixed-citation></ref><ref id="B169"><label>169.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>W-K</given-names></name><name name-style="western"><surname>Moon</surname><given-names>J-Y</given-names></name><name name-style="western"><surname>Cho</surname><given-names>J-S</given-names></name><name name-style="western"><surname>Ochirkhuyag</surname><given-names>E</given-names></name><name name-style="western"><surname>Akanda</surname><given-names>MR</given-names></name><name name-style="western"><surname>Park</surname><given-names>B-Y</given-names></name><etal/></person-group>. <article-title>Protective efficacy of an inactivated <italic toggle="yes">Brucella abortus</italic> vaccine candidate lysed by GI24 against brucellosis in Korean black goats</article-title>. <source>Can J Vet Res.</source> (<year>2019</year>) <volume>83</volume>:<fpage>68</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">30670904</pub-id><pub-id pub-id-type="pmcid">PMC6318821</pub-id></mixed-citation></ref><ref id="B170"><label>170.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ji</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Immune responses and protection induced by <italic toggle="yes">Brucella suis</italic> S2 bacterial ghosts in mice</article-title>. <source>Vet Immunol Immunopathol.</source> (<year>2015</year>) <volume>166</volume>:<fpage>138</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetimm.2015.04.008</pub-id><pub-id pub-id-type="pmid">26022514</pub-id></mixed-citation></ref><ref id="B171"><label>171.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Moon</surname><given-names>JY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>WK</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Hur</surname><given-names>J</given-names></name></person-group>. <article-title>Protection efficacy of the <italic toggle="yes">Brucella abortus</italic> ghost vaccine candidate lysed by the N-terminal 24-amino acid fragment (GI24) of the 36-amino acid peptide PMAP-36 (porcine myeloid antimicrobial peptide 36) in murine models</article-title>. <source>J Vet Medical Sci.</source> (<year>2016</year>) <volume>2016</volume>:<fpage>16</fpage>&#8211;<lpage>0036</lpage>. <pub-id pub-id-type="doi">10.1292/jvms.16-0036</pub-id><pub-id pub-id-type="pmid">27349900</pub-id><pub-id pub-id-type="pmcid">PMC5095622</pub-id></mixed-citation></ref><ref id="B172"><label>172.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moyle</surname><given-names>PM</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I</given-names></name></person-group>. <article-title>Modern subunit vaccines: development, components, and research opportunities</article-title>. <source>ChemMedChem.</source> (<year>2013</year>) <volume>8</volume>:<fpage>360</fpage>&#8211;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.201200487</pub-id><pub-id pub-id-type="pmid">23316023</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>